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Abstract		
The presented work unites several distinct lines of research, asserting that the broader 
construct of complexity (with its various connotations) may be uniquely relevant and 
informative to our understanding and management of psychotic disorders.  
 
Part 1 outlines the candidate’s contributions to the development of EEG methodology in 
clinical populations in an effort to most directly capture neural noise and complexity. The 
advent of oscillatory analysis facilitated the study of ongoing background activity of the EEG. 
Further exploration of this background activity demonstrated that increased neural noise (as 
quantified by Lempel-Ziv complexity) is highly correlated with, and conceptually very relevant 
to, positive symptoms of psychosis. Part 2 describes how considering the complexity of 
clinical psychosis states justifies the use of human laboratory studies using psychotomimetic 
drugs such as tetrahydrocannabinol and ketamine. Part 3 explains how the ideas and 
inferences from the work in Parts 1 and 2 can inform the environment of psychotic disorders, 
specifically the candidate’s work in prescribing practices and first episode psychosis service 
design. 
 
The thesis concludes that EEG studies of clinical populations face particular methodological 
challenges, however the resultant technical advancements have expanded our view of neural 
function to the particular benefit of our understanding of psychosis. EEG measures of 
complexity may be amongst the most sensitive biomarkers associated with positive 
symptoms, however more empirical research is called for to confirm this observation. Human 
laboratory studies of psychotomimetic drugs in healthy humans may continue to prove useful, 
in circumventing the phenomenological and patho-etiological complexity of clinically occurring 
psychosis. As a next step, multi-modal studies (combining biophysical signals, individual 
phenomenology and even population level outcomes) in combination with data mining 
techniques might further characterize the complexity within psychosis. Psychotic disorders, as 
complex problems, warrant framing and intervention informed by complexity.  
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Preface	
 
The following body of work and related commentary is humbly submitted for the award of 
PhD by Publication. It represents a synopsis of a singular line of scientific enquiry (albeit, but 
vitally, spanning a diverse range of techniques and fields) - using the notion of complexity as 
a core concept to guide translational research in psychiatry (and more specifically psychosis) 
through developing new research methodologies and clinical approaches more attuned to this 
orientation.  
 
The selected publications represent a pragmatic program of research, by a clinical academic, 
leveraging opportunities to collaborate across diverse fields and modes of investigation, in 
order to apply translational concepts in ways not otherwise possible. When not primary 
author, the candidate has made specific and substantive intellectual contributions to the work, 
derived from and germane to the unifying thesis presented here. This body of work and 
associated research training and experience (including completion of core didactics and 
coursework for the PhD program at the University of Nottingham, UK and completion of 3 
years clinical research fellowship in psychotic disorders at Yale University, USA) has been 
used to support and inspire the candidate’s current work as an independent researcher 
(Assistant Professor at Yale University): 2 ongoing research grants, international 
presentations, a textbook in preparation, 2 course directorships and other submitted 
manuscripts. This ongoing work and other possible future directions will also be discussed. 
 
WORK TITLE AUTHORSHIP % CONTRIBUTION 
PEER-REVIEWED WORKS 
1 Electrophysiological indices of abnormal 
error-processing in adolescents with 
attention deficit hyperactivity disorder 
(ADHD)  
Second (of 
seven) 
35 
2 Psychotomimetic and Cognitive Effects of 
Delta9-Tetrahydrocannabinol in Laboratory 
Settings  
First (of six) 45 
3 The psychosis-like effects of Δ 9-
tetrahydrocannabinol are associated with 
increased cortical noise in healthy humans  
Second (of ten) 30 
4 Testing differences in the activity of event-
related potential sources: important 
implications for clinical researchers  
Second (of six) 45 
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5 The Endocannabinoid System and 
Schizophrenia: Links to the Underlying 
Pathophysiology and to Novel Treatment 
Approaches  
Co-first (of 
four) 
45 
6 A Prescription for “Deprescribing” in 
Psychiatry  
Co-first (of 
two) 
50 
7 Psychopharmacology Prescribing Workshops: 
A Novel Method for Teaching Psychiatry 
Residents How to Talk to Patients About 
Medications  
Second (of 
twelve) 
28 
8 Building Early Intervention Services for 
Psychotic Disorders: A Primer for Early 
Adopters in the US  
Second (of 
three) 
35 
NON PEER-REVIEWED SUPPLEMENTARY WORKS 
S1 Impaired synchronization of neural 
oscillations immediately following auditory 
stimuli represents a pervasive deficit in brain 
recruitment in schizophrenia 
First (of five) 80 
S2 Pre-stimulus theta power predicts the 
suppression of beta synchronization during 
motor response: Does a disrupted effect in 
schizophrenia reflect pathological baseline 
theta activity?  
First (of five) 80 
S3 Cannabinoids Generate Neural Noise in 
Humans: A Nonlinear Analysis of EEG Signals  
Second (of 
eleven) 
30 
S4 Ketamine and depression  First (of one) 100 
Total % contributions 603 
Table 1. Summary of works with percent contributions (per joint authorship declarations) 	
Complex	systems	and	problems	
 
The etymology of the word ‘complexity’ draws from the Latin complexus – meaning ‘together’ 
and plectere, ‘to weave’ or ‘braid’. Therefore the more entwined, connecting parts within a 
system, the more complex it is. Individual parts exhibit different properties when viewed in 
isolation than in the context of the whole system, and dramatic unpredictable changes may 
result from seemingly minor changes in the system’s environment. Real world systems 
demonstrating complexity, such as weather systems and the brain are often referred to as 
complex adaptive systems [2]. 
 
Complex systems are non-linear and produce high degrees of noise, tension and fluctuation in 
their interaction with the environment [3]. By virtue of manifesting nonlinear feedback, they 
allow for emergence, self-organization, adaptation and learning [4]. Non-linear feedback in 
complex systems is facilitated by the presence of multiple interacting feedback loops, making 
the output difficult to predict and control [4]. Their outcomes can be probabilistic, uncertain 
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and non-predictable, and emergence can also occur. Emergence is the appearance of novel 
phenomena (on a macro-level) resulting from self-organization of a complex system [5].  
 
Complex systems may manifest complex problems. In conceptualizing approaches to health 
care reform, Glouberman and Zimmerman illustrated the distinction between a simple, 
complicated and complex problem [3] (see Table 2). Simple problems, when mastered, yield 
easily predictable outcomes. Complicated problems are comprised of multiple interconnected 
elements, at large scale, but can be predicted once understood. Whereas complex problems 
possess both simple and complicated components, with added sensitivity to context, 
interdependency, adaptation and non-linearity [3]. Therefore, complex problems, due to their 
nature, must be addressed as entire systems, to be influenced and not controlled [6]. 
 
 Approaching Simple, Complicated versus Complex Problems
Simple: Following a Recipe Complicated: Sending a 
Rocket to the Moon 
Complex: Raising a Child 
The recipe is essential Formulae are critical and 
necessary Formulae have a limited application 
Recipes are tested to assure 
easy replication Sending one rocket increases assurance that the next will 
be OK 
Raising one child provides 
experience but no assurance 
of success with the next 
No particular expertise is 
required. But cooking 
expertise increases success 
rate 
High levels of expertise in a 
variety of fields are necessary 
for success 
Expertise can contribute but is 
neither necessary nor 
sufficient to assure success 
Recipes produce standardized 
products Rockets are similar in critical ways Every child is unique and must be understood as an individual 
The best recipes give good 
results every time There is a high degree of certainty of outcome Uncertainty of outcome remains 
Optimistic approach to 
problem possible Optimistic approach to problem possible Optimistic approach to problem possible 
Table 2. Comparing simple, complicated and complex problems. Adapted from [3]	
Psychosis	as	the	prototypic	‘complex	problem’	in	psychiatry	
 
Per the American Psychiatric Association’s Diagnostic and statistical manual of mental 
disorders, schizophrenia spectrum and other psychotic disorders span schizophrenia, other 
psychotic disorders, and schizotypal (personality) disorder and are defined by abnormalities in 
one or more of the five domains: delusions (fixed, false beliefs, held in the face of 
contradictory evidence), hallucinations (perceptions in the absence of an external stimulus), 
disorganized thinking, grossly disorganized or abnormal motor behavior (including catatonia), 
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and negative symptoms [7]. Disorganized thinking or formal thought disorder refers to 
abnormal connections and flow between thoughts. The individual may flit from one topic to 
another (loose associations), respond obliquely (tangentiality) or talk around a topic 
(circumstantiality). Motor behavior may also be disorganized, ranging from fatuousness to 
unpredictable agitation. Negative symptoms of psychosis, most prominent in schizophrenia, 
account for a substantial portion of the morbidity of the disorder. They include diminished 
emotional expression, avolition (decreased self-initiated purposeful activities), alogia 
(diminished speech output), anhedonia (decreased derived pleasure), and asociality (lack of 
interest in social interactions) [8]. 
 
Psychosis can be experienced as acute and transient, chronic and persistent, or relapsing and 
remitting, and can rise to the level of a disorder - generally defined by the level of resultant 
distress and dysfunction. In this work, schizophrenia will be accepted as the prototypic, 
chronic primary psychotic disorder. Beyond schizophrenia however, psychosis and psychosis-
like experiences can complicate a wide range of mental and physical illnesses (such as mood 
disorders and delirium), as well as drug use (e.g. cannabis) but are also prevalent in 
approximately 7% of the general population - perhaps representing a transdiagnostic and 
extended phenotype [9]. 
 
Following decades of study, schizophrenia has been associated with a broad array of deficits 
and despite valiant efforts, eludes a widely accepted, unifying pathophysiology [10, 11]. 
Congruently, it has been described as a ‘complex disorder’ [12]. Complexity is likely relevant 
to all mental illness by virtue of the fact that the brain is a complex adaptive system, but 
specifically, an increase in the level of complexity (either via a mal-coordination of interacting 
elements or the additional of noisy or aberrant processes) may be hypothesized in psychosis. 
Of the properties of a complex system outlined above it may be that their non-predicable 
outcomes, noise and emergent phenomena may be most relevant to psychotic phenomena. 
Within this view, disorganized thinking and behavior may be framed in terms of non-
predictability and noise, whereas hallucinations and delusions may be conceived as 
(pathological, not physiological) emergent phenomena of the brain. 
 
In order to frame what follows, figure 1 proposes a multi-level, pluralistic view of psychosis as 
a disorder affecting expanding layers of function from neurons, to the individual person, to 
social systems. It offers both domains of functional impairment and specific examples of 
abnormalities observed, proposing the potential for a common principle (complexity) being 
relevant across all levels of the disorder.  
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Figure 1. A concentric, multi-layer model of observations associated with psychotic disorders, 
proposing complexity as a common principle 
 
In this way psychosis aligns well the idea of ‘translational research’. Although first appearing 
in the medical literature in 1993, this term only really became in vogue in the 2000s with 
growing interest in connecting basic science with clinical and population based research [13]. 
Rather than being unidirectional however, it has more recently been conceived as a 
“multidirectional integration of basic research, patient-oriented research and population based 
research with the long-term aim of improving the health of the public” [13]. 
	
Aims	
 
Tandon et al. 2002, observed that our conceptualization of schizophrenia has evolved 
alongside the techniques available to study it [11]. Similarly, the overarching aim of this body 
of work was to advance research methodology to better study psychiatric populations (but 
more specifically psychotic disorders) with the general hypothesis that increased complexity is 
a core feature that pervades all levels of these disorders and has profound relevance for their 
management. The published work will be presented, largely chronologically, however many 
ideas evolved in parallel, reflecting a multidirectional approach to translational research. The 
aim is also to demonstrate the candidate’s diverse, yet connected contributions to research 
methodology, pathophysiology, clinical practice and pedagogy relevant to this thesis. 
 
Part 1 reviews the candidate’s contributions to the development of EEG methodology in 
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clinical populations towards tapping into the brain’s complexity. The opportunity to perform 
secondary oscillatory analyses of event related potential EEG paradigms launched the 
exploration of resting state, pre-stimulus and non-stimulus-locked activity and finally neural 
noise measures. Increased neural noise (as quantified by Lempel-Ziv complexity) observable 
in psychosis states is also conceptually echoed in the phenomenology of the clinical 
syndromes. Part 2 exams the relevance of complexity to the study of psychosis states on the 
level of the person. Safe and rigorous research methodology is necessary towards 
understanding the clinical syndrome and advancing its management. Appreciating and 
adapting to the complex nature of psychosis can inform research approaches. Specifically, 
human laboratory studies using psychotomimetic drugs (in contrast to clinical psychosis) may 
offer a more controlled way of exploring this syndrome. Part 3 explicates how the ideas and 
inferences from the work in Parts 1 and 2 may be extrapolated to inform the environment of 
psychotic disorders - approaches to clinical care, (both on an individual patient and population 
level) as well as clinical education.																																	
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PART	1)	NEURONS:	Advancing	EEG	methods	for	clinical	research	in	psychiatry	
1.1	Overview	of	published	works	
 
o SUPPLEMENTARY WORK S1. Impaired synchronization of neural oscillations 
immediately following auditory stimuli represents a pervasive deficit in brain 
recruitment in schizophrenia [1] 
o Contribution to the work: generated hypothesis, designed and conducted 
analysis and independently wrote manuscript 
 
o SUPPLEMENTARY WORK S2. Pre-stimulus theta power predicts the suppression of 
beta synchronization during motor response: Does a disrupted effect in schizophrenia 
reflect pathological baseline theta activity? [14] 
o Contribution: generated hypothesis, designed and conducted analysis and 
independently wrote manuscript 
 
o WORK 1: Electrophysiological indices of abnormal error-processing in adolescents with 
attention deficit hyperactivity disorder (ADHD) [15] 
o Contribution: introduced the novel measure of inter-trial coherence (ITC) to 
the group, hypothesizing that it would be more sensitive than existing ERPs, 
participated in data collection, designed and conducted EEG data analysis, 
participated in preparation of manuscript 
 
o SUPPLEMENTARY WORK S3: Cannabinoids Generate Neural Noise in Humans: A 
Nonlinear Analysis of EEG Signals. [16] 
o Contribution: significant contribution to the hypothesis, design and conduct of 
the EEG analysis and interpretation of the results, contributed to preparation of 
the manuscript 
1.2	Commentary	
 
Bioelectrical potentials are routinely measured throughout medicine to diagnose and study 
disease. The flow of ion-based currents generated around the selectively permeable 
membranes of excitable tissues generate the electromyogram (EMG), electrocardiogram 
(ECG) and electroencephalogram (EEG). The EEG was first reported in 1875 by Richard Caton 
who noted electrical oscillations on the exposed cortex of animals. The first description of 
human EEG was offered by psychiatrist Hans Berger in 1929 [17]. It captures perturbations in 
voltage at the scalp caused by net local field potentials generated in dendrites of cortical 
pyramidal cells (summated inhibitory and excitatory post synaptic potentials). It offers a high 
John	D.	Cahill,	September	2017	
	 	 	 12	
temporal resolution, which aligns well with the timescale of perception [18] and cognition 
[19], and therefore is an ideal technique with which to explore the underlying 
psychophysiology of psychosis – most directly, abnormalities in those same domains: 
perception (e.g. hallucinations) and cognition (e.g. thought disorder). 
 
ERPs are stereotyped transient changes in the EEG associated with an external or internal 
event [20]. They have been widely studied since the 1960s, are elicited through a battery of 
experimental paradigms and thought to reflect specific sensory or cognitive processes. The 
history of studies conducted in psychiatric populations includes ERP responses to conflicting 
information, attention and memory [21-24]. ERP components are characterised on the basis 
of functional context [25], amplitude, time course and scalp topography and inferred 
anatomical origins [26]. 
 
ERPs can in fact represent the summation of many neurological processes overlapping in time 
and space, which do not necessarily originate in the area of cortex directly beneath the scalp 
topography of the ERP.  However, if regarded as epiphenomena, meaningful interpretations 
may be made from ERPs, without full knowledge of the neural basis of each waveform. They 
hence can lend themselves to the arbitrary comparison of patient and control populations – 
where the functional significance underlying the ERP is inferred through the context of the 
experimental manipulation [17, 27]. 
 
ERP paradigms generally involve the repeated presentation of a stimulus, which, subject to 
experimental conditions, elicits characteristic responses. These components emerge from the 
ongoing EEG activity when epochs, defined around onset time of the event of interest, are 
averaged across stimulus presentations (or trials). This increases the signal to noise ratio of 
the activity consistent in time course across trials (through constructive and destructive 
interference – see Figure 2) hence the resultant ERP represents stimulus-locked activity. As 
signal to noise ratio improves with an increasing number of trials averaged, the number of 
available trials may bias ERP analyses, especially when dealing with smaller amplitude 
phenomena or subtle group differences. For example, it is suggested that the P3 ERP requires 
30-60 trials, the N1 150-200 and the P1, 400-800 in order to adequately detect and study 
[17]. Achieving this in psychiatric populations can be challenging for a couple of reasons. 
Lengthy paradigms can be grueling for subjects, potentially deterring participation and 
affecting task performance. Secondly data may be lost due to common sources of artifact 
(such as movement and skin potentials), which may be greater due to underlying illness or 
treatment (e.g. hyperactivity of ADHD or extrapyramidal side effects caused by neuroleptic 
medications).  
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Given the above challenges and limitations of ERP-based studies in clinical populations, the 
establishment of novel EEG methodology for psychiatric populations (in order to capitalize on 
hard-earned and donated data) became a significant early focus of the candidate’s work. This 
was towards two general goals: 1) to better illuminate the pathophysiology of psychosis with 
more proximate and/or functionally meaningful measurements and 2) to yield biomarkers to 
aid detection, prediction and monitoring of deficits. 
1.2.1.	Oscillatory	analysis	reveals	previously	undetectable	deficits	in	neural	recruitment	in	
schizophrenia	(Supplementary	Work	S1)	
 
“Impaired synchronization of neural oscillations immediately following auditory stimuli 
represents a pervasive deficit in brain recruitment in schizophrenia” [1] [Please see Appendix 
1] 
 
Observing that the majority of EEG studies in psychiatry involved ERP analyses, the candidate 
was reminded that when Hans Berger first studied human in EEG in 1929, the initial 
phenomenon described was an oscillation (alpha wave) [17]. Around the time of the Works of 
this Part, spectral or oscillatory analysis (opening up a new dimension into the EEG) was 
starting to burgeon in clinical research, but ERP studies still dominated – offering the more 
established candidate biomarkers [15]. Oscillatory analysis is based on the parsimonious 
assumption that the EEG is derived from the summation of multiple neural oscillators and can 
be entirely decomposed into a spectrum of simple oscillations/sine waves (see Fourier 
Theorem - [28]). Fourier analysis and other more novel methods (e.g. wavelet and Hilbert 
transforms) all yield values for both amplitude and phase angle for a given frequency at a 
given time point (or rather window) - this is conventionally expressed as a single complex 
number [29].  
 
Perhaps more proximate and physiologically-meaningful than ERPs, oscillations are thought to 
represent the rhythmic changes in local field potentials at specific frequencies, dependent on 
the anatomical and physiological properties of the generating networks [30-33]. The full 
Classical	Model	of	ERP	
(noise	+	signal)	
In-phase															An+-phase	
(construc+ve)					(destruc+ve)	
Figure 2. An illustration of 
the two types of 
interference: constructive 
and destructive. Oscillations 
in-phase summate; whereas 
those 180 degrees out of 
phase (‘anti-phase’) cancel 
out.	
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frequency spectrum of human EEG is conventionally divided in the following bands: delta (0-
4Hz), theta (4-7Hz), alpha (8-12Hz), beta (12-30Hz) and gamma (30-100Hz). The strength 
of the signal at the scalp implies a degree of synchronisation between multiple neural 
generators, which may serve to recruit covert, behaviourally relevant networks. Functionally, 
oscillations of different frequencies could theoretically provide a dynamic medium of 
communication across a wide range of temporal resolutions. More specifically, theta and 
gamma have been proposed as a fundamental property of cortical circuits, used to ‘code’ 
cognition [34]. Higher frequency beta and gamma oscillations have been associated with local 
communication and cognitive events, whereas lower frequencies, more commonly, with longer 
distance communication and top-down modulation [35-37]. 
 
The ‘classical model’ for the generation of ERPs, describes a stimulus locked phasic signal, 
which occurs on top of relatively unaltered background EEG as the brain mobilizes to the 
incoming stimulus. Alternatively, the ‘oscillatory model’ is based on the concept of 
interference of ongoing oscillations - where the stimulus imposes a transient, non-random 
distribution of phase angles resulting in interference to produce a burst of amplitude 
perturbation in the EEG [38, 39]. This resetting of phase of pre-stimulus oscillations may 
contribute to the generation of an ERP, without requiring actual amplitude perturbation of 
these oscillations [40]. This revealed a previously un-tapped dimension of EEG data. Novel 
spectral analysis techniques meant raw datasets from established ERP paradigms could be 
further mined for new effects through secondary analysis (Figure 3). Oscillatory analysis 
demonstrated abnormalities in schizophrenia during both resting state and the processing of 
information [30]. These relatively new methodological advances (at the time) were leveraged 
in this Part’s Works for the study of clinical populations. 
 
Neural oscillations observed in the EEG had gained support in their potential role in brain 
recruitment [41]. Schizophrenia, with its clinical heterogeneity and varied biological 
abnormalities may have a fundamental impairment of neural recruitment at its core [30, 31, 
42]. Psychosis may be regarded as a syndrome of network dysfunction [30, 43-45]. 
Documented abnormalities in glutamate, GABA, dopamine and endocannabinoid systems 
converge around the ‘cortical microcolumns’ – functional units comprised of cortical pyramidal 
neurons (and their associated interneurons), which generate the ongoing EEG signal [45]. 
Winterer et al. demonstrated an increased broadband pre-frontal ‘noise’ in an oddball task in 
schizophrenia which was negatively related to P300 amplitude and behavioural performance 
[46, 47]. ‘Noise’ was defined here as the ongoing non stimulus-locked power during the task. 
He introduces the idea that patients do not merely fail to activate the cortex, but fail to 
integrate processes in a task-related, frequency specific manner. Instead of generating a 
stimulus phase-related ‘signal’, they develop task irrelevant ‘noise’, perhaps as an aberration 
of a stochastic resonance effect (where noise and performance show an inverted ‘U’ 
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relationship) [46]. In other words, patients’ ongoing neural activity may be disordered in such 
a way as to undermine a normal event-related response. In general, time-locked responses 
(i.e. ERP and evoked spectral activity measures) are diminished in schizophrenia. This may be 
related to increased levels of random variation of electrophysiological responses in the 
context of time-locked-response paradigms [47-50]. As proposed by Winterer and 
Weinberger, neural noise reflects the inability of neural circuits to suppress spontaneous 
background firing while enhancing time-locked stimulus-evoked coordinated activity [51]. 
Drawing from their further findings in siblings and genetic analysis, Winterer further proposed 
that this increased broadband noise is a potential trait marker/endophenotype for 
schizophrenia [47, 52].  
 
 
Figure 3: An illustration of a spectral decomposition of the P300 ERP. Top panel depicts classic ERP 
signal (voltage/time) for patients with schizophrenia (black line) vs controls (red line) at Pz. Scalp 
map depicts spatial distribution of activity at peak (vertical blue line). Bottom panel depicts a 3 
dimension ‘scalogram’ for the same signal time course - both groups combined. Y-axis is frequency 
(Hz), x is time in milliseconds and color denotes amplitude per the scale (previously unpublished 
data derived from dataset yielding Works S1 and S2) 
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In the Works of Part 1 spectral decomposition was performed using discrete windowed Fourier 
transforms. Evoked (or direct) power was derived by first averaging the raw EEG across trials 
and then taking squared spectral estimates. Evoked power reflects stimulus locked activity 
and is expressed as an absolute power value. Total power was estimated by the spectral 
decomposition of individual trials before averaging across them - it reflects all activity. 
Induced (or indirect) power was calculated by subtracting the stimulus locked signal (across 
trials) from the activity at each trial, having undergone spectral decomposition and then 
averaging across trials - it reflects non-stimulus locked activity. Both total and induced power 
were considered most meaningfully expressed as a percent change from pre-stimulus baseline 
(akin to Event Related Synchronisation (ERS) [53]). Evoked/induced ratio was calculated as 
the evoked power divided by the percentage change in induced power. Inter-trial phase 
coherence (ITC) was calculated according to [54, 55] as a spectral measure developed to 
capture trial-by-trial variability. ITC quantifies the consistency of phase alignment across 
trials and is related to the ‘Phase Locking Factor’ described by Lachaux [38, 56]. In brief, it 
quantifies the extent of the distribution of phase angles in a given frequency across trials, 
giving values of 0 to 1 at each time point (where 0 represents completely randomly 
distributed phase angles between all trials and 1, identical phase at all trials). As such, ITC is 
independent of amplitude [54, 55]. As with ERPs, an incoming stimulus may ‘recruit’ the brain 
via the generation (or enhancement) of oscillations either phase-locked to stimulus onset of 
endogenously generated phase – both these processes, however are likely to occur. 
Therefore, the magnitude of evoked activity (defined above - where averaging occurs across 
trials) may be affected by not only the amplitude of the phase locked signal at each trial, but 
the consistency of the phase-relationship to stimulus onset across trials. 
 
At the time of Work S1, decreased ITC had just been demonstrated in schizophrenia using the 
40Hz ‘steady state’ auditory stimulation paradigm – a task designed to recruit a stereotyped 
cortical response [57]. Hypothesizing a even more fundamental deficit in basic neural 
recruitment in schizophrenia, in Work S1, the candidate proposed that this recruitment deficit 
might also be found during the initial pan-spectral oscillatory burst underlying the early ERP 
components (including N100 and extending into the latency of the P300), which was not well 
described at the time (see Figure 3). This burst of activity follows any attended stimulus and 
is likely related to sensory encoding and early recruitment [53, 58]. Work S1 was the first 
study to hypothesise and demonstrate a relative deficit in this initial, pan-spectral neural 
recruiting response in patients with schizophrenia in response to simple attended auditory 
stimuli (common tone of P300 paradigm). This deficit was manifest in a range of stimulus 
phase- and non phase-locked measures. The effect is most marked in the ratio of evoked to 
induced power, framed in this Work as signal/noise ratio [1]. 
 
John	D.	Cahill,	September	2017	
	 	 	 17	
 
  
 
These results were in concordant with Winterer’s findings of aberrant background neural noise 
and impaired recruitment in schizophrenia [46, 47]. The candidate further reflected in Work 
S1 that oscillatory analysis of the EEG had opened a new dimension in psychiatric research, 
which particularly lent itself to the framing of schizophrenia as an illness with neural disorder 
and noise at core concepts.  
1.2.2.	Exploring	pre-stimulus/background	EEG	activity	(Supplementary	Work	S2)	
 
“Pre-stimulus theta power predicts the suppression of beta synchronization during motor 
response: Does a disrupted effect in schizophrenia reflect pathological baseline theta 
activity?” [14] [Please see Appendix 2] 
 
In Work S2, the candidate further proposed that the pre-stimulus activity and interplay with 
post stimulus responses might be of considerable interest in schizophrenia. The functional role 
of pre-stimulus activity had received limited attention at the time of Work S2 [59]. Pre-
clinically, enhanced alpha and theta interactions had been demonstrated during expectant 
states in cats and greater pre-stimulus alpha phase synchrony has been associated with 
reduced reaction times in an oddball task [60]. Pre-stimulus activity was thought to be task 
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ratio) is decreased in 
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frequency spectrum (Solid lines = 
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Patients)). Adapted from [1] 
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specific in its regulation of executive control and a deficit in this effect has been implicated in 
schizophrenia [61]. Studies of the resting state in schizophrenia had shown an increased delta 
and theta activity [62]. 
 
Although many schizophrenia studies focused on the gamma (and beta) bands (associated 
with cognition [63, 64]) the candidate focused on fronto-central theta oscillations due to their 
link with dopaminergic function - implicated in the optimization of signal to noise ratio of local 
cortical microcircuits [52, 65, 66] and the prevailing neurotransmitter deficit model of the 
disorder. The ratio of D1/D2 dopaminergic signaling appears to modulate the excitability of 
prefrontal GABA- and glutamatergic neurons. Hence the reduction in D1/D2 receptor ratio 
reported in schizophrenia could provide a mechanism for destabilization of local cortical 
networks and increased neural ‘noise’ [52] [67]. Fronto-central theta is associated with both 
stimulus anticipation [68] and tasks involving working memory [69, 70].  
 
Accordingly, in Work S2, the candidate tested the relationship between pre-stimulus theta 
activity and a putative oscillatory marker of executive function: beta event-related 
desynchronization (ERD) observable in event-related paradigms requiring a motor response 
(projecting from motor cortical and sub-cortical sources) and peaking at average response 
time [71] [72]. This beta ERD is thought to reflect a release of tonic inhibition of parieto-
dependent motor networks for a learned action (i.e. sensory-motor transformation), and is 
followed by a rebound of beta power (event-related synchronization or ERS). The results of 
Work 2 showed preliminary evidence for a pre-stimulus theta/post-stimulus beta relationship 
detectable in health controls and significantly weakened in individuals with schizophrenia. This 
study was significant as one of the first studies to attempt to examine cross-spectral, pre/post 
stimulus relationships in schizophrenia.  
1.2.3.	Oscillatory	measures	prove	more	sensitive	and	relevant	to	task	performance	than	
conventional	ERPs	in	ADHD	(Work	1)	
 
“Electrophysiological indices of abnormal error-processing in adolescents with attention deficit 
hyperactivity disorder (ADHD)” [15] [Please see page 46] 
 
As discussed above, the candidate sought to identify EEG techniques that would yield more 
sensitive and clinically relevant measures in difficult to study clinical populations. One 
especially challenging population to study is children with Attention deficit hyperactivity 
disorder (ADHD).  ADHD may have significant genetic, phenotypic and pathophysiological 
overlap with some features of schizophrenia [73]. Both disorders also involve abnormalities in 
dopamine neurotransmission, a system hypothesized to be involved in the mal-coordination of 
cortical activity discussed in section 1.2.2 and perhaps reflected in theta oscillations. ADHD 
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affords the further distinct advantage of allowing researchers to more readily manipulate 
dopaminergic tone (than in schizophrenia) via stimulant medications with more rapid onset 
and offset of therapeutic effects. 
 
In the first study of its kind, the candidate applied (then novel) ITC analysis within a better-
established visual go/no-go ERP paradigm (error-related negativity - ERN and Error positivity 
- Pe) with the hypothesis that it would more sensitively differentiate patients with ADHD from 
controls, and correlate more readily with clinical measures of executive function. Evoked theta 
power and ITC were measured in two time windows corresponding to those used for detection 
of the ERN and Pe. Whereas only a statistical trend was detected for a reduced Pe in the 
ADHD group, significant reductions were detected in evoked theta in the ERN window and 
theta ITC in both windows. Furthermore, theta ITC most strongly predicted post error slowing 
(a behavioral measure of response adjustment in trials immediately following an error) [15]. 
These findings were used to recommend the wider use of this novel EEG methodology in this 
clinical population. 
 
The second significant contribution the candidate’s work from this lab (University of 
Nottingham, UK) made to psychiatric EEG methodology was the adaptation and application of 
a novel artifact handling technique (independent component analysis [55]). Among the first 
clinical EEG studies to implement this technique, it allows researchers to correct rather than 
reject trials that contain artifact (an especially problem when studying children with ADHD 
who exhibit significant amounts of movement). This allows preservation of trials where 
conventional pre-processing techniques would warrant discarding of significant portions of 
hard-earned data, weakening a study’s ability to detect a signal of interest. 
1.2.4.	From	‘complex	analyses’	to	analysing	complexity	(Supplementary	Work	S3)	
 
“Cannabinoids Generate Neural Noise in Humans: A Nonlinear Analysis of EEG Signals” [16] 
[Please see Appendix 3] 
 
Although oscillatory analysis revealed an additional dimension of the EEG (beyond ERP 
analysis) and allowed ‘more complex’ analyses (in a colloquial sense) to take place (e.g. pre-
post stimulus interacts, isolating phase and amplitude, cross-spectral analyses), the actual 
mathematical complexity of the EEG signal was not being directly captured. 
 
The term ‘noise’ in signal processing implies disorder or randomness. However, established 
measures of EEG ‘noise’ (induced and spontaneous baseline activity) are far from random in 
nature and reflecting a relationship (or rather lack of) with functionally-important, top-down 
processes such as attention and cortical tuning [74]. Therefore, our definition of ‘noise’ must 
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evolve beyond the activity’s relationship to an event or task to fully capture disorder and 
complexity. 
 
Lempel-Ziv Complexity (LZC) is a non-linear measure first developed to characterize the 
randomness of finite length sequences [75] and has been increasingly theoretically and 
empirically validated in the study of electrophysiological signals [76]. Its value reflects the 
number of different patterns or words contained in a sequence and the rate at which new 
words occur [75]. For random sequences (e.g. white noise) LZC approaches 1, while for 
regular/periodic sequences (e.g. seizure activity) it approaches 0 [77, 78]. Although not all 
sources of variation of LCZ are understood, in any given physiological signal, there likely 
exists a functionally optimal, intermediate level, with potential dysfunction at the extreme 
values. 
 
 
Figure 5. Lempel-Ziv complexity in periodic, electroencephalographic, and random signals. This 
figure depicts the steps followed to calculate LZC in three different types of signals: periodic 
(regular), electroencephalographic, and white noise. From top to bottom, the first step consists of 
coding the signal into a binary (1’s and 0’s) symbolic sequence; then the sequence is parsed in 
order to obtain the distinct symbolic subsequences or ‘words’ forming it (for each type of signal, 
different words are shown as different color sequences separated by dots); finally, the number of 
distinct words is determined and the result normalized to obtain an LZC value that approaches 0 for 
a regular sequence and 1 for a random sequence (when the length of the signal (𝑛) tends to 
infinity). Note that the number of distinct words is minimal for the periodic signal and maximal for 
random noise, while the number of words of the electroencephalographic signal lies between both 
extremes. Adapted from [79] 
 
LZC’s conceptual advantage as a biomarker of neural noise is that it more data-driven, 
reflecting a dynamic state of the system and not requiring the presence of a task for its 
definition. LCZ’s practical advantages are that it is sensitive to both the power spectrum and 
temporal amplitude distributions, but is independent of absolute signal amplitude [79]. LCZ 
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represents a paradigm shift, but may be complementary to the aforementioned measures of 
cortical ‘noise’: signal to noise ratio (which is highly sensitive to inter-trial variations in 
timing) and baseline power (which is a gross measure dependent on the overall amplitude, 
rather than content, of the signal). LCZ has been measured in schizophrenia with mixed 
results, possibly attributable to burgeoning evidence that negative symptoms decrease, 
whereas positive symptoms increase, complexity [80-82].   
 
Supplementary Work S3 was significant as the first ever report of increased neural ‘noise’ in a 
psychosis state induced by THC during a human laboratory study. Now, finally armed with a 
direct measure of EEG complexity, the candidate aimed to explore the prediction that 
increased EEG complexity, as a unifying principle in psychosis, would correlate highly with 
psychotomimetic effects. Work 3 of Part 2 represents this more extensive experiment, 
examining the potential utility of LCZ as a marker of psychosis states. 																				
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PART	2)	THE	PERSON:	Advancing	Clinical	Research	Approaches	to	Explore	Psychosis		
2.1	Overview	of	published	work	
 
o WORK 2. Psychotomimetic and Cognitive Effects of Delta9-Tetrahydrocannabinol in 
Laboratory Settings [83]  
o Contribution: created outline and main points of the chapter, took overall 
responsibility for the material and wrote majority of text 
 
o WORK 3. The psychosis-like effects of Δ 9-tetrahydrocannabinol are associated with 
increased cortical noise in healthy humans [79] 
o Contribution: significant contribution to the hypothesis, design and conduct of 
the EEG analysis and interpretation of the results, contributed to preparation of 
the manuscript 
 
o SUPPLEMENTARY WORK S4. Ketamine and depression [84] 
o Contribution: Solely responsible for preparation of the work 
 
o WORK 4. Testing differences in the activity of event-related potential sources: 
important implications for clinical researchers [85] 
o Contribution: equal primary contribution to design, conduct and reporting of 
the study 
2.2	Commentary	
 
The candidate had the opportunity to translate the basic science concepts and EEG 
methodology developed at the University of Nottingham, to more clinically oriented research 
within the Schizophrenia and Neuropsychopharmacology Group at Yale University, CT, USA.  
 
Much of the candidate’s prior study of psychosis had been in the context of recruited patients 
diagnosed with schizophrenia via conventional diagnostic criteria. However the value of such 
diagnostic classifications of psychotic disorders (based purely on clinical interview) had begun 
to be broadly challenged [9]. Schizophrenia is still being reimagined as group of disorders 
with multiple candidate genes, risk factors and underlying abnormalities and hence is both a 
heterogeneous and patho-physiologically complex syndrome [10, 12] [86].  
 
In keeping with the idea of a complex system, outlined in the preface, this patho-etiological 
complexity would denote a high number of interacting, context-dependent, adaptive 
processes contributing to a similarly complex clinical syndrome. Therefore when recruiting 
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subjects to study psychosis on the basis of clinical interview and diagnostic classification, one 
can yield a patho-physiologically diverse group, potentially reducing the power to test the 
hypothesis in question. In response to this assertion, the NIMH launched the Research 
Domain Criteria (RDoC) initiative - but not without debate [87, 88]. It called for shifting the 
primary focus of research from diagnostic classifications to variations in neural circuitry - with 
levels of analysis progressing either ‘upwards’ to clinically relevant variables, or ‘downwards’ 
to the genetic and molecular/cellular factors [87]. One interpretation of RDoC is that subjects 
might for example be recruited on the basis of experiencing positive symptoms (such as 
specifically auditory hallucinations) and not by a diagnosis of schizophrenia. A key criticism of 
this approach was that it attempts to arbitrarily further split the construct of psychosis into a 
number of interacting domains of dysfunction [88] [89]. This critique is perhaps most 
challenging as it might encourage the treatment of psychosis as complicated rather than 
complex problem.  
2.2.1	Addressing	the	patho-etiological	complexity	of	psychosis	with	psychotomimetic	drug	
models	(Work	2)	
 
“Psychotomimetic and Cognitive Effects of Delta9-Tetrahydrocannabinol in Laboratory 
Settings” [83] [please see page 59] 
 
An alternative to tackling the patho-etiological complexity faced when studying clinical 
psychosis is the study of experimentally induced psychosis (psychotomimetic drug models) in 
otherwise healthy individuals. This type of study recruits healthy controls (free of psychosis) 
and under laboratory conditions induces a transient psychosis state using a standardized 
administration of a medication or drug known to have predictable psychosis-like effects. 
These so-named psychotomimetic effects can include perceptual abnormalities (illusions and 
hallucinations), delusional beliefs and feelings, disorganization of thoughts and speech, and 
altered perceptions of self (such as dissociation). Some psychotomimetic drug models may 
also produce effects that resemble negative symptoms (i.e. apathy, anhedonia, alogia, 
asociality and avolition) and also impair several aspects of cognition (memory, attention and 
executive function). A more homogeneous psychosis state can be obtained, without 
complicating effects of trait features associated with heterogeneous clinical psychotic 
disorders. In other words, psychotomimetic drugs can simulate core elements of psychosis in 
the absence of some of the collateral deficits observable in complete clinical syndromes such 
as schizophrenia. Examples of such psychotomimetic agents include phencyclidine, ketamine, 
tetrahydrocannabinol (THC), amphetamine and lysergic acid diethylamide (LSD) [90] [84] 
[83]. 
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Human laboratory Studies using THC, conducted since the 1970’s, have reliably demonstrated 
a range of dose-dependent psychotomimetic and cognitive effects in healthy humans (as well 
as in individuals with cannabis use disorder, increased risk of psychosis, and schizophrenia). 
In Work 2 the candidate assimilates this literature and produces guidelines to clinical 
researchers seeking to conduct or draw inferences from this type of study. Broadly, deficits 
are observable in domains most relevant to schizophrenia: positive, negative, dissociative, 
and disorganization cluster symptoms and impairment in working and verbal memory [91] 
(see Table 3).  
 
Subject	Quote	 							Symptom	
I	thought	you	could	read	my	mind,	that’s	why	I	didn’t	answer	 Suspiciousness/paranoia	
I	thought	you	all	were	trying	to	trick	me	by	changing	the	rules	of	the	
tests	to	make	me	fail	
I	could	hear	someone	on	typing	on	the	computer…	and	I	thoughts	you	
all	were	trying	to	program	me	
I	thought	you	all	were	giving	me	THC	through	the	BP	machines	and	
the	sheets	
I	couldn’t	keep	track	of	my	thoughts…	they’d	suddenly	disappear	 Formal	thought	disorder	
It	seemed	as	if	all	the	questions	were	coming	to	me	at	once…	
everything	was	happening	in	staccato	
My	thoughts	were	fragmented…	the	past,	present	and	future	all	
seemed	to	be	happening	at	once	
I	felt	I	could	see	into	the	future…	I	thoughts	I	was	God	 Grandiosity	
The	AC	that	I	couldn’t	hear	before	suddenly	became	deafening	 Perceptual	abnormalities	
I	thought	I	could	hear	the	dripping	of	the	iv	and	it	was	louder	than	
your	voice	
Table 3. The quality of psychotomimetic effects reported by health individuals following the 
intravenous infusion of 2.5 or 5mg of THC, interpreted within common phenomenological domains of 
schizophrenia (adapted from [83], originally reprinted with permission from [91]) 
 
The acute administration of cannabinoids in tightly controlled laboratory settings allows for 
both a clearer inference of causality of effects and a more detailed characterization of those 
effects. In this way, they attempt to simplify a complex problem as a first step to 
understanding it. However they are not without limitations. The degree to which 
psychotomimesis reflects any other type of psychosis state remains subject to debate. Tight 
inclusion and exclusion criteria, operationalized cannabinoid administration and the inevitable 
influence of the laboratory setting on subjective effects experienced by the participant 
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constrain the generalizability and/or limit the interpretation of this type of study. Subjects 
may self-select due to past positive or negative associations with cannabis and/or laboratory-
based research in general. Most notably, those who have experienced past adverse effects 
from cannabinoids are unlikely to volunteer for such studies. Despite providing a useful 
laboratory model of psychosis in humans, HLS using cannabinoids are unlikely to ever 
adequately replicate the full range of deficits observed in psychotic disorders and therefore 
can only provide a restricted, though penetrating, view [83].  
2.2.2.	Lempel-Ziv	complexity	promises	a	sensitive	measure	closely	associated	with	psychosis	
symptoms	(Work	3)	
 
“The psychosis-like effects of Δ 9-tetrahydrocannabinol are associated with increased cortical 
noise in healthy humans” [79] [please see page 114] 
 
Lempel-Ziv complexity was introduced above, as a nonlinear measure of signal randomness 
[16]. Work 3 reports the acute, dose-related effects of Δ9-THC on Lempel-Ziv complexity and 
signal power in 24 individuals who completed 3 test days during which they received 
intravenous Δ9-THC (placebo, 0.015 and 0.03 mg/kg) in a double-blind, randomized, 
crossover, and counterbalanced design. The larger study producing Work 3 was also 
significant as a multi-modal study of a single clinical phenomenon in keeping with the 
translational perspective of this thesis. For the larger study, outcomes were collected in the 
following modalities: subjective and objective behavior, cognition, vital signs, EEG, genetic 
screening of common psychosis relevant polymorphisms and serum cannabinoids. As 
hypothesized in Work 3, Δ9-THC increased neural noise in a dose-related manner. The 
candidate, drawing on the work presented in Part 1 and the ideas outlined in the preface, 
further hypothesized that Lempel-Ziv complexity (as more proximate measure complexity) 
would correlate highly with the THC-induced psychosis-relevant clinical effects, specifically 
positive and disorganization symptoms. The analysis in Work 3 confirmed a strong positive 
relationship, which was independent of total signal power. These results are consistent with a 
report that (a different measure of) EEG complexity is increased in the context of clinical 
decompensation in schizophrenia and normalizes with antipsychotic treatment [92]. 
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Figure 6. Δ9-THC-induced positive and disorganization symptoms versus Lempel-Ziv complexity 
uncorrected for signal power. The figure shows the linear regression lines and standardized 
coefficients of the positive (A) and disorganization (B) symptoms factors of the PANSS on Lempel-
Ziv complexity (LZC) uncorrected for signal power. PANSS scores and LZC values are presented in z 
scores. Adapted from [79] 
 
Of significant note, the level of correlation between LZC and these clinical effects exceed that 
of the major established psychosis biomarkers at time of publication [93]. The relative effect 
sizes are illustrated in the following figure. These results further lend support to a couple of 
assertions of this thesis – that the evolution of EEG methodology has yielded measures closer 
to the core pathophysiology of psychosis and secondly, that experimentally-induced psychosis 
states may hold inferential advantages over the study clinical psychosis (which can have 
significant confounding factors as a result of the underlying illness or its treatment). 
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Figure 7. Contextualization of magnitude of Cohen’s d effects size amongst established 
neurophysiologic and neurocognitive biomarkers in schizophrenia. A and B are adapted from 
[93] and C is based on the r value for the relationship between level of EEG noise and PANSS 
positive score from [79]. LNS=letter number span; WCST=Wisconsin Card Sorting Test; 
CVLT=California Verbal Learning Test; PPI=pre-pulse inhibition. 
	
2.2.3.	Embracing	serendipity	with	caution:	ketamine	psychotomimesis	and	rapid	
antidepressant	effects	(Supplementary	Work	S4)	
 
“Ketamine and depression” [84] [please see Appendix 4] 
 
The psychoactive effects of THC in human laboratory studies (HLS) resolve spontaneously 
within a number of hours and have no reported long lasting effects [94]. This is also generally 
true of ketamine, another psychotomimetic drug with which the candidate has worked [95]. 
Ketamine’s principal action in the brain is on N-methyl-D-aspartate (NMDA) receptors, where 
it blocks the action of the brain’s principal excitatory neurotransmitter, glutamate. As a 
derivative of phencyclidine (PCP), ketamine shares some notoriety as a commonly abused 
club drug, going under the street names K and Special K. It is a schedule III controlled 
substance in the United States. At lower, so-called sub-anesthetic doses (at which 
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consciousness is largely preserved), ketamine produces dissociative (out-of-body) and 
hallucinogenic effects. These effects led to its early study in psychiatric research, as a 
pharmacological model of psychosis [84]. 
  
When conducting HLS with ketamine however, investigators serendipitously observed a longer 
lasting, rapid onset antidepressant effect in depressed subjects. This led to a line of 
experimentation that now shows promise for an entirely novel class of antidepressant and 
highlighted the complexity inherent in the patho-physiology of depression, but also 
ketamine’s mechanism of action. In Supplementary Work S4, as ketamine’s potential use as a 
rapid antidepressant begins to garner wider public attention, the candidate assimilates the 
history and evidence in order to examine ketamine’s future value as psychiatric medication. 
Critically, Supplementary Work S4 argues for rigor in the face of this observed complexity 
(and hence uncertainty) – and weighing the risks and benefits of ketamine burgeoning use, 
which still continues largely on the basis of case report level evidence (and not large 
randomized, placebo-controlled trials) [84]. 
 
2.2.4	Applying	novel	methodologies	to	clinical	research	with	rigor:	catching	a	widespread	error	
in	interpretation	of	EEG	source	analysis	in	clinical	studies	(Work	4)	
 
“Testing differences in the activity of event-related potential sources: important implications 
for clinical researchers” [85] [please see page 124] 
 
A further example of the candidate’s advocacy for the retention of methodological rigor when 
being challenged by the complexity of the brain is Work 4. As described above, spectral 
measures such as ITC broadened our view and understanding of the activity underlying ERPs 
in the temporal domain. Spatially however, new techniques were also emerging in the 
methods literature. The EEG only allows researchers to infer the underlying neural activity 
from the electrical potentials measured at each electrode site on the scalp. This is referred to 
as the inverse problem [96]. Source analysis techniques have been developed to estimate the 
location and activity of the underlying ‘neural generators’ of the scalp EEG.  
 
Although there is theoretically no unique solution to the ‘inverse problem’, Low Resolution 
Electromagnetic Tomography (LORETA) was, and remains, a more commonly used technique 
[97]. LORETA’s popularity may have been aided by its ease of use (incorporated into a user-
friendly GUI interface) and it has been used on hundreds of scientific publications [98]. 
Unfortunately, perfunctory application and extension of this novel technique to compare 
clinical with control groups (for which the methodology was not fully developed) resulted in 
some inferential errors in at least eight studies. Work 4 alerted clinical researchers to this fact 
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and provided guidance on interpreting the results of LORETA in clinical research. The subtext 
of Work 4 is that perhaps at times, our hasty desire as researchers to explain (and simplify) 
observations of the brain’s complexity may be premature or even misguided. 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
John	D.	Cahill,	September	2017	
	 	 	 30	
PART	3)	THE	ENVIRONMENT:	Translating	Principles	of	Complexity	to	Clinical	Practice,	Services	
Development	and	Education	
3.1	Overview	of	published	work	
 
• WORK 5. The Endocannabinoid System and Schizophrenia: Links to the Underlying 
Pathophysiology and to Novel Treatment Approaches. [99] 
o Contribution: equal principal contribution to the concept, message and 
content of the paper 
 
• WORK 6. A Prescription for “Deprescribing” in Psychiatry [100] 
o Contribution: equally responsible for the ideas and concepts in the paper 
 
• WORK 7. Psychopharmacology Prescribing Workshops: A Novel Method for Teaching 
Psychiatry Residents How to Talk to Patients About Medications. [101] 
o Contribution: principal role in designing and disseminating this course and 
significant contribution to the text 
 
• WORK 8. Building Early Intervention Services for Psychotic Disorders: A Primer for Early 
Adopters in the US [102] 
o Contribution: helped developed model for building such a clinical service (as 
medical director of STEP clinic) and made significant contribution to the text 
3.2	Commentary	
 
Part 3 outlines an array of related efforts to translate the key ideas and inferences from the 
methodological, basic science and clinical research of Parts 1 and 2 into clinical practice via 
the development of new treatments, optimization of health services and dissemination of 
related perspectives and skills through novel pedagogy.  
 
Psychotic disorders, as complex problems within a complex system, warrant complex 
solutions. Sturmberg and Martin, 2013, suggest that one must work on multiple parts of the 
system and seek to influence it and not provide a unique solution [2]. Similarly, as discussed 
above, Glouberman and Zimmerman imply that one should neither be seeking a ‘simple 
recipe’, nor a ‘complicated set of procedures’, but rather a nuanced, optimistic, problem-
solving stance, tolerant of uncertainty and the dynamics of system – which they compare to 
raising a child well [3]. Petticrew, 2011 offers urban regeneration programs as an example of 
a complex public health intervention. These programs target health outcomes and reduce 
health inequalities via the socio-economic determinants of health via complex packages of 
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interacting ‘components’: such as employment, education, income, crime and housing 
interventions. Petticrew also notes that services research conducted from a complex 
orientation could assess; how and whether these components work individually and together, 
interactions between multiple health and non-health outcomes, as well as the process by 
which these components bring about change [103]. 
3.2.1	Identifying	more	complex	pharmaco-therapeutic	targets	relevant	to	psychosis	(Work	5)	
 
“The Endocannabinoid System and Schizophrenia: Links to the Underlying Pathophysiology 
and to Novel Treatment Approaches” [99] [please see page 129] 
 
Despite the wide availability of conventional antipsychotics (sharing a common mechanism of 
blocking dopamine receptors) for over 50 years, psychotic disorders remain one of the most 
severe and difficult-to-treat psychiatric illnesses. While a range of alternative therapeutic 
targets, such as the glutamatergic system, have attracted attention (for negative symptoms 
and cognitive dysfunction [104]), novel treatments for the core positive symptoms of 
schizophrenia remain lacking [105].  
 
The endocannabinoid system (ECS), despite being relevant to both the pathophysiology and 
treatment of psychotic disorders has been largely overlooked, and is differentiable from the 
dopamine neurotransmitter system as a brain homeostatic and neuromodulatory system. 
Cannabinoid-1 receptors are highly expressed in the brain regions implicated in the putative 
neural circuitry of schizophrenia, including the cerebral cortex, basal ganglia, hippocampus, 
anterior cingulate cortex, and cerebellum [106] where they interact with other key 
neurotransmitter systems implicated in psychosis: modulating presynaptic glutamate and 
GABA release [107] [108], enhancing dopaminergic function in the prefrontal cortex and 
hippocampus and inhibitory feedback on mesolimbic dopamine neurotransmission [109, 110]. 
Furthermore, given that psychotic episodes are commonly precipitated by stress and that 
schizophrenia has been hypothetically linked to disorders of lipid membranes, oxidative stress 
and more recently inflammation, it is noteworthy that endocannabinoids (e.g. anandamide) 
are increased in response to stress, possess intrinsic antioxidant properties, and are 
precursors of membrane lipids, leukotrienes, and prostaglandins. The endocannabinoid 
system is therefore ubiquitous, pleotropic and unique in its significant interplay with other 
major physiological systems [99, 111]. Framing it is as a complex system, contextualizes the 
uncertainty and contradictory results observed in the clinical literature examining the link 
between endocannabinoids and psychosis [83, 99].  
 
In keeping with the above principles of influencing change in complex systems the candidate 
contributes in Work 5 the argument that in designing novel treatments that target the 
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endocannabinoid system, consideration of the context and stage of illness is crucial. The 
candidate further proposes that working with naturally occurring compounds with similarly 
complex mechanisms of action, such as cannabidiol (a secondary psychoactive constituent of 
marijuana with uncertain, wide ranging effects) and anandamide (the brain’s principal 
endocannabinoid) may be a productive starting point. 
3.2.2	Promoting	principles	of	complexity	in	prescribing	whilst	minimizing	harm:	deprescribing	
(Work	6)	
 
“A Prescription for “Deprescribing” in Psychiatry” [100] [please see page 134] 
 
Despite uncertainties that continue to surround the mechanism of action of many 
psychotropics, in general, medications can be considered ‘simple’ interventions – they have 
predictable effects on a principal target (e.g. receptor). In contrast, the act of prescribing and 
maintaining a psychiatric medication regimen is a complex intervention – a multitude of 
interacting factors from biological (e.g. age and medication interactions), psychological 
(nocebo and placebo effect, psychodynamic meaning of the medication) and social (cost of 
medication, sources of environmental stress) may influence the ability for that prescription to 
mediate an impact on the target symptom or disorder. 
 
As discussed above, a nuanced, optimistic, problem-solving stance, tolerant of uncertainty 
and the dynamics of system is essential when offering a complex intervention. The candidate 
hypothesized that emergent driving forces arising from the complexity of patient-prescriber 
relationships (perhaps echoing the inherent complexity of the patients psychiatric disorder 
itself) could adversely influence therapeutic alliance and prescribing outcomes with a range of 
negative effects (for example excessive dosing, inappropriate medication choice, non-
adherence, irrational polypharmacy and nocebo effects). Many of these adverse effects may 
be symptomatic of a loss of nuance or inappropriate simplifications during the prescribing 
interaction (e.g. reduction to a linear or cursory transaction of symptom report and dose 
change). 
 
For example, a patient suffering from an acute exacerbation of a psychotic disorder attends 
outpatient clinic with a very chaotic and complex presentation - disorganization of thought, 
hallucinations, paranoia, delusions, dysregulated behavior and stressors in their social 
environment (such as estrangement from their family and homelessness). The disorientation 
and discomfort often felt by the patient can be easy transmitted to the provider when faced 
with such an overwhelming admixture of issues, complicating efforts to make a clinical 
assessment and implement a treatment (inevitably a complex intervention). The antipsychotic 
dose was immediately doubled with remission of symptoms of positive symptoms over the 
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next week and the psychiatrist feels relieved and that dose continued for months (to prevent 
further relapse). Unfortunately, the patient’s homelessness is not addressed, he feels 
disempowered, left out of the decision-making process surrounding the changes and he 
develops severe emotional flattening, cognitive dulling and bradykinesia attributable to side 
effects of increased antipsychotic dose (so called secondary negative symptoms) [112].  
 
When viewed within the ‘complex perspective’, the exacerbation of psychosis is associated 
with increased neural, clinical and environmental complexity (or noise) for the patient. Most 
effective treatments may be framed as being able to organize or quiet this noise in some 
fashion (e.g. providing respite housing could simplify the client’s social environment, or more 
judicious and collaborative dose titration). Unfortunately, in this vignette, the rapid and 
isolated dose increase perhaps represented a reactive oversimplification (an overzealous 
imposition of order) in the providers’ hope (unconscious or otherwise) of imposing simplicity 
on a highly complex clinical scenario, and therefore proved misguided. 
 
Due in part to limited durations of follow-up in efficacy trials of psychotropics, there remains a 
relative paucity of evidence for the effectiveness of open-ended continuation of many of these 
medications; moreover discontinuation studies have shown that there is a subset of patients 
that may not require continuous pharmacological treatment [113-115].  Despite this, even in 
the face of long-term side effects, psychotropic medications from all classes are continued 
unchanged for years, on the presumption of the initial risk/benefit calculation carried forward.  
Further, it has been observed that psychiatry is increasingly becoming a specialty in which 
polypharmacy has become the rule rather than an exception [116-118]. Prescriber 
discomfort, related to sitting with difficult patients, the prescriber’s own anxieties as well as 
uncertainties around risk, prognosis and therapeutic adequacy, if unchecked, could 
theoretically lead to the irrational and counter-therapeutic prescription of medications. 
Furthermore, fear of precipitating a relapse might encourage ‘inertia’ surrounding potential 
medication regimen reduction or discontinuation.   
 
Deprescribing has been previously defined (in the primary, palliative and geriatric medicine 
literatures) as the systematic process of identifying and discontinuing drugs in instances when 
existing or potential harms outweigh existing or potential benefits. It takes into account 
medical status, current level of functioning, patient values and preferences [119]. In doing so, 
the patient and prescriber recruits key providers (e.g. primary care provider, therapist and 
visiting nurse) and supports (e.g. peers, family and friends), in addition to expert consultants 
(e.g. pharmacist) to be involved in the process. Seeking to address irrational polypharmacy in 
additional to other potentially sub-optimal prescribing practices in psychiatry, Work 6 was 
significant as the first application of deprescribing to psychiatry and proposes some broad 
principles for clinical practice. The candidate’s unique contribution includes attention to the 
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‘complex perspective’ in designing this approach. Specific principles integrated include: sitting 
well with uncertainty, paying attention to dynamic changes in risk/benefit ratios (and also the 
patient-prescriber relationship), seeking to influence a client’s system of care holistically and 
comprehensively using multi-stakeholder/shared decision-making approach, remaining 
flexible and not insisting upon a unique solution. 
 
Figure 8. The 7 steps of deprescribing in psychiatry. Adapted from [100] 
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3.2.3	Teaching	complexity	in	prescribing	using	complex	pedagogy	(Work	7)	
 
“Psychopharmacology Prescribing Workshops: A Novel Method for Teaching Psychiatry 
Residents How to Talk to Patients About Medications” [101] [please see page 139] 
 
Work 7 tests the principle that in order to teach a complex intervention (i.e. prescribing) a 
complex pedagogy is warranted. The candidate’s contribution to Work 7 was as the principal 
designer of a novel course, classroom approach and curriculum for teaching physicians in 
advanced psychiatry specialty training (Yale Psychiatry Residency program). This course was 
developed at Yale University over 2 years before it was exported, implemented and tested at 
Columbia University, NY, USA.  
 
Traditional psychopharmacology curricula tend to rely on lecture-based presentation of core 
knowledge. However, there are several limitations to this approach. First, there is a large 
body of literature demonstrating that lectures are a relatively ineffective means of 
transmitting content to adult learners [120]. Second, the act of good prescribing requires 
more than acquired knowledge: psychiatrists must draw upon the confluence of 
communication skills, ethics, therapeutic process and professional identity. Lastly, the ability 
to recognize and process anxiety that is evoked by the experience of prescribing is vital to a 
trainee’s development [121, 122]. 
 
The key learning objective is that residents will be safe and effective prescribers of 
psychotropic agents. Instead of reviewing static material in a didactic format, classroom time 
was restructured so as to focus explicitly on behavioral proficiencies, influencing attitude and 
approach and allowing unique problem solving towards the central objective rather than 
enforcing a universal solution. To optimize active engagement with the material, each session 
incorporates self-directed learning (‘flipped classroom’), skills, role-play, peer feedback, group 
process and modeling of using the ‘complex perspective’ in prescribing by the facilitator.  
 
3.2.4	Implementing	and	disseminating	the	Coordinated	Specialty	Care	model	guided	by	the	
‘complex	perspective’	(Work	8)	
 
“Building Early Intervention Services for Psychotic Disorders: A Primer for Early Adopters in 
the US [102] [please see page 146] 
 
Recent changes in federal U.S. healthcare policy launched a national initiative towards 
specialty team-based models adapted to care for young individuals with recent onset 
psychosis. The RAISE (Recovery After an Initial Schizophrenia Episode) initiative, sponsored 
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by the NIMH (National Institute of Mental Health) [123] and the STEP clinic (Specialized 
Treatment Early in Psychosis) [124] helped define such Coordinated Specialty Care (CSC) 
services as a new benchmark for care across the U.S.. As the directorship of the STEP clinic, 
the authors of Work 8 were invited to offer guidance to early adopters and supplement 
resources with a focus on the process of setting up such programs. In doing so, this Work 
follows the principles of the complex perspective: not providing a unique solution to this task 
(such as a manualized approach) but seeking to engender and empower a flexible, optimistic 
problem-solving stance grounded by both guiding principles and a set of multi-stakeholder 
derived clinical benchmarks [125]. 
 
As medical director of the STEP clinic, the candidate’s specific contribution to Work 8 
surrounded multi-disciplinary and pluralistic clinical formulation and treatment planning, 
managing uncertainty in the medical workup, and psycho-socially informed medication 
management. Practically this translates into the clinical heuristics of: meeting a patient where 
they are, and working within their current frame of reference rather than attempting to 
impose order/enact a reactive oversimplification (e.g. countering a delusion or being inflexible 
around appointment times); striving for shared decision making around minimum effective 
dosing of antipsychotics (e.g. to avoid imposing medication compliance and precipitating side 
effects); simplifying medication regimens (e.g. monotherapy and increased use of long acting 
injectable antipsychotics), increased awareness and management of negative symptom 
syndromes and maintaining the patient in the minimally restrictive environment that safety 
allows (e.g. minimize hospitalization and advocate for ‘jail diversion’ when appropriate).  
 
As introduced above, it is proposed that reactive oversimplification in the face of a complex 
problem like psychosis can do harm on any level of the disorder: exclusion and stigma from 
family and friends, disempowerment by paternalistic care, secondary negative symptoms 
from medications, long-term hospitalization or even incarceration. All stakeholders might 
benefit from remaining mindful of this potential dynamic and seek balance when interfacing 
with an individual suffering from a psychotic disorder. 
Conclusions,	significance	and	future	directions:	
 
This thesis has attempted to outline a perspective on translational research in psychiatry, 
informed by concepts of complexity. Acknowledging the brain as a complex adaptive system 
and psychiatric syndromes (such as psychosis) as complex problems, underlines the need to 
design both research methodologies that account for this complexity, as well as complex 
interventions to positively influence clinical course. Specifically, sub-optimal outcomes 
(inferential, in context of research and clinical, in the context of care) may arise when 
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reactive oversimplification occurs in the face of attempting to sit with high levels of 
complexity in the field of psychiatry. The continued advancement and rigorous application of 
novel multi-modal methodologies, closely informed by a holistic understanding of the 
syndromes under investigation, are vital to the future of psychiatric research. The presented 
work links converging lines of evidence to suggest that the broad construct of complexity 
(with its several connotations) may be germane to psychotic disorders (and other psychiatric 
disorders) on the level of the neuron, person and environment. More empirical evidence is 
necessary to test this assertion. However until this evidence exists, complexity theory could 
guide the generation of hypothesis-driven research, as well as clinical thinking in psychiatry. 
If the principles of complexity science (as with any new methodologies) are to be successfully 
applied to psychiatry, rigor will be necessary.  
 
EEG measures of complexity may be more proximate to the core deficits in psychosis [15, 
79]. Related biomarkers may be further developed towards predicting and monitoring clinical 
decompensation as well as treatment response [126]. Human laboratory studies of 
psychotomimetic drugs in healthy humans have their role, in simplifying the 
phenomenological and patho-etiological complexity, which can frustrate the study of psychotic 
disorders in clinical populations. Broader multi-modal and multi-level study designs 
(combining biophysical signals, individual phenomenology and even population level 
outcomes), alongside data mining techniques, may help to further characterize the complexity 
within psychosis (and perhaps even help re-classify the clinical syndrome itself).  
 
Complex problems warrant complex interventions. These may include more nuanced 
approaches to drug development, prescribing, services design as well as clinical education of 
those providing these services. When attempting to care for individuals suffering from 
psychosis, all stakeholders would do well to remain mindful of the degree of complexity on 
multiple levels of the disorder and of any dynamics at play that might risk the unfavorable 
imposition of order. 
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Electrophysiological indices of abnormal
error-processing in adolescents with attention
deficit hyperactivity disorder (ADHD)
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Background: Impaired cognitive control has been frequently observed in children and young people
with attention deficit hyperactivity disorder (ADHD) and might underlie the excessive hyperactivity and
impulsivity in this population. We investigated behavioural and electrophysiological indices relevant to
one domain of cognitive control; namely error processing. Methods: Adolescents aged 14 to 17 with
ADHD (n = 23) and a typically developing control group (HC; n = 19) performed a visual go/no-go task.
Electro-encephalography (EEG) data were collected simultaneously and response-locked error trials
were averaged to derive two event-related potentials, the error-related negativity (ERN) and error posi-
tivity (Pe). Evoked theta power and inter-trial phase coherence (ITC) were measured in two time windows
(‘early’ and ‘late’) equivalent to those used for detection of the ERN and Pe. Results: Analysis revealed
normal ERN amplitude and a statistical trend for smaller Pe amplitude at a fronto-central electrode site
in the ADHD group. The group also showed significant reductions in late evoked theta power and early
and late theta ITC. Relationships between behavioural measures and ITC were different between groups,
particularly for post-error slowing, a measure of strategic response adjustment on trials immediately
following an error. Conclusions: The results reveal abnormalities in behavioural and electrophysio-
logical indices of error processing in adolescents with ADHD and suggest that ITC is more sensitive than
traditional ERP measures to error-processing abnormalities. Keywords: ADHD, electrophysiology,
ERN, cognitive control, adolescence.
Attention deficit hyperactivity disorder (ADHD)
is characterised by developmentally inappropriate
levels of hyperactivity, impulsivity and inattentive-
ness (APA, 1994). At the cognitive level, children with
ADHD show significant impairment in paradigms
such as the go/no-go task and stop signal task (SST)
in which inhibition of a prepotent or planned motor
response is required (Nigg, 2001; Willcutt, Doyle,
Nigg, Faraone, & Pennington, 2005). In addition to
increased error rates, which are taken as evidence of
failures in the inhibitory process, children with
ADHD show greater variability in response times and
are also less likely to slow their responses on trials
that immediately follow an error (post-error slowing)
(Schachar et al., 2004; Sergeant & van der Meere,
1988), indicating a more general impairment in
cognitive control, particularly response regulation.
Crucial to the successful performance of tasks that
require cognitive control, such as the go/no-go and
SST, is error monitoring. To perform well, partici-
pants must detect and evaluate errors as they arise
in order to make the necessary adjustments to their
response strategies both immediately and over the
course of the task. It is therefore important to
establish whether deficits in response inhibition and
in the adaptive control of response strategies in
ADHD are accompanied by abnormalities in error
monitoring.
Electrophysiology is the ideal approach for mea-
suring cognitive functions which are carried out
covertly, such as error monitoring. Two electro-
physiological markers of error processing, the error-
related negativity (ERN) and the error positivity (Pe),
are obtained by averaging response-locked segments
of electroencephalography (EEG) data on error trials.
The ERN is a fronto-central negative voltage deflec-
tion peaking within 100 milliseconds (ms) of an
erroneous response in forced choice reaction time
(RT) tasks and in tasks requiring inhibition of a
prepotent or ongoing response, such as the go/no-go
task and SST (Falkenstein, Hoormann, Christ, &
Hohnsbein, 2000; Gehring & Fencsik, 2001). The
ERN is followed by the Pe, a centro-parietal positive
deflection occurring between 200 and 500 ms after
an error. The ERN is hypothesised to reflect the
activation either of an error detection system which
responds in the event of a mismatch between the
intended and actual outcome of a response (Gehring,
Goss, Coles, Meyer, & Donchin, 1993; Holroyd &
Coles, 2002) or of a general conflict monitoring
system which increases activity when competition
between alternative response sets is high (Botvinick,
Nystrom, Fissell, Carter, & Cohen, 1999); errors
being one example of high response conflict.
Whereas the ERN is thought to be triggered relativelyConflict of interest statement: No conflicts declared.
Journal of Child Psychology and Psychiatry 51:1 (2010), pp 66–76 doi:10.1111/j.1469-7610.2009.02128.x
 2009 The Authors
Journal compilation  2009 Association for Child and Adolescent Mental Health.
Published by Blackwell Publishing, 9600 Garsington Road, Oxford OX4 2DQ, UK and 350 Main Street, Malden, MA 02148, USA
automatically, the Pe has been suggested to index
conscious response evaluation (Nieuwenhuis, Rid-
derinkhof, Blom, Band, & Kok, 2001; O’Connell
et al., 2007) and to be related to response adjust-
ment strategies such as post-error slowing (Hajcak,
McDonald, & Simons, 2003). Functional dissociation
of the ERN and Pe is supported by source-localisa-
tion studies seeding them to different regions of
anterior cingulate cortex (ACC) (Mathalon, Whitfield,
& Ford, 2003) and by developmental studies showing
that the ERN increases non-linearly throughout
childhood and adolescence whereas the Pe does not
differ in amplitude between children and adults
(Davies, Segalowitz, & Gavin, 2004; Ladouceur,
Dahl, & Carter, 2004; Santesso, Segalowitz, &
Schmidt, 2006; Wiersema, van der Meere, & Roe-
yers, 2007). Investigating behavioural and electro-
physiological indices of error monitoring in ADHD
will provide information as to which aspects of the
error monitoring system are deficient in this popu-
lation and how these abnormalities relate to deficits
in cognitive control at the behavioural level.
Research investigating the ERN and Pe in children
with ADHD has produced mixed results. Reduced
ERN amplitude was reported by one study using the
SST (Liotti, Pliszka, Perez, Kothmann, & Woldorff,
2005) and two others using the Eriksen Flanker task
(Albrecht et al., 2008; van Meel, Heslenfeld, Oos-
terlaan, & Sergeant, 2007). However, two studies
using the go/no-go task have found normal ERN
amplitude, reduced Pe amplitude and reduced post-
error slowing in children (Wiersema, van der Meere,
& Roeyers, 2005) and adults (Wiersema, van der
Meere, & Roeyers, 2009) with ADHD, indicating
intact automatic error detection (normal ERN
amplitude) with faulty error evaluation (reduced Pe
amplitude) resulting in a failure to adjust response
strategies following an error (lack of post-error
slowing). One study using the Eriksen Flanker task
reported normal ERN and reduced Pe amplitude in
children with ADHD but normal post-error slowing
(Jonkman, van Melis, Kemner, & Markus, 2007),
whereas another Flanker study found the opposite
profile (reduced ERN, normal Pe) (Albrecht et al.,
2008). A novel finding of enhanced ERN amplitude in
ADHD children compared with typically developing
controls has been reported (Burgio-Murphy et al.,
2007) and might be attributable to the use of a
simple task aimed at equating performance between
groups. Research to date therefore suggests that
abnormalities at either stage of error processing are
not reliably present in ADHD and may depend on
task design. The finding of normal ERN with reduced
Pe in adults with ADHD (Wiersema et al., 2009)
suggests that this profile may be a stable trait mar-
ker, present throughout the ADHD lifespan. How-
ever, considering the mixed results in this field,
further work is needed to replicate this finding and
also to determine whether this profile occurs in
adolescents with ADHD.
ERPs provide useful information about the tem-
poral aspects of cognitive processes but the averaged
waveform may include several overlapping subcom-
ponents, each with different phase and frequency
characteristics (Yordanova, Falkenstein, Hohnsbein,
& Kolev, 2004). In recent years, time-frequency
analysis of EEG data has become more prevalent,
revealing important information about frequency-
specific oscillations which are time- and phase-
locked to an event of interest and which are believed
to be crucial to the coordination of activity in differ-
ent brain regions (for a recent review of methods and
approaches, see Roach & Mathalon, 2008). Recent
research has shown that the ERN can be largely
accounted for by an increase in evoked (event-
related) theta power and inter-trial phase coherence
(ITC) following an error (Luu, Tucker, & Makeig,
2004; Trujillo & Allen, 2007; Yordanova et al., 2004).
In ADHD there is evidence of abnormal spontaneous
(non-evoked) neuronal oscillations in the form of
increased theta/beta ratio (reviewed in Barry,
Clarke, & Johnstone, 2003) and one study has
shown increased evoked theta power on target trials
in an auditory oddball task in children with ADHD
(Yordanova, Heinrich, Kolev, & Rothenberger, 2006).
It is unknown whether young people with ADHD
show abnormalities in error-related theta oscilla-
tions. Applying time-frequency analysis methods to
the investigation of error monitoring in ADHD may
help characterise the nature of abnormalities in this
population.
First, this study sought to investigate whether the
ERN/Pe abnormalities identified in children with
ADHD are also present in adolescents with ADHD.
Second, we included other electrophysiological
measures, evoked theta power and ITC, to determine
whether the ADHD group show abnormalities in the
phase and amplitude of oscillations in the theta
band. EEG data were collected from adolescents
aged 14 to 17 with a diagnosis of ADHD and a control
group of typically developing adolescents, while they
performed a go/no-go task. We predicted signifi-
cantly reduced ERN and Pe amplitudes and
decreased post-error slowing in the ADHD group. We
also predicted significantly less evoked theta power
and ITC in the ADHD group.
Method
Full ethical approval for the study was granted by the
Trent Multi-Centre Research Ethics Committee (MREC)
and by the Research and Development department of
Nottinghamshire Healthcare NHS Trust. Participants
were23adolescentswithADHD (ADHD) (21males,mean
age = 16.20 ± .28 years) and19healthy control subjects
(HC) (10males,meanage = 16.14 ± 2.03 years). All were
aged 14 to 17 years and were free from current
significant substance abuse and neurological disorder,
with IQ at least 70 on the Wechsler Abbreviated Scale of
Intelligence (WASI; Wechsler, 1999) (see Table 1 for
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mean IQ). Participants were provided with written
information and gave fully informed consent if aged
16 years or older; parental consent (with participant
assent) was obtained for those aged less than 16 years.
There were no significant differences between groups in
age (t(40) = .831, p > .1) or parental socio-economic
status, measured using the National Statistics for
Socio-Economic Classification (Statistics, 2004)
(v2 = 5.850, p > .1). The ADHD group had a significantly
higher male:female ratio than the HC group (v2 = 8.05,
p < .01).
The samples included in the present analysis were
drawn from a larger study comparing mental health,
cognitive function and brain activity in young people
with schizophrenia; their siblings; healthy adolescents
and adolescents with ADHD (see Groom et al., 2008). In
this analysis, we focus on the HC and ADHD groups to
enable a fuller exploration of error-processing abnor-
malities in adolescents with ADHD. Furthermore, be-
cause ERN amplitude has been shown to fluctuate
during adolescence and because the full HC and ADHD
groups in the main study differed significantly in mean
age, for the present analysis we selected participants
aged 14 to 17 years from the HC and ADHD groups.
This age range was chosen because only two partici-
pants in the ADHD group were older than 17 (1 aged 19;
1 aged 20) and the sub-sample was therefore not very
different, quantitatively or qualitatively, from the
original sample. Sample characteristics are described
below.
ADHD group
Forty-six young people aged 14 to 21 years with a
clinical diagnosis of ADHD were referred to the study
team by consultant psychiatrists and other healthcare
professionals. Of those contacted, 34 were willing to
take part and thorough psychiatric assessment was
conducted using the Parental Account of Childhood
Symptoms (PACS; Taylor, Schachar, & Hepstinall,
1993). This is a semi-structured interview conducted
with parents/carers of children who are showing signs
of ADHD. Parents are asked to rate the presence/
severity of each of a range of behaviours indicative of
the core symptoms of ADHD: hyperactivity, impulsivity,
inattentiveness. The information obtained from the
PACS interview, the Strengths and Difficulties Ques-
tionnaire (SDQ; Goodman, 1997) (completed by parents
and self-rated) and from the medical records of each
potential participant was reviewed by 3 psychiatrists
in a consensus diagnostic conference to determine
whether criteria for a DSM-IV diagnosis of ADHD com-
bined type (DSM-IV code: 314.01) were met and that
each case was free from other major psychiatric dis-
orders, except conduct disorder (CD) and oppositional
defiant disorder (ODD). All satisfied these criteria.
However, 3 with IQ less than 70 were excluded and 3
were excluded due to scoring greater than 22 on the
Social Communication Questionnaire (Rutter, 2003), a
threshold used to detect possible pervasive develop-
mental disorder. Contact was lost with 1 participant
and 2 did not complete ERP testing. For this analysis, 2
participants aged over 17 years were excluded, leaving
a sample of 23. All participants were receiving stimu-
lant medication which was withdrawn 24 hours before
testing.
Healthy control group (HC)
Healthy control participants aged 14–21 years were
recruited to the main study from local schools and
further education centres and from the University of
Nottingham, UK. Exclusion criteria were: score greater
than 5 on the hyperactivity-inattentiveness subscale of
the SDQ (parent- and self-rated); major psychiatric
disorder and/or family history of psychosis (assessed
using the Schedules for Clinical Assessment in Neuro-
psychiatry, Wing et al., 1990), reading/language dis-
order (assessed by self-report). Of an initial sample of
89 recruited to the main study, 12 were excluded
(6 above SDQ cut-off; 1 family history of psychosis;
2 reading/language disorder; 3 dyslexia), contact was
lost with 1 and 2 withdrew, leaving 74 potential
participants. Time constraints made it impractical to
test all participants; 36 individuals who provided a
pairwise match to the siblings of schizophrenia patients
recruited to the main study were selected. Of these 36
participants, 1 was unable to complete all ERP testing.
For this analysis 16 participants aged over 17 years
were excluded, leaving a final sample of 19.
Table 1 Group comparisons of clinical and behavioural measures
HC ADHD Group difference
SDQ Hyp-Inattentivea 1.25 (.25–3.75) 9.00 (7.00–10.00) z = 5.25**
SDQ Conduct problemsa 1.00 (.00–2.00) 6.00 (3.00–9.00) z = 4.80**
IQb 105.16 (13.33) 93.41 (12.86) t = 2.87**
Error rateb .56 (.17) .67 (.14) t = )2.116*
d-primeb 1.40 (.6) .69 (.45) t = 4.92**
Criterionb ).72 (.09) ).75 (.07) t = 1.86#
Hit RTb 327.58 (27.79) 336.76 (23.14) t = )1.33
Error RTb 296.22 (21.92) 296.08 (16.61) t = .03
Hit RT_SDb 73.91 (18.06) 93.39 (15.55) t = )3.67**
Post-error slowingb 21.32 (30.28) 22.86 (37.78) t = ).17
SDQ = Strengths & Difficulties Questionnaire; hyp-inattentive = hyperactivity-inattentiveness sub-scale of SDQ. # p < .1; * p < .05;
**p < .01.
aData are median (inter-quartile range). Group differences were tested using Wilcoxon independent-samples non-parametric test.
b Data are mean (standard deviation). Group differences were tested using independent-samples parametric t-test.
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Median scores on the SDQ hyperactivity-inattention
and conduct problems sub-scales of the SDQ are shown
in Table 1.
Go/no-go paradigm
The letters ‘X’ and ‘K’were presented onaflat-screenLCD
monitor. Stimulus duration was 250 ms and inter-
stimulus interval was randomly jittered between 1.5 and
2.5 seconds. The stimuli were 400 by 400 mm equating
to 3 by 3 degrees of visual angle. Participants were
instructed to press the ‘M’ key as quickly as possible
when the letter X (the frequent ‘go’ stimulus) appeared,
but to withhold the response if a letter K (the infrequent
‘no-go’ stimulus) appeared. Therewere 304 trials in total,
with 80% go trials. The task was split into 4 blocks of
2.5 minutes with a short rest period between blocks. To
ensure that participants developed a strong prepotent
response to the go stimulus, responses occurring later
than 450 ms after stimulus onset were followed by the
word ‘TIME’ appearing on-screen 900 ms after stimulus
onset. This served as a reminder to participants to
increase their response speed. This manipulation
ensured that the task challenged inhibitory processes
and produced sufficient numbers of error trials for
analysis. Group mean error rates indicate that this was
successful (see Table 1). The proportion of hits (correct
responses to go stimuli) and errors (responses to no-go
stimuli) were used to calculate d-prime (z (hit rate) – z
(error rate)) and Criterion (–.5*z(hit rate) + z(error rate)).
These indices provide information about the relation-
ships between hit rate and error rate which cannot be
obtained by considering each in isolation. D-prime is a
measureof target sensitivity (e.g., highvalues reflecthigh
hit rateand lowerror rate, indicatinghighsensitivity) and
Criterion represents response threshold (e.g., high
values reflect low hit and error rates, indicating a
cautious response style). Distributional differences
between hit rate and error rate are removed by trans-
forming each into Gaussian distributions (z-scores).
Post-error slowing was measured as the difference
between mean RT for hit trials following an error and hit
trials not following an error. Mean RT was measured on
go trials with response occurring within a 100–900 ms
time window (‘Hit RT’). RT variability was measured as
the inter-trial standard deviation of RT onHits trials (‘Hit
RT_SD’).
Electrophysiological recording
Voltage potentials were recorded at the scalp using 128
active silver/silver chloride (Ag/AgCl) electrodes (Active
II system, Biosemi, Amsterdam) positioned according
to the 10-5 system (Oostenveld & Praamstra, 2001).
Eye movements were recorded from flat, sintered Ag/
Ag-Cl electrodes placed adjacent to the outer canthus
of each eye and vertically, at the inner-orbital ridge
below each eye. Additional flat electrodes were placed
on the right and left mastoids and the tip of the nose.
The raw data were recorded using a referential mon-
tage with each electrode referenced to the Common
Mode Sense (CMS) located immediately to the left of
electrode Cz. Data were filtered at .1 to 100 Hz and
digitised at 256 Hz.
Electrophysiological data processing
Analysis was carried out using Brain Vision Analyser,
version 1.05 (Brain Products, Germany). Data were
re-referenced to the nose electrode and filtered with
Butterworth zero-phase filters at 1.0 and 20 Hz. Ocular
artefacts were corrected using the Gratton regression
method (Gratton, Coles, & Donchin, 1983); the left
vertical ocular reference channel and right frontal scalp
electrode were reference points. Further data processing
was conducted on error trials only, which were defined
as all no-go trials with a response occurring within a
0–700 ms time window. Data were corrected to a
pre-stimulus baseline ()500 to )200 ms) before removal
of epochs with amplitudes exceeding )90 and +90 lV
and derivation of response-locked epochs 1500 ms in
length with 500 ms preceding the response. One dataset
with only 5 trials available for averagewas excluded from
the ADHD group, leaving 22 datasets available for
analysis. The remaining participants all had 18 trials or
more per ERP average (HC group 32.42 ± 10.54; ADHD
group 36.27 ± 8.37; t(38) = )1.522, p > .1).
ERP analysis. Based on inspection of group average
ERPs (see Figure 1) the ERN was defined as the maxi-
mum negative peak within )50 to 100 ms of the re-
sponse. The Pe was defined as the maximum positive
peak within 100–350 ms of the response. The ERN was
measured at Fz, FCz and Cz and the Pe at FCz, Cz and
Pz on the basis of previous research (Falkenstein et al.,
2000) and because inspection of the data confirmed
this topography (see Figure 2). Peak amplitudes and
latencies were exported for analysis.
Analysis of evoked theta power and ITC. Calcula-
tion of evoked power and ITC was conducted in MatLab
usingEEGlab (Delorme&Makeig, 2004). Epochsof)500
to 1000 ms centred on response were decomposed using
320 overlapping discrete-windowed Fourier transforms
of 250 ms (zero-padded to 1000 ms) to give a frequency
resolution of 1 Hz and sampling rate of 3.91 ms. Further
analysis was restricted to the theta band (4–7 Hz).
Evoked activity was computed as the absolute power
(lV2) of the averaged time-domain signal across trials.
Inter-trial phase coherence (ITC), ameasureof thedegree
to which the phase of the evoked response aligns across
trials, independently of amplitude, was computed
(Delorme & Makeig, 2004). A value of 0 represents no
consistency in the phase of the evoked response across
trials; 1 represents perfect phase consistency. Two time
windows of )50 to 100 ms and 100 to 350 ms were
chosen to correspond to the windows used to detect the
ERN and Pe, respectively. Within these windows
mean evoked power and ITC were calculated for each
dataset. Evoked theta power measures were logarithm-
transformed (log10) to correct non-normal distribution.
The following indices were used in statistical analysis:
early evoked theta power (log); late evoked theta power
(log); early theta ITC; late theta ITC.
Statistical analysis
Behavioural data. Independent-samples t-tests were
conducted to compare the HC and ADHD groups on
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d-prime, Criterion, Hit RT, Hit RT_SD, Error RT, and
post-error slowing.
Electrophysiological data. Separate mixed-design
ANCOVAs with age as covariate were conducted on
each of the following measures: ERN latency; ERN
amplitude; Pe latency; Pe amplitude; early and late
evoked theta power; early and late theta ITC. Each
ANCOVA included 1 between-groups factor with two
levels (HC; ADHD) and 1 within-subjects factor,
Electrode with 3 levels: Fz, FCz, Cz for analysis of the
ERN, early evoked theta power and ITC; FCz, Cz, Pz
for analysis of the Pe, late evoked theta power
and ITC. Greenhouse–Geisser adjusted results are
reported where necessary. Significant main effects of
Electrode were followed with Helmert contrasts.
Group*Electrode interactions significant at p < .05
and trends towards significance (p = .05 to .1) were
explored further by investigating inter-electrode dif-
ferences within groups using repeated measures
ANOVA and by comparing the HC and ADHD groups
at each electrode site with univariate ANCOVAs.
Covariates: Age was covaried in all analyses to correct
for the lack of pairwise age-matching between groups
and because there were significant correlations between
age and several electrophysiological measures (Pe
amplitude, late evoked theta, late ITC) in the HC group
which were non-significant in the ADHD group. It was
not possible to control gender effects because there
were only 2 females in the ADHD group. However, there
were no significant effects of gender in the HC group
and removal of the 2 female ADHD participants did not
change the results. To test the effects of IQ and CD/
ODD symptoms on the results, all analyses were con-
ducted with and without IQ and scores on the ‘conduct
problems’ sub-scale of the SDQ included as additional
covariates with age. Results remained robust to inclu-
sion of IQ and other covariates and results are reported
without covariates.
Relationships between electrophysiology and
behaviour. Within-groups Pearson’s correlation
coefficients were calculated between each of the
Figure 2 Group scalp maps of ERN and Pe ampli-
tudes. The figure shows the topography of the ERN
(top panel) and Pe (bottom panel) in HC and ADHD
groups at the time points of maximal amplitude in the
HC group (35 ms for the ERN; 200 ms for the Pe). The
darkest shade represents maximum amplitude in
both plots; negative amplitude for the ERN and posi-
tive amplitude for the Pe. White represents ‘0 lV’ in
both plots
Figure 1 Group average waveforms at midline elec-
trode sites. Each plot shows amplitude on the y-axis in
microvolts (lV) and time in milliseconds (ms) on the
x-axis at the following midline electrode sites: Fz (fron-
tal); FCz (fronto-central); Cz (central); Pz (parietal).
Vertical dashed line indicates response-onset; the HC
group are shown by the thin line; the ADHD group by
the thick line
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behavioural variables (d-prime, Criterion, Hit RT, Hit
RT_SD, Error RT, post-error slowing) and theta ITC in
the early and late time windows at FCz, with age effects
controlled. Calculations were restricted to these ITC
variables to reduce the total number of correlations
computed and were conducted with age controlled to
prevent between-group differences in developmental
factors masking group differences in relationships be-
tween behaviour and ITC. Group differences in corre-
lation coefficients were examined by first applying the
Fisher z-transform to normalise each correlation coef-
ficient and calculating the z-score of the difference be-
tween the transformed correlations.
Results
Group comparisons of behavioural and
electrophysiological measures
Group comparisons of behavioural data are shown in
Table 1.
ERPs: Group averaged ERP waveforms are pre-
sented in Figure 1. Figure 2 presents scalp maps for
each group showing midline topography for both
components. ERP amplitudes and latencies, evoked
power and ITC are shown in Table 2. There were no
significant latency differences between groups; for
brevity the analysis is not presented.
For ERN amplitude, there was no significant effect
of Group (F(1,37) = 1.779, p > .1) or Group*Electrode
interaction (F(2,74) = 2.515, p > .1). Analysis of Pe
amplitude revealed a significant Group*Electrode
interaction (F(2,74) = 5.644, p = .006). This was
explored further by examining the main effect of
electrode within each group and by exploring group
differences at each electrode site. There was a signif-
icant effect of Electrode in the HC group only
(F(2,34) = 3.9, p = .03) with greater amplitude at Cz
than Pz (p = .02). Univariate ANCOVAs revealed a
trend towards a significant group effect at FCz only
(F(1,37) = 2.919, p = .096).
To determine whether the Group*Electrode inter-
action remained significant when overall amplitude
differences between groups were controlled, repeated
measures ANCOVA was conducted on vector nor-
malised (McCarthy & Wood, 1985) Pe amplitudes.
The interaction was significant (F(2,74) = 3.190,
p = .04).
Evoked theta power: Analysis of evoked theta in
the early time window revealed no significant main
effects or interactions (all p > .1) but in the late time
window there was a significant Group*Electrode
interaction (F(2,74) = 4.349, p = .018). Further
analysis revealed a significant effect of Electrode in
the ADHD group only (F(2,40) = 3.533, p = .04) with
greater amplitude at FCz than Cz and Pz combined
(p = .02). Univariate ANCOVA revealed greater power
in the HC group at FCz only (F(1,37 = 5.018,
p = .031).
Table 2 Descriptive data for electrophysiological measures
Latency Amplitude
HC ADHD HC ADHD
ERNa
Fz 36.19 (31.21) 25.48 (49.81) )1.77 (2.45) )1.85 (1.63)
FCz 32.32 (31.47) 31.93 (42.20) )2.68 (4.32) )1.62 (2.48)
Cz 33.11 (36.17) 43.48 (42.88) ).70 (4.42) ).02 (3.78)
Pea
FCz 200.12 (48.01) 207.03 (52.43) 10.56 (4.14) 7.86 (3.68)
Cz 194.22 (37.92) 215.63 (58.65) 11.55 (4.29) 9.67 (3.90)
Pz 191.44 (66.63) 209.69 (73.13) 9.52 (3.09) 8.66 (4.06)
Early evoked thetab
Fz – – 3.39 (.47) 3.28 (.41)
FCz – – 3.81 (.45) 3.52 (.38)
Cz – – 3.70 (.48) 3.60 (.32)
Late evoked thetab
FCz – – 3.93 (.36) 3.67 (.33)
Cz – – 3.88 (.37) 3.73 (.41)
Pz – – 3.53 (.36) 3.49 (.35)
Early theta ITCc
Fz – – .33 (.14) .28 (.09)
FCz – – .38 (.13) .28 (.11)
Cz – – .37 (.14) .29 (.11)
Late theta ITCc
FCz – – .45 (.18) .33 (.10)
Cz – – .45 (.18) .36 (.13)
Pz – – .34 (.15) .29 (.10)
aMean (SD) for ERN and Pe latency (ms) and amplitude (lV) at each relevant electrode site: Fz (frontal); FCz (fronto-central); Cz
(central); Pz (parietal).
bMean (SD) for the logarithm of evoked theta power (originally expressed as lV2) at each electrode.
cMean (SD) for inter-trial phase coherence (ITC) at each electrode.
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Theta ITC: Group*Electrode interactions were
found for early (F(2,74) = 7.485, p = .002) and late
(F(2,74) = 5.468, p = .012) theta ITC. Further anal-
ysis revealed significant effects of Electrode in the
HC group for early theta ITC (F(2,34) = 5.181,
p = .02) with lower ITC at Fz than Cz and FCz
combined (p = .03) and greater ITC at FCz than Cz
(p = .03) and in the ADHD group for late theta ITC
(F(2,40) = 3.491, p = .04) with greater ITC at FCz
than Cz and Pz combined (p = .003). Univariate
ANCOVAs comparing groups at each electrode
showed significant effects at Fz in the early time
window (F(1,37) = 10.901, p = .002) and at FCz in
the late time window (F(1,37) = 6.621, p = .014).
Relationships between behavioural measures and
ITC
Correlations between theta ITC at FCz and behavio-
ural measures, corrected for age, are presented in
Table 3.
Discussion
This study compared adolescents with ADHD and
typically developing controls on behavioural and
electrophysiological indices of error processing. The
ADHD group had significantly lower d-prime than the
control group but equivalent response speed and
equivalent post-error slowing, suggesting a failure to
adopt amore conservative response style despite poor
performance. The ADHD group also showed greater
RT variability on go trials, indicating moment-to-
moment fluctuations in attention. Analysis of ERN
and Pe amplitudes revealed no group differences or
group*electrode interactions for the ERN but a
group*electrode interaction for the Pe. Further anal-
ysis of the interaction revealed that Pe amplitude in
theHCgroupdiffered significantly between electrodes
(greatest amplitude at Cz) whereas inter-electrode
differences in the ADHD group were not statistically
significant. Additional analysis conducted on
normalised amplitudes confirmed topographical
differences between groups, although it should be
noted that this approach has limitations (Urbach &
Kutas, 2002). Simple main effects analysis on the
original (non-normalised) data also identified a trend
towards greater amplitude in the HC group than the
ADHD group at FCz, indicating a weak reduction
in Pe amplitude, but not ERN amplitude, in the
ADHD group. This conflicts with previous reports of
significantly reduced ERN in children with ADHD
(Albrecht et al., 2008; Liotti et al., 2005; van Meel
et al., 2007) but is consistent with findings of reduced
Pewith normal ERN (Jonkman et al., 2007;Wiersema
et al., 2005). The results provide tentative support for
previous work showing a profile of normal ERN with
smaller Pe in children (Wiersema et al., 2005) and
adults (Wiersema et al., 2009) with ADHD, suggesting
that the profile may be stable throughout develop-
ment, although further replication is needed. Current
hypotheses are that the Pe reflects subjective/
emotional evaluation of error commission (Falken-
stein et al., 2000; Nieuwenhuis et al., 2001;O’Connell
et al., 2007) suggesting that the reduced Pe identi-
fied here and in previous studies of ADHD reflects
a failure to process the emotional significance of
errors, possibly because as errors increase in fre-
quency, they become less salient (Falkenstein et al.,
2000).
Evoked theta power and ITC
Analysis revealed group*electrode interactions for
evoked theta power in the late time window and theta
ITC in both the early and late time windows. Again,
further exploration of these interactions indicated
topographical differences between groups and also
suggested that at fronto-central electrode sites, there
were group differences in late evoked theta power
and in early and late theta ITC with both indices
being significantly reduced in the ADHD group.
Previous research has shown that ERN amplitude
can be largely explained by evoked power and phase
coherence in the theta band (Luu et al., 2004; Truj-
illo & Allen, 2007). It therefore seems feasible to
suggest that error processing, as indexed by the ERN
and Pe, is, to some extent reflected by theta ITC in
Table 3 Correlations between theta ITC and behavioural measures
Early theta ITC at FCz Late theta ITC at FCz
HCa ADHDa zb HCa ADHDa zb
D-prime .50* .24 .90 .47* .19 .94
Criterion .20 .21 ).l8 .09 .02 .21
Hit RT .25 .24 .03 ).17 ).21 .12
Error RT .01 ).18 .57 ).29 ).37 .26
Hit RT_SD ).34 .11 )1.37# ).56* ).35 ).79
Post-error slowing ).44# .50* )3.01** ).13 .56** )2.25**
aPearson’s correlation coefficient calculated within HC or ADHD group with age controlled.
bOne-tailed z-score of the difference between the Fisher-transformed correlation coefficients.
#p < .1; *p < .05; **p < .01.
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the early and late time windows respectively, and
that these indices reveal impaired error processing in
ADHD, arising from less efficient coordination of
evoked brain activity. This is congruent with evi-
dence of increased inter-trial variability in ADHD
on behavioural (Castellanos et al., 2005; Johnson
et al., 2007) and neural (Lazzaro et al., 1997) mea-
sures. Perhaps because of this variability, ITC
appears more sensitive to abnormality in the ADHD
group than the evoked power and ERP amplitude
measures.
Relationships between behavioural measures and
ITC
The HC group showed significant correlations
between theta ITC, d-prime and RT variability,
indicating that better performance (greater d-prime,
low RT variability) was associated with greater
phasic consistency in the neural response to errors,
particularly in the late time window. Previous
research has suggested not only that the ERN and Pe
are generated by ACC (Mathalon et al., 2003) but
also that connections between ACC and pre-frontal
cortex (PFC) are important for guiding future
behaviour on the basis of current performance
(MacDonald, Cohen, Stenger, & Carter, 2000;
Ridderinkhof, van den Wildenberg, Segalowitz, &
Carter, 2004). Weaker error-related signals from
ACC to PFC arising from less consistent phasic
activation of the neural response might underlie the
poorer inhibitory performance (lower d-prime) of the
ADHD group and might account for the weaker,
non-significant correlations between d-prime and
ITC in this group. Another important finding is that
although there was no group difference in post-error
slowing, there were significant differences between
the groups in the correlation between this index and
ITC. In the HC group there were non-significant
negative correlations whereas in the ADHD group
there were significant positive correlations. This
suggests that ITC is related to different aspects of
performance in each group; to short-term adjust-
ments immediately following an error in the
ADHD group (post-error slowing) and to longer-
term, more global adjustments in response style
(d-prime, RT variability) in the HC group.
Further work is needed to investigate relationships
between behavioural and neural measures of error
monitoring.
Study limitations and implications for future
research
The sample sizes might have produced too little
power to detect subtle differences in ERN amplitude
between groups, although previous evidence of
normal ERN amplitude in children with ADHD
suggests that the finding is reliable. Secondly,
although analyses were conducted to ensure that
differences in gender ratio between the groups were
unlikely to influence the results, further research is
needed using gender-matched samples to ensure
that this is the case. The results are applicable to
DSM-IV ADHD combined subtype. It will also be
important to determine whether the profile identi-
fied here is generalisable to the ADHD inattentive
sub-type. Here, we were able to show that comor-
bidity with CD/ODD in the ADHD sample did not
affect the results.
The go/no-go task employed here included a
feedback signal on go trials when RT was longer
than a specified time limit. Although the primary
instruction given to participants was to be accurate
on no-go trials, it is possible that the feedback
signal decreased the motivational salience of no-go
trials by encouraging participants to focus on go
trials, potentially resulting in a smaller Pe. Given
that the groups did not differ in median go RT, this
is unlikely to account for the difference between
groups reported here, but may be an issue for
comparability with other studies which have not
used a speed instruction. The Pe identified in the
present study had a shorter mean latency and
slightly more fronto-central topography than is
typical, possibly because of the faster RTs of
participants. In fact, the discrepancy in results
between studies investigating ERN and Pe ampli-
tude in ADHD indicates that issues such as para-
digm design are likely to be important. For instance,
recent studies using error awareness paradigms
have described a frontal Pe occurring at around
100–150 ms (Endrass, Reuter, & Kathmann, 2007;
O’Connell et al., 2009, 2007) which is topographi-
cally and functionally dissociable from the classic
late Pe and which is reduced in adults with ADHD
(O’Connell et al., 2009). An important aim for future
research is to understand more fully the influence
of factors such as task design and varying motiva-
tional salience on electrophysiological measures of
error processing in ADHD; this will enable more
accurate interpretation of abnormalities in this
population and may help explain the discrepancy in
results between studies.
Conclusions
In conclusion, this study identified significant
abnormalities in electrophysiological measures of
error processing in adolescents with ADHD and
suggests that ITC is more sensitive than traditional
ERP measures to error-processing abnormalities.
These abnormalities may underlie the poor perfor-
mance typically found in this population when car-
rying out tasks requiring efficient error-monitoring
for successful performance such as the go/no-go
task employed here and may also underlie the
impulsive, error-prone behaviour observed clinically
in ADHD.
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Key points
• Deficits in cognitive control, including error monitoring, may be one factor underlying hyperactive and
impulsive behaviour in ADHD as young people with ADHD are less able to utilise performance feedback to
regulate ongoing behaviour.
• Understanding the neural basis of error monitoring deficits can give important clues to the underlying
physiology of ADHD.
• Abnormalities in electrophysiological indices of error processing, particularly increased variability in the
phasic neural response to errors (inter trial coherence; ITC), provide novel insights into the neural cor-
relates of these behavioural features.
• The work extends previous findings in children with ADHD to those in adolescence.
• The development of treatments that target deficient cognitive control, including error monitoring, in ADHD
might ameliorate some aspects of symptomatology in this population.
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INTRODUCTION
A drug, in the context of human laboratory studies (HLS), is said to be psychoto-
mimetic when its actions mimic signs and symptoms characteristic of psycho-
sis, namely perceptual abnormalities (illusions and hallucinations), delusional 
beliefs and feelings, disorganization of thoughts and speech, and altered percep-
tions of self (such as dissociation). In addition, drugs may produce effects that 
resemble negative psychotic symptoms (apathy, anhedonia, alogia, asociality, 
avolition). Finally, drugs may also impair several aspects of cognition (mem-
ory, attention, executive function). Psychosis may be viewed as a core cluster 
of deficits in a number of functional domains, notably perception, cognition, 
and reward, and is observable in a range of acute (e.g., substance induced) and 
chronic (e.g., schizophrenia) conditions. Each condition may possess a unique 
admixture of additional deficits, for example in schizophrenia, where further, 
specific cognitive, affective, and functional impairments may also manifest. In 
this way, psychotomimetic drugs simulate core elements of psychosis in the ab-
sence of some of these collateral deficits, rather than a complete clinical picture.
This chapter will first discuss the properties of Δ9-tetrahydrocannabinol
(THC) and related cannabinoids used in HLS alongside key considerations 
when designing and interpreting these studies. Second, it will outline the psy-
chotomimetic and cognitive effects in healthy humans and clinical populations 
that are relevant to schizophrenia, followed by factors that modulate those ef-
fects. Lastly, it will summarize biomarkers associated with these clinical effects 
with views toward future work (Fig. 1).
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DESIGNING AND INTERPRETING HLS OF 
CANNABINOIDS
Properties of Cannabinoid Formulations Used in Laboratory 
Studies
THC, the principal psychoactive constituent of cannabis, is a partial agonist of 
type 1 (CB1) and type 2 (CB2) cannabinoid receptors. Various formulations of 
THC and related cannabinoids have been used in HLS in the United States (US): 
oral Dronabinol (THC), oral Nabilone (Cesamet), smoked National Institute 
of Drug Abuse (NIDA) standard cigarettes, and intravenous (IV) THC. Oral 
Dronabinol (Marinol) (10 mg capsule) is a US Food and Drug Administration 
(FDA)-approved synthetic form of THC that is typically used to treat anorexia 
in AIDS (acquired immunodeficiency syndrome) (and other wasting diseases), 
emesis in cancer patients undergoing chemotherapy, and chronic pain. Similarly, 
the 9-trans-ketocannabinoid Nabilone (Cesamet), a synthetic analog of THC, is 
indicated in the US for the treatment of chemotherapy-induced nausea. Of signifi-
cance for investigators, these two oral agents are classed as schedule 3 (opposed 
to 1) substances due to their FDA-approved clinical indication, and thus have 
lesser regulatory requirements around use. NIDA manufactures and supplies stan-
dard cannabis cigarettes for medical research purposes in a range of THC poten-
cies and more recently, cannabidiol (CBD) content. IV THC can be formulated 
for research use under the purview of the FDA as an investigational new drug, 
and stored under a schedule 1 license with the Drug Enforcement Administration 
(DEA). However, with the legalization of cannabis for medical and recreational 
purposes in the US, some states are in the process of making it possible to conduct 
research with cannabinoids, circumventing the schedule 1 license.
A key consideration in designing HLS is whether the pharmacokinetic and 
pharmacodynamic properties of the cannabinoid provide an adequate time 
window of neuropharmacological activity during which measurements can 
be made to answer the research question of interest. As noted by numerous 
studies, herbal marijuana contains over 400 chemicals belonging to 18 differ-
ent classes (ElSohly et al., 2016; Mehmedic et al., 2010; Turner, Elsohly, & 
Boeren, 1980). The other lesser constituents that vary widely in concentration 
may have individual, interactive, or possibly entourage effects, which are not 
well understood and may confound the effects of the principle psychoactive 
FIG. 1 Chemical structure of THC.
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constituent, THC. The use of THC alone hence provides a more precise and 
controlled probe of the principal psychoactive effects of cannabis. However, it 
is important to recognize that THC may not accurately capture the full range of 
effects of herbal cannabis.
Another factor that determines the ecological validity of HLS is the degree 
to which the pharmacokinetic and pharmacodynamic properties of the admin-
istered THC parallel that of socially normative use. While smoking (and va-
porizing) cannabis remains the most common method of consumption, the use 
of “edibles” or oral cannabinoid preparations has been steadily increasing in 
recent years. Homemade cannabis products (e.g., brownies and “cannabutter”) 
are popular, and an array of commercial “edibles” including cannabis-infused 
drinks, candies, baked goods, and “dissolvables” (e.g., Cannastrips, Cannalixir) 
are widely available. Oral, IV, and vaporized cannabinoids have different phar-
macodynamic and pharmacokinetic properties that provide unique opportuni-
ties for HLS to capture more ecologically valid scenarios of cannabis use.
THC is metabolized primarily in the liver by the cytochrome P450 (CYP) 
enzymes CYP2C9, CYP2C19, and CYP3A (Watanabe, Matsunaga, Yamamoto, 
Funae, & Yoshimura, 1995; Watanabe, Yamaori, Funahashi, Kimura, & Yamamoto, 
2007). The primary metabolite, 11-hydroxy-delta-9-tetrahydrocannobinol 
(11-OH-THC), is at least as potent as THC, has a similar pharmacokinetic pro-
file, and is thought to contribute significantly to the effects of THC (Perez-Reyes, 
Timmons, Lipton, Davis, & Wall, 1972). 11-OH-THC is further metabolized into 
the inactive metabolite 11-nor-9-carboxy-tetrahydrocannobinol (THC-COOH). It 
is THC-COOH that is detected in urine drug tests. Tissue distribution of THC and 
its major metabolites is dependent on its high lipophilicity (Garrett & Hunt, 1974; 
Hunt & Jones, 1980), causing it to distribute readily into highly vascularized tis-
sue (Ho et al., 1970) and lipophilic tissue such as body fat (Garrett & Hunt, 1974; 
Johansson, Noren, Sjovall, & Halldin, 1989). THC also demonstrates significant 
plasma-protein binding (95%–99%) (Garrett & Hunt, 1974; Hunt & Jones, 1980). 
In plasma, low THC concentrations can be measured for extended periods af-
ter administration due to initial rapid redistribution and subsequent slow release 
(“reabsorption”) from fatty tissue into the bloodstream (Hunt & Jones, 1980; 
Leuschner, Harvey, Bullingham, & Paton, 1986; Ohlsson et al., 1982); however, 
whether this release is of pharmacological relevance is not clear. Several models 
for the pharmacokinetics of THC have been published in studies with humans af-
ter IV (Lemberger, Tamarkin, Axelrod, & Kopin, 1971), oral (Wall, Sadler, Brine, 
Taylor, & Perez-Reyes, 1983), and intrapulmonary administration via smoking 
(Chiang & Barnett, 1984; Cocchetto, Owens, Perez-Reyes, DiGuiseppi, & Miller, 
1981; Harder & Rietbrock, 1997) and using a vaporizer (Strougo et al., 2008).
Oral Administration
Orally consumed cannabinoids have a pharmacokinetic profile that is very 
different from inhaled or IV cannabinoids. The effects have a slower onset 
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of action but last much longer. Absorption is slower when cannabinoids are 
ingested, with lower, more-delayed peak THC concentrations (Agurell et  al., 
1986; Hampson, Grimaldi, Axelrod, & Wink, 1998; Harder & Rietbrock, 1997). 
Dose, route of administration, vehicle, and physiological factors such as absorp-
tion and rates of metabolism and excretion can influence drug concentrations in 
circulation. A high octanol/water partition coefficient (P) of THC (estimated to 
be between 6000 and > 9 × 106) is thought to be responsible for its high rate of
absorption. Perez-Reyes et al. examined the efficacy of five different vehicles 
(ethanol, sesame, glycocholate, emulsion of Tween-80, combination of ethanol 
and glycocholate) for oral administration of THC in gelatin capsules (Perez-
Reyes et al., 1973). They found that glycocholate and sesame oil improved bio-
availability although there was considerable variability in absorption and peak 
serum levels even within vehicles. Wall et al. have reported the bioavailability 
of oral THC to be 10%–20% (Wall et al., 1983). This complements a more ac-
curate assessment of the oral bioavailability of THC by Ohlsson et al. based on 
gas chromatography/mass spectroscopy (GC/MS) experiments (Ohlsson et al., 
1980). The peak THC concentration following ingestion of 20 mg of THC in a 
chocolate cookie occurred 1–5 h later and ranged from 4.4 to 11 ng/mL; the es-
timated oral bioavailability was 6%. Factors that may be responsible for the ob-
served pharmacokinetics include variability in absorption, degradation of THC 
in the stomach, and significant first-pass metabolism to active 11-OH-THC as 
well as inactive metabolites in the liver.
In a study of 17 volunteers, following oral administration of a single capsule 
of Dronabinol (containing 10 mg of THC), mean peak plasma concentrations 
obtained 1–2 h later were as follows: THC = 3.8 ng/mL (range 1.1–12.7 ng/mL), 
11-OH-THC = 3.4 ng/mL (range 1.2–5.6 ng/mL), and THC-COOH = 26 ng/mL 
(range 14–46 ng/mL) (Hampson et al., 1998). THC and 11-OH-THC concentra-
tions were comparable, while consistently higher THC-COOH concentrations 
were observed. Also, interestingly, two THC peaks were frequently observed, 
possibly due to enterohepatic circulation. Compared to the smoked route, fol-
lowing ingestion of Dronabinol the onset of effects is delayed, peak THC con-
centrations are lower, and duration of pharmacodynamic effects is generally 
prolonged (Hampson et al., 1998; Ohlsson et al., 1980; Perez-Reyes et al., 1973; 
Plasse et al., 1991; Wall et al., 1983). Oral Nabilone has also been specifically 
shown to have a delayed onset of action (1–2 h) and long duration of effects 
(8–12 h) (Lemberger & Rowe, 1975). There are significant implications for 
recreational use as well as study dosing protocols and procedures. With the 
inhaled route, the dose can be titrated in real time. In contrast, given the de-
layed onset and longer duration of effects when administered orally, little can be 
done to alleviate negative effects (e.g., panic or psychosis), once they emerge. 
Furthermore, since the duration of effects is longer with oral consumption, indi-
viduals who are not familiar with the effects of cannabis may feel overwhelmed. 
Moreover, the inability to titrate effects with oral consumption may contribute 
to a greater sense of loss of control.
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Intravenous Administration
The use of IV THC to probe the endocannabinoid system in the laboratory 
offers several advantages: it standardizes drug delivery and minimizes inter- 
and intraindividual variability in plasma THC levels, has rapid onset of action 
(10–15 min), and has a predictable peak (30–60 min), which enables research-
ers to capture time-locked psychophysiological measures relevant to the study. 
The pharmacokinetics of oral, inhaled (smoked), and IV cannabinoids were re-
viewed by Agurell et al. (1986) (Fig. 2). They reported that the plasma profiles 
of IV THC were comparable to those of smoked THC, although bioavailability 
was higher following smoking among heavy cannabis users versus light can-
nabis users. Ohlsson et al. compared the effects of oral, inhaled (smoked), and 
IV (5 mg over 2 min) THC in 11 healthy male volunteers. Compared to THC 
plasma levels after smoking and IV injection, THC plasma levels after oral 
doses were lower and irregular, indicating slow and erratic absorption (Ohlsson 
et al., 1980). As discussed, THC has low oral bioavailability due to degradation 
in the gut and extensive first-pass metabolism in the liver (Wall et al., 1983), 
which may account for these observations. Plasma levels of THC after smoking 
were similar to plasma levels after IV administration but were about 50% lower. 
Based on AUC0–360 min, systemic availability of THC after smoking and after 
oral administration were 18% ± 6% and 6% ± 3%, respectively. Wall et al. com-
pared the pharmacokinetics of IV and oral THC in male and female volunteers 
(Wall et al., 1983). They found no significant differences in dynamic activity, 
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FIG. 2 Comparison of plasma Δ9-tetrahydrocannabinol concentrations over time (in hours) fol-
lowing intravenous injection, smoking, and oral administration. Reprinted with permission from 
Agurell, S., Halldin, M., Lindgren, J. E., Ohlsson, A., Widman, M., Gillespie, H., et  al. (1986). 
Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with 
emphasis on man. Pharmacological Reviews, 38, 21–43 and originally adapted from Ohlsson, A., 
Lindgren, J. E., Wahlen, A., Agurell, S., Hollister, L. E., & Gillespie, H. K. (1980). Plasma delta-9 
tetrahydrocannabinol concentrations and clinical effects after oral and intra venous administration 
and smoking. Clinical Pharmacology and Therapeutics, 28, 409–416.
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 metabolism, excretion, and kinetics between the two groups; however, the ratio 
of the concentrations of 11-OH-Δ-9-THC to Δ-9-THC in plasma after IV dos-
ing was 1:10–20 versus 0.5–1:1 after oral dosing (Wall et al., 1983).
Smoking and Vaporization
Although smoking is a well-established route of administration, vaporization 
is a relatively new technology that allows for cannabinoids to be heated to a 
temperature below the point of combustion (which occurs at 230°C and above), 
where active cannabinoid vapors are rapidly formed while suppressing the pro-
duction of pyrolytic toxic compounds and eliminating the harmful effects of 
secondhand smoke. In a number of studies, the vaporization of cannabis sam-
ples was systematically tested to show its advantages over smoking. A variety 
of vaporization and smoking devices (including water pipes) used for canna-
bis consumption have been systematically studied. When compared with direct 
smoking of cannabis, only vaporizers were found to be capable of achieving 
reductions in tar intake (McPartland & Pruitt, 1997). Furthermore, prior studies 
have shown that cannabis vaporization is more efficient than burning the plant 
material, due to reduced THC degradation (Abrams et  al., 2007), and when 
compared to standard smoking, participants have shown preference for vapor-
ization (Fischedick, Van Der Kooy, & Verpoorte, 2010). One study evaluated the 
Volcano vaporizer to test the variability of vaporizing parameters with respect 
to using pure cannabinoid preparations (THC and tetrahydrocannabinolic acid 
(THCA) diluted as ethanolic solutions) and cannabis plant material (200 mg at 
12% THCA) (Hazekamp, Ruhaak, Zuurman, van Gerven, & Verpoorte, 2006). 
Their findings indicated that the vaporization of the cannabis plant material 
resulted in a maximum THC delivery of 29%, while the vaporization of pure 
THC resulted in a maximum THC delivery of about 53.9%, at a temperature of 
226 ± 5°C. In addition, their results indicated that 30%–40% of inhaled THC
was not absorbed by the lungs. In light of these findings, the difference in THC 
delivery yield between pure THC vaporization and cannabis plant material va-
porization must be taken into account while deciding on an inhaled THC dose. 
The vaporization of 0.45 g of NIDA cannabis plant material (at a THC concen-
tration of 1.7%) has been reported to produce a peak mean “high” effect of ~60, 
measured on a 0–100 visual analog scale (VAS) (Abrams et  al., 2007). This 
effect is comparable to the effects of 2 mg of IV THC, which was reported to 
produce a peak “high” effect of ~50, measured on a 0–100 VAS (Borg, Gershon, 
& Alpert, 1975).
The rate at which THC enters the brain largely determines its effects. Thus, 
for smoking and vaporizer studies, the administration of each puff cycle, includ-
ing the durations of inhalation, holding the smoke/vapor in lungs, and exhala-
tion, has to be standardized by using a cued puff procedure such as the “Foltin 
Puff Procedure” (Fischman, Foltin, & Brady, 1988; Foltin, Fischman, & Byrne, 
1988). In this procedure, participants are prompted to inhale for approximately 
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5 s, hold vapor in their lungs for approximately 10 s, and exhale and wait for ap-
proximately 45 s, after which the entire process is repeated.
A previous study comparing the administration of cannabis by vaporiza-
tion to standard cannabis smoking found that subjective effects and plasma 
THC concentrations were generally similar in both administration techniques 
(Abrams et al., 2007). Their results indicated that the self-reported “high” did 
not differ during vaporization compared to smoking overall (6-h AUC), or at 
any observation point after consumption of cannabis. Furthermore, their find-
ings indicated that the two modalities were not significantly different from one 
another at any of the three THC strengths (1.7%, 3.4%, and 6.8%) in the 6-h 
area under the plasma THC concentration-time curve (AUC), or for the peak 
THC plasma concentration measured at 2 min (Abrams et al., 2007).
Safety and Tolerability
The unpleasant psychoactive effects of THC include anxiety, panic, paranoia, 
and rarely, psychosis; all of these may be extremely distressing. However, the 
extent to which THC effects are perceived as unpleasant is context-dependent 
and can be reduced by preparing individuals in advance for the possible effects 
of THC. The acute physical effects of THC include motor incoordination, trem-
ulousness, muscle weakness, hypo or hypertension, tachycardia, conjunctival 
injection, dry mouth, and increased appetite, which generally resolve spontane-
ously (Carbuto et al., 2012b). The estimated lethal dose of THC is 30 mg/kg 
(2100 mg in a 70-kg individual), which is several thousand times the amount of 
THC in a standard cannabis joint. It should be noted that no fatalities have been 
reported with cannabis overdose.
THC has been administered in very large oral doses (50–712 mg) and mod-
est IV doses (1–10 mg) to cannabis users without any serious adverse events 
(Hollister, 1986). D'Souza et al. have conducted a series of studies with vary-
ing doses of THC (1.75–5 mg) administered over varying times (2–20 min) to 
several groups of subjects (n > 400) including cannabis users, nonusers, and pa-
tients with schizophrenia (D'Souza et al., 2005), and have shown that it was safe 
and well tolerated (Ranganathan & D'Souza, 2006b).
There are no major differences between the type of unpleasant behavioral 
and acute physical effects induced by IV THC, smoked cannabis, and oral 
Dronabinol. Hypotension may be more likely to be observed with IV THC 
(D'Souza: unpublished observations). However, as discussed earlier, the slower 
onset and longer duration of effects of oral THC may have implications if ad-
verse effects are experienced during a study.
The majority of the studies that make up the existing literature on the ef-
fects of cannabis consumption use standard smoking as their drug administra-
tion method, which exposes subjects to a variety of toxins produced by the 
combustion of the cannabis plant material. Previous studies that investigated the 
smoke harm reduction associated with vaporization of cannabis showed that the 
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vaporizers produced qualitative reduction in carbon monoxide and particulates, 
and complete elimination of benzene, toluene, and naphthalene, which are three 
toxic hydrocarbons produced by standard cannabis smoking. Another study that 
investigated vaporization as a smokeless means of delivery of inhaled Cannabis 
sativa reported no adverse events and indicated that vaporization of cannabis 
is a safe and effective mode of delivery of cannabinoids (Abrams et al., 2007).
Many recent studies that have investigated the administration of vaporized 
THC point to the conclusion that vaporized THC administration may be a safer 
method, producing cognitive and psychotropic effects similar to oral and IV 
THC, with no adverse events reported. In terms of somatic effects produced 
by vaporization, previous studies using THC dissolved in an ethanolic solution 
reported side effects such as slight irritation of the throat and upper respira-
tory tract as well as mild coughing (Hazekamp et al., 2006; Naef, Russmann, 
Petersen-Felix, & Brenneisen, 2004). These side effects were reversible within 
30 min of finishing the inhalation. One study found that these complaints were 
also observed during inhalation of placebo and were attributed to effects of re-
sidual ethanol. No serious adverse events were reported.
HLS in clinical populations have been controversial due to theoretical safety 
concerns and ethical considerations. However, it has been demonstrated that 
the administration of THC in laboratory contexts induces symptoms only tran-
siently and has no effect on the participants' desire to use cannabis for up to a 
year after study participation (Carbuto et  al., 2012a). One study reported an 
event of hospitalization for exacerbation of hypertension, which the subject 
failed to disclose at the time of screening. As with healthy controls, nausea and 
dizziness were the common minor side effects at the higher end of IV dosing. 
Study participation did not impact the course of illness or cannabis use in pa-
tients with schizophrenia in a 6-month follow-up study (Carbuto et al., 2012a).
Some Considerations on Study Design
Multiple lines of evidence have indicated a role for the endocannabinoid system 
in the pathophysiology of schizophrenia (Bossong, Jansma, Bhattacharyya, & 
Ramsey, 2014; Gupta, Cahill, Ranganathan, & Correll, 2014). Therefore, in addi-
tion to inducing nonphysiological states in healthy individuals, laboratory-based 
THC challenge studies can be used to probe abnormalities in the endocannabinoid 
systems of individuals with schizophrenia in order to identify markers of disease. 
Further, conducting similar studies in individuals at genetic risk for disease but 
without psychosis may help elucidate pathophysiology without confounds such 
as collateral effects of the illness and the presence of antipsychotic medications. 
THC challenge studies in individuals with different degrees of genetic and clini-
cal risk also form a paradigm for probing gene–gene interaction related to the 
role of cannabis in the pathophysiology of schizophrenia. THC challenges in 
individuals with a genetic diathesis for psychosis may also serve as a test for 
the extent of their vulnerability for psychosis and may assist in identification 
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of at-risk individuals who might benefit from early interventions to prevent the 
development of schizophrenia (Gupta, Ranganathan, & D'Souza, 2016b).
It is recognized that individuals with psychotic disorders and comorbid can-
nabis use disorder have a significantly worse prognosis than those with psychotic 
disorders alone (Swendsen, Ben-Zeev, & Granholm, 2011). Their cannabis use 
leads to symptom exacerbation (Buckley, Miller, Lehrer, & Castle, 2009), an 
increased likelihood of psychotic relapse, and an overall worse global function-
ing (Zammit et  al., 2008). However, subjective reports from some psychotic 
individuals who use cannabis indicate that they experience a relief of symptoms 
when they use cannabis (Schofield et  al., 2006). Further, a small case series 
of the use of dronabinol in the treatment of schizophrenia has indicated some 
efficacy (Schwarcz, Karajgi, & McCarthy, 2009). In the situation where subjec-
tive reports contradict large-scale empirical data, a controlled laboratory-based 
measurement of the effects of THC on individuals with psychosis is of immense 
value. Studies of the effects of THC in schizophrenia have helped clarify these 
contradictory findings. Further, these challenge studies can serve as a paradigm 
to test specific treatments for comorbid cannabis use and schizophrenia, target-
ing either the cognitive or the subjective euphoric effects of cannabis (similar to 
the use of naltrexone in alcohol or opioid dependence).
The acute administration of cannabinoids in tightly controlled laboratory 
settings allows for both a clearer inference of causality of effects and a more 
detailed characterization of those effects. In the laboratory, the high variabil-
ity in cannabinoid content (specifically THC and CBD) of street cannabis 
products available and the manner and route of consumption (greatly affect-
ing bioavailability) can be controlled, facilitating more precise delineation 
of dose-response relationships. Similarly, the biological, psychological, and 
the social context of cannabinoid administration can be better described and 
controlled through a careful selection and characterization of subjects, the en-
forcement of study restrictions, and the rigorous standardization of the study 
environment and procedures. Furthermore, given recent evidence questioning 
the validity of self-reported cannabinoid effects, HLS allow for the ongoing in-
vestigation of a potential dissociation between subjective and objective effects. 
Lastly, although HLS have direct inferential value in studying the nature of 
acute,  intoxication-related cannabinoid-induced psychosis, the degree to which 
psychotomimesis reflects any other type of clinical psychosis remains subject to 
debate. Nevertheless, the induction of these transient psychosis-like (and cogni-
tive) effects in healthy controls allows for the isolation of “state” (opposed to 
“trait”) features and biomarkers that are, at the very least, phenomenologically 
relevant to psychosis. This differentiation of state and trait may further facilitate 
the discovery of potential overlaps in the seemingly heterogeneous pathoetiolo-
gies of psychotic states.
HLS with cannabinoids are not without limitations. Tight inclusion and ex-
clusion criteria, operationalized cannabinoid administration, and the inevitable 
influence of the laboratory environment on effects experienced constrain the 
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generalizability and/or limit the interpretation of this type of study. Subjects 
may self-select due to past positive or negative associations with cannabis and/
or laboratory-based research in general. Most notably, those who have expe-
rienced past adverse effects from cannabinoids may be unlikely to volunteer 
for such studies. Despite providing a useful laboratory model of psychosis in 
humans, HLS using cannabinoids are unlikely to ever adequately replicate the 
full range of deficits observed in psychotic disorders and therefore can provide 
only a restricted, though penetrating, view. They remain a vital complement to 
epidemiological and other more ecologically valid study designs.
EFFECTS OF Δ9-TETRAHYDROCANNABINOL IN HUMAN
LABORATORY STUDIES
Effects in Healthy Individuals
Experimental studies have shown that the acute effects of cannabinoids re-
semble, in an attenuated way, some core phenomenology of psychosis and 
schizophrenia; these effects have been captured using standardized scales 
such as the Positive and Negative Symptom Scale for Schizophrenia (PANSS) 
(Fig.  3), Clinician Administered Dissociative Symptoms Scale (CADSS), 
Psychotomimetic States Inventory (PSI), and the Brief Psychiatric Rating Scale 
(BPRS). These psychotomimetic effects include positive- and disorganization-
like symptoms such as suspiciousness, paranoid and grandiose delusions, 
perceptual alterations, conceptual disorganization, and fragmented thinking. 
Furthermore, they also include negative-like symptoms such as blunted affect, 
reduced rapport, emotional withdrawal, psychomotor retardation, and lack of 
spontaneity (D'Souza et  al., 2004; Kleinloog et  al., 2012b; Liem-Moolenaar 
et al., 2010; Morrison & Stone, 2011; Morrison et al., 2009), which are not an 
effect of the sedating and cataleptic effects of THC (Morrison & Stone, 2011). 
In addition, cannabinoids have been shown to induce dissociative symptoms 
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such as depersonalization, derealization, altered body perception, feelings of 
unreality, and extreme slowing of time (D'Souza et al., 2004; Kleinloog et al., 
2012b; Liem-Moolenaar et al., 2010; Morrison & Stone, 2011; Morrison et al., 
2009). Table 1, adapted from D'Souza 2004, illustrates the quality of a range of 
psychotomimetic symptoms expressed on a retrospective report of peak THC 
effects (D'Souza et al., 2004).
More than 50 HLS have been published since the 1970s featuring THC as 
the predominant interventional agent, as summarized in Table 2.
The types of psychotomimetic effects of cannabinoids have been shown to be 
consistent across a range of doses and routes of administration, such as smoked 
cannabis, oral cannabis extract/THC (5–20 mg), IV THC (~0.015–0.06 mg/kg), 
and inhaled vaporized THC (Bhattacharyya, Crippa, et al., 2012c; D'Souza et al., 
2004; Englund et al., 2013a; Kaufmann et al., 2010; Martin-Santos et al., 2012a; 
TABLE 1 The Quality of Psychotomimetic Effects Reported by Healthy 
Individuals Following Intravenous Infusion of 5 or 2.5 mg of THC as It Relates 
to Typical Signs and Symptoms of Schizophrenia
Subject Quote Symptom
I thought you could read my mind, that's why I didn't 
answer
Suspiciousness/paranoia
I thought you all were trying to trick me by changing 
the rules of the tests to make me fail
I could hear someone on typing on the computer… 
and I thoughts you all were trying to program me
I thought you all were giving me THC through the BP 
machines and the sheets
I couldn't keep track of my thoughts… they'd suddenly 
disappear
Formal thought disorder
It seemed as if all the questions were coming to me at 
once… everything was happening in staccato
My thoughts were fragmented… the past, present and 
future all seemed to be happening at once
I felt I could see into the future… I thoughts I was God Grandiosity
The AC that I couldn't hear before suddenly became 
deafening
Perceptual abnormalities
I thought I could hear the dripping of the iv and it was 
louder than your voice
Reprinted with permission from D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., 
Wu, Y. T., et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in 
healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29, 1558–1572.
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Morrison & Stone, 2011; Morrison et al., 2009). However, the intensity of ef-
fects has also been shown to be dose dependent and to have distinct time courses 
depending on the route of administration (D'Souza et al., 2004; Kleinloog et al., 
2012b; Liem-Moolenaar et al., 2010; Morrison & Stone, 2011; Morrison et al., 
2009).
In a first study of its kind, D'Souza et al. (2004) administered two doses of 
IV THC (2.5 and 5 mg) to healthy adults using a double-blind, randomized, 
placebo-controlled, crossover design (D'Souza et al., 2004). The study found 
that THC induced perceptual alterations, a wide range of psychotomimetic 
symptoms, mood symptoms such as euphoria and anxiety, and cognitive deficits 
affecting attention and working and verbal memory. These findings were first 
replicated by Morrison et al. (2009) using a lower dose of IV THC (2.5 mg), and 
then by a number of researchers using a range of doses (1.25–3.5 mg) and infu-
sion times (10–20 min) (Bhattacharyya et al., 2009, 2010, 2015; Bhattacharyya, 
Crippa, et  al., 2012d; D'Souza, Braley, et  al., 2008; D'Souza et  al., 2012a; 
Freeman et al., 2015).
Nabilone, a synthetic analog of THC (Leweke, Schneider, Radwan, Schmidt, 
& Emrich, 2000; Leweke, Schneider, Thies, Munte, & Emrich, 1999), and 
Dronabinol, a synthetic isomer of THC (Koethe et al., 2006), have been shown 
to share a similar profile of effects with THC. In addition, in healthy controls, 
they have been found to induce deficits in the binocular depth inversion illusion 
task, a potential surrogate marker for psychosis present in patients with acute 
paranoid schizophrenia and schizophreniform psychosis (Koethe et al., 2006; 
Leweke et al., 1999, 2000).
As summarized in Table 2, in healthy humans, cannabinoids have also been 
shown to acutely induce a range of transient, dose-related deficits in cognitive 
processes, such as verbal learning, short-term memory, working memory, ex-
ecutive function, abstract thinking, decision-making, and attention (Hart, van 
Gorp, Haney, Foltin, & Fischman, 2001; Heishman, Huestis, Henningfield, & 
Cone, 1990; Hooker & Jones, 1987; Leweke et al., 1998; Marks & MacAvoy, 
1989; Miller, McFarland, Cornett, & Brightwell, 1977; Ranganathan & D'Souza, 
2006a). These findings have been consistent with the acute effects of cannabi-
noids observed in nonhuman primates and rodents (for a review, see Lichtman, 
Varvel, & Martin, 2002; Wilson & Nicoll, 2002). Importantly, the profile of cog-
nitive deficits induced by cannabinoids is similar to that observed in schizophre-
nia (Heinrichs & Zakzanis, 1998): in both cases, working and verbal memory 
are the most affected domains (Heinrichs & Zakzanis, 1998; Ranganathan & 
D'Souza, 2006a).
Although a number of studies have shown that THC consistently induces 
acute deficits in working memory, deficits are not consistent across different 
tasks. For instance, while THC has been shown to increase reaction time and 
disrupt performance on the Sternberg and N-back tasks (Bocker et  al., 2010, 
Hunault et  al., 2009; Ilan, Gevins, Coleman, ElSohly, & de Wit, 2004, 2005; 
Ilan, Smith, & Gevins, 2004), the effects on digit span and delayed match to 
The Complex Connection between Cannabis and Schizophrenia
sample tasks have been mixed (Ballard & de Wit, 2011; D'Souza et al., 2004; 
D'Souza, Ranganathan, et al., 2008c; Morrison et al., 2009) and no effects have 
been detected on the serial sevens task (Curran, Brignell, Fletcher, Middleton, 
& Henry, 2002). Regarding verbal memory, THC has been shown to induce ro-
bust dose-dependent deficits in verbal learning and recall as measured by the 
Hopkins Verbal Learning Test (HVLT): THC disrupted both immediate and de-
layed (30 min) verbal recall (Fig. 4), and increased the number of “false positive” 
and “intrusion” responses (D'Souza et al., 2004, 2005; Morrison et al., 2009).
Finally, abnormalities in time perception that have been reported in schizo-
phrenia (Carroll, O'Donnell, Shekhar, & Hetrick, 2009; Davalos, Kisley, & 
Ross, 2003; Tysk, 1983) are reproduced in healthy people under the acute ef-
fect of cannabinoids (Hicks, Gualtieri, Mayo, & Perez-Reyes, 1984; Mathew, 
Wilson, Turkington, & Coleman, 1998; McDonald, Schleifer, Richards, & 
de Wit, 2003a; Sewell et  al., 2013b; Stone et  al., 2010; Tinklenberg, Kopell, 
Melges, & Hollister, 1972). In the largest experimental study to date, Sewell 
et al. (2013a, 2013b) showed that different doses of THC acutely induce time 
overestimation and underproduction in healthy people (Sewell et al., 2013b). 
This is consistent with studies in nonhuman primates and rodents, which have 
also found that cannabinoids acutely induce deficits in time perception (Conrad, 
Elsmore, & Sodetz, 1972; Han & Robinson, 2001; McClure & McMillan, 1997; 
Schulze et al., 1988).
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FIG.  4 Effects of THC on learning, immediate free recall, delayed free recall, delayed 
cued and recognition recall in healthy individuals, measured by a 12-word learning task 
(Hopkins Verbal Learning Test). Reprinted with permission from D'Souza, D. C., Perry, E., 
MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y. T., et al. (2004). The psychotomimetic effects 
of intravenous delta-9- tetrahydrocannabinol in healthy individuals: Implications for psychosis. 
Neuropsychopharmacology, 29, 1558–1572.
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Effects in Individuals With Schizophrenia
Psychopharmacological challenge studies in clinical populations such as indi-
viduals with psychosis, cannabis use disorders, and a genetic risk for psycho-
sis have been carried out using a variety of pharmacological stimuli including 
ketamine (Lahti, Koffel, LaPorte, & Tamminga, 1995), amphetamine (Laruelle 
et  al., 1996), methylphenidate (Lieberman et  al., 1984), and THC (D’Souza 
et al., 2005). Such studies have the potential to elucidate the complex involve-
ment of individual neurotransmitter systems in the pathophysiology of various 
psychotic symptoms and substance use disorders and develop paradigms for 
testing treatments. However, perhaps due to theoretical safety and tolerability 
concerns, in addition to important ethical considerations, these studies are less 
numerous. Most of the HLS using cannabinoids in clinical populations are sub-
sequently summarized in detail.
D'Souza 2005 (D'Souza et al., 2005): This was a 3-day, double-blind, ran-
domized, placebo-controlled study, in which the behavioral and cognitive 
effects of 0 mg (placebo) and two active doses (2.5 and 5 mg IV THC) were 
characterized in 13 stable, antipsychotic-treated schizophrenia patients. Out of 
the 13 subjects, 10 were on typical antipsychotics (haloperidol and fluphen-
azine) and three were on atypical antipsychotics (risperidone and olanzapine). 
Behavioral outcomes included the PANSS and showed that THC transiently 
increased scores of the positive symptoms subscale (dose × time F (4,68) = 4.90, 
P < 0.0016) (Fig.  2). The positive symptoms induced by THC were not new
symptoms, but symptoms previously endorsed by the subjects. On the negative 
subscale, THC transiently increased the scores with a significant effect of dose.
Overall this study showed that THC caused a transient increase in positive 
and negative symptoms, and worsened cognitive deficits in clinically stable pa-
tients with schizophrenia who were treated with antipsychotic drugs. Compared 
with matched controls, schizophrenia patients were more vulnerable to the 
 psychosis-increasing and memory-impairing effects of THC. There were no 
serious short- or long-term adverse events associated with study participation, 
other than a case of exacerbation of hypertension that a subject failed to disclose 
at the time of screening. Furthermore, that THC did not reduce any of the core 
symptoms of schizophrenia raised questions about the commonly held view of 
a “self-medication” hypothesis of cannabis use and schizophrenia.
Henquet 2006 (Henquet et al., 2006a): Henquet et al. hypothesized that psy-
chometric psychosis (measured by the Community Assessment of Psychotic 
Experiences or CAPE) and functional polymorphisms of the Catechol-O-
Methyltransferase (COMT) gene (Val-Val/Val-Met/Met-Met) represented two 
different mechanisms impacting the same final common pathway of developing 
psychosis after cannabis exposure. To replicate and extend this finding, they 
conducted a double-blind, placebo-controlled crossover design in which pa-
tients with a psychotic disorder (n = 30), relatives of patients with a psychotic 
disorder (n = 12), and healthy controls (n = 32) were exposed to THC or placebo 
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cigarettes, followed by cognitive assessment and assessment of current psy-
chotic experiences. In the 30 patients, lifetime diagnoses were: schizophrenia 
(n = 11), schizoaffective disorder (n = 11), and psychosis not otherwise specified 
(n = 8). Twenty-two patients were using antipsychotic medication at the time 
of testing and eight were medication-free or used medication other than anti-
psychotic medication. Within the relatives group, three subjects had a lifetime 
diagnosis of bipolar disorder and one major depressive disorder. The COMT 
genotype distribution in the whole sample was 26% (Met/Met), 27% (Val/Val), 
and 47% (Val/Met).
On behavioral outcomes as measured by the PANSS, THC was not associ-
ated with a significant increase in positive symptoms, and no significant 
 condition-by-genotype interaction was observed on the psychotic symptom 
outcome. However, there was a significant three-way condition-by-genotype-by-
CAPE-trait interaction, which indicated that preexisting psychosis liability influ-
enced the genetic moderation of THC-induced expression of psychosis. Thus, there 
was a significant condition-by-genotype interaction in the high CAPE-trait group.
On the Dutch visual verbal learning test, THC impaired verbal memory per-
formance on immediate and delayed free recall as well as on delayed recognition. 
On the delayed recognition task, THC exposure caused significant impairment 
in subjects with the Val/Val genotype. The two-way  condition-by-genotype in-
teraction suggested that the effect in the Val/Val genotype was greater than that 
in the Val/Met and Met/Met genotypes.
In brief, Henquet et  al. found that genetic predisposition and psychomet-
ric psychosis influenced the impact of THC on cognition and psychosis out-
comes. They also concluded that the functional polymorphism of the COMT 
gene moderated sensitivity to the effects of THC on psychotic symptoms and 
that the differential sensitivity to THC associated with COMT genotype was in 
part conditional on additional evidence of psychosis liability (Val carriers with 
higher psychometric psychosis liability experienced more THC-induced tran-
sient psychotic symptoms compared with Val carriers without these additional 
measures of liability). This conditionality on additional psychometric psychosis 
liability was less evident for the cognitive measures.
Effects in Cannabis Users
Ramaekers 2009 (Ramaekers, Kauert, Theunissen, Toennes, & Moeller, 2009): 
This study tested whether heavy cannabis users developed tolerance to the 
 cognition-impairing effects of THC. To test this, 24 subjects (12 occasional can-
nabis users and 12 heavy cannabis users) participated in a double-blind, placebo- 
controlled, two-way mixed model design. Both groups received single doses of 
placebo and 500 μg/kg THC by smoking. Performance tests included measures
of perceptual motor control (critical tracking task), dual task processing (di-
vided attention task), motor inhibition (stop signal task), and cognition (Tower 
of London). They found that THC-induced impairment of critical  tracking 
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performance only occurred in occasional cannabis users when compared with 
heavy users as indicated by a significant THC-by-cannabis use history inter-
action (P = 0.027). Performance in the divided attention task was significantly 
affected by THC, as indicated by increased tracking error (P = 0.013) and the 
number of control losses (P = 0.032) in the primary task and a decreased number 
of hits in the secondary task (P = 0.024). Again, the overall effect of THC was 
more prominent in occasional cannabis users compared with heavy users. In the 
stop signal task, stop reaction time was affected by THC-by-time after smoking 
and there was no influence of a previous cannabis use history. Performance on 
the Tower of London task was not affected by THC. Overall, these data indi-
cated that cannabis use history strongly determined the cognitive response to 
single doses of THC.
D'Souza et al. (2008a): In this 3-day, double-blind, randomized, placebo-
controlled study, the dose-related effects of 0, 2.5, and 5 mg IV THC were stud-
ied in 30 individuals who used cannabis about once weekly and were compared 
to 22 healthy controls. THC transiently increased (dose × time P < 0.0001) 
 clinician-rated perceptual alteration scores. Weekly users showed smaller THC-
induced increases in the perceptual alterations scores (group × dose × time 
P < 0.001), group × dose effect (P < 0.069), and group effect (P < 0.006). THC 
transiently increased psychosis (PANSS total scores) in both groups (dose × time 
P < 0.0001), but weekly users had smaller increases compared with healthy
controls (group × dose × time P < 0.0025). THC also transiently increased VAS
“high” scores in both groups (dose × time P < 0.0001), but there was no group
effect on this increase.
On cognitive measures, THC impaired immediate recall in both groups in a 
dose-related manner (P < 0.0001) with a significant group-by-dose interaction
(P < 0.03), with weekly users performing worse at baseline (placebo condition),
yet showing smaller THC-induced recall impairments than controls. THC im-
paired delayed recall in both groups with a significant group-by-dose interaction 
(P < 0.02), with weekly users showing smaller THC-induced recall impairments
than controls. On tasks of vigilance, THC increased omission and commission 
errors in both groups. While there was no group effect for both omission and 
commission errors, there was a significant group-by-dose interaction, such that 
the difference between 5 mg and placebo dose was significant in weekly users 
but not in controls. Overall, these data suggested that weekly users of cannabis 
are either inherently blunted and/or develop tolerance to their response to the 
psychotomimetic, perceptual altering, and amnestic effects of cannabinoids.
Kuepper et  al. (2013a): In this study, striatal dopamine release following 
smoked THC was measured using a single dynamic positron emission tomog-
raphy (PET) scanning session in nine healthy cannabis users (average risk of 
psychotic disorder), eight patients with psychotic disorder (high risk of psy-
chotic disorder), and seven unrelated first-degree relatives (intermediate risk of 
psychotic disorder). Compared with the control group, both patients and rela-
tives showed significant displacement of the ligand (F18Fallypride) in striatal 
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subregions, indicative of dopamine release. This was most pronounced in the 
caudate nucleus. Behavioral measures including visual analog ratings of “feel-
ing high,” “internal perception,” and “external perception” did not differ based 
on group (control, relatives, or patients).
Ranganathan et al. (2014): This study tested the effects of THC on individu-
als with a family history of alcoholism based on preclinical evidence suggesting 
that brain cannabinoid receptor function may mediate the effects of alcohol and 
risk for developing alcoholism. Thirty healthy subjects with varying degrees 
of family history of alcoholism were enrolled in this 3-day test study, during 
which they received 0.018 and 0.036 mg/kg of THC or placebo intravenously 
in a randomized, counterbalanced order under double-blind conditions. Greater 
degree of family history was correlated with greater “high” and perceptual al-
terations induced by THC, measured by a VAS and the CADSS, respectively. 
The interaction between THC dose and degree of family history on peak change 
in self-reported “high” was significant (P = 0.03). On the HVLT, THC signifi-
cantly reduced total immediate free recall and long delayed free recall in a dose-
dependent manner, but there was no effect of family history of alcoholism.
FACTORS MODULATING THE PSYCHOTOMIMETIC AND 
COGNITIVE EFFECTS OF Δ9-TETRAHYDROCANNABINOL
IN HLS
Gene-Drug Interactions
As mentioned above, cannabinoids have been shown to induce a number of 
transient schizophrenia-like effects in healthy people. The intensity of these ef-
fects varies across individuals with similar levels of exposure to cannabinoids. 
The effects can range from small perceptual alterations to transient episodes 
of frank paranoia or psychosis in a very small percentage of people. It is likely 
that some of these individual differences could be explained by genetic poly-
morphisms implicated in schizophrenia. In one of the first gene-by-environment 
studies, Caspi et al. demonstrated that a common polymorphism of the COMT 
gene, which encodes for an enzyme that plays an important role in the break-
down of dopamine in the prefrontal cortex (Papaleo et al., 2008), moderated the 
risk of schizophrenia in individuals exposed to cannabis (Caspi et al., 2005). 
The longstanding association between schizophrenia and alterations in the do-
paminergic system (Howes & Kapur, 2009) has led others to explore the rela-
tionship between the acute response to cannabinoids and genes involved in the 
transmission or metabolism of brain dopamine.
A common variant of the COMT gene is the Val158Met polymorphism 
(rs4680), in which a G/A base-pair substitution results in an amino acid change 
from valine (Val) to methionine (Met) at codon 158 (Lachman et  al., 1996). 
The rate of dopamine catabolism of the Val variant is up to 4 times the rate of 
the Met variant; thus, Val carriers have lower levels of extracellular dopamine 
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in the prefrontal cortex (Chen et al., 2004). It has been proposed that the Val 
variant confers an increased risk for schizophrenia in people exposed to can-
nabis during adolescence; however, a number of studies examining this issue 
have shown mixed results (Caspi et al., 2005; Kantrowitz et al., 2009; Pelayo-
Teran et  al., 2010; Zammit et  al., 2007). In a study assessing the interaction 
between the COMT polymorphism and acute effects of cannabinoids, Henquet 
et al. (2006a, 2006b, 2006c) found that in individuals having both one copy of 
the Val allele and high scores on a measure of psychosis liability, THC induced 
greater schizophrenia-like effects (Henquet et  al., 2006b). Furthermore, indi-
viduals with two copies of the Val allele had increased sensitivity to the acute 
effects of THC on cognition.
The Dopamine Transporter 1 gene (DAT1/SLC6A3) encodes the dopa-
mine transporter (DAT), a transmembrane transport protein that regulates the 
reuptake of dopamine from the synapse into the presynaptic terminal. In the 
striatum, the clearance of dopamine from the synapses is highly dependent 
on the DAT; thus, it has been argued that polymorphisms of the DAT1 gene 
may be involved in the high levels of striatal dopaminergic activity observed in 
some patients with schizophrenia. Concordantly, a polymorphism of the DAT1 
gene associated with higher striatal dopamine has been linked to schizophrenia 
(Talkowski et al., 2008).
The AKT1 gene encodes the protein kinase B, an integral component 
of the dopamine signaling cascade (Beaulieu, Gainetdinov, & Caron, 2007) 
that has been associated with schizophrenia (Emamian, Hall, Birnbaum, 
Karayiorgou, & Gogos, 2004; Thiselton et al., 2008). Regarding the association 
between DAT1 variations and the acute effect of cannabinoids, Bhattacharyya 
et al. showed that carriers of the 9-repeat allele of the DAT1 gene which were 
also G homozygotes of the rs1130233 SNP of the AKT1 gene had increased 
 schizophrenia-like symptoms in response to THC (Bhattacharyya, Atakan, 
et al., 2012b). Cannabinoids activate the AKT1 pathway via CB1 and CB2 recep-
tors, representing a potential mechanism for psychosis. However, Bhattacharya 
et al. found that the GG genotype (a single nucleotide polymorphism) of the 
AKT1 gene reduced sensitivity to the acute psychosis-inducing effects of THC. 
More recent large epidemiological studies have further implicated other poly-
morphisms of this gene in increased susceptibility for THC-induced psychosis, 
supporting the HLS.
Other genetic variation in AKT1 has been hypothesized to increase sensi-
tivity to the psychotomimetic effects of cannabis as well as confer increased 
risk for cannabis-associated psychotic disorders. This has been supported by 
case–control studies showing that a polymorphism of the AKT1 rs2494732 lo-
cus (C/C versus T/T) interacts with cannabis use to infer a greater likelihood 
of later developing a psychotic disorder (Di Forti et al., 2012) as well as worse 
performance in a continuous performance task in individuals with psychosis 
(van Winkel, van Beveren, Simons, & Genetic Risk and Outcome of Psychosis 
(GROUP) Investigators, 2011). Recently, using a hybrid naturalistic challenge 
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study design, Morgan, Freeman, Powell, and Curran (2016) studied the acute 
response to smoked cannabis in 442 healthy young cannabis users while intoxi-
cated with their own cannabis. They found that variation at the rs2494732 locus 
of the AKT1 gene predicted acute psychotomimetic response (as measured by 
total score on the PSI, (Mason, Morgan, Stefanovic, & Curran, 2008)), depen-
dence on the drug, and baseline schizotypy (Morgan et al., 2016). Another study 
indicates that a variant in the D2 receptor gene may also increase psychosis risk, 
and that the risk may be greater in carriers of both this variant and the AKT1 risk 
allele (Colizzi et al., 2015).
Interactions With Other Drugs
A further significant finding of HLS using THC is the dissociation between 
serum levels and peak clinical effects. Even following IV administration, sub-
jective effects can be delayed by 15 min. This might suggest that the psychoto-
mimetic effects of THC are downstream to its primary site of action—the CB1 
receptor. The ubiquitous nature and known neuromodulatory role of the en-
docannabinoid system suggests that THC induces its psychotomimetic effects 
via interactions with other neurotransmitter systems with more established 
links to schizophrenia.
Preclinical studies demonstrate that THC administration increases striatal 
dopamine, but human data are mixed. D2 receptor blockade (via single doses 
of olanzapine or haloperidol) attenuated the acute psychotomimetic effects of 
THC in healthy subjects in two (Kleinloog et al., 2012a) of the three HLS using 
this paradigm (D'Souza, Braley, et al., 2008). In individuals with schizophrenia, 
long-term antipsychotic use failed to protect them from the acute psychosis- 
exacerbating effects of THC (D'Souza et  al., 2005). Results of preclinical 
and human studies exploring the ability of THC to increase striatal dopamine 
(Barkus et al., 2011; Bossong et al., 2009; Kuepper et al., 2013b; Stokes, Mehta, 
Curran, Breen, & Grasby, 2009), as well as direct interactions between CB1 and 
D2 receptors (Glass & Felder, 1997; Munoz-Arenas et al., 2015), are similarly 
mixed. Pooling of two cohorts, in order to achieve higher power, a small but 
significant displacement of [11C]raclopride was observed in the ventral striatum 
after THC administration (Bossong et al., 2009), indicating increased endog-
enous dopamine activity at D2 receptors, but whether this small change can 
explain the psychotomimetic effects of THC is not clear.
Confirming a wealth of preclinical data indicating extensive interac-
tions between the endocannabinoid and GABAergic systems, Radhakrishnan 
et  al. showed that a pharmacologically induced GABA deficit (produced by 
Iomazenil—a GABA-A negative allosteric modulator) enhanced THC-induced 
psychotomimetic effects in healthy humans (Radhakrishnan et  al., 2015). 
Particularly prevalent in the cortex and hippocampus, the activation of CB1 re-
ceptors inhibits the release of GABA by cholecystokinin basket cells, leading 
to disruption of the cortical inhibitory/excitatory balance (Farkas et al., 2010). 
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This mechanism may have particular relevance to the connection between can-
nabis and schizophrenia (Sherif et al., 2016).
As the second most pharmacologically significant cannabinoid in cannabis, 
CBD has garnered increasing attention in both the scientific literature and popu-
lar press. Although its effects on the endocannabinoid system have not been fully 
elucidated, contrary to THC, it exhibits CB1 receptor antagonism/inverse ago-
nism and fatty acid amide hydrolase (FAAH) inhibition. This pattern of effects, 
alongside limited clinical evidence, has identified CBD as the potential natural 
modulator of effects of THC in cannabis (Leweke, 2007), prompting several 
HLS. Pretreatment with CBD has been shown to attenuate THC-induced psy-
chotomimetic effects, paranoia, and verbal memory impairment (Bhattacharyya 
et  al., 2015; Englund et  al., 2013b; Ilan et  al., 2005; Leweke et  al., 2000; 
Martin-Santos et al., 2012b). Head to head, THC produced increased psychotic 
symptoms and skin conductance responses during processing of fearful faces, 
whereas CBD produced a reduction in anxiety and decreased skin conductance 
(Fusar-Poli et al., 2009). Second, during functional magnetic resonance imaging 
(fMRI) tasks testing verbal recall, response inhibition, processing fearful faces, 
and auditory and visual processing, THC and CBD had divergent effects on 
blood-oxygen-level dependent (BOLD) response (Bhattacharyya et al., 2010; 
Borgwardt et al., 2008; Fusar-Poli et al., 2009).
PSYCHOPHYSIOLOGICAL MARKERS OF 
PSYCHOTOMIMETIC AND COGNITIVE EFFECTS OF Δ9-
TETRAHYDROCANNABINOL IN HUMAN LABORATORY 
STUDIES
Typical techniques of measuring the psychotomimetic and cognitive effects of 
THC in HLS involve rating scales and hence are limited by subjectivity on both 
the part of the participant and the rater. Biomarkers—neural correlates of these 
clinical effects—may provide a complementary set of objective measures. In 
HLS, the neural effects of cannabinoids have been primarily studied using elec-
troencephalography (EEG), which is one of the only noninvasive techniques 
capable of capturing neural activity in real time. In general terms, at the cel-
lular level, neural activity consists of controlled exchanges of ions between the 
intra- and extracellular spaces of neurons. These exchanges cause fluctuations 
in the extracellular electric potential fields, that, when summed together across 
large populations (hundreds of millions) of similarly oriented groups of neu-
rons (particularly pyramidal cells) (Niedermeyer & da Silva, 2005), produce 
electric potential fluctuations that can be measured at the scalp with an EEG. 
The strength of the resulting signals would depend on both the number of active 
pyramidal cells and the level of synchronization of the active neurons, given 
that desynchronized neurons would tend to cancel out by destructive interfer-
ence their individual contributions to the summed electric potential (Lachaux, 
Axmacher, Mormann, Halgren, & Crone, 2012).
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Brain functions such as attention, working memory, emotions, and language, 
rely on the integrity of both short-scale (within areas) and long-scale (between 
areas) neural networks (Bullmore & Sporns, 2009; Varela, Lachaux, Rodriguez, 
& Martinerie, 2001). By engaging their nodes in synchronous patterns of os-
cillatory electrical activity, neural networks integrate and process information 
(Singer, 1999). Thus, deficits affecting the generation of neural oscillations, the 
signal-to-noise ratio of the circuit, or the communication between nodes such as 
the ones observed in schizophrenia and under the acute effect of cannabinoids 
(Cortes-Briones, Cahill, et al., 2015b; Diez, Suazo, Casado, Martin-Loeches, & 
Molina, 2013; Díez et al., 2014; Higashima et al., 2007; Hinkley et al., 2011; 
Kubicki et  al., 2003, 2005; Lawrie et  al., 2002; Seok et  al., 2007; Uhlhaas, 
Haenschel, Nikolić, & Singer, 2008; Whitfield-Gabrieli et al., 2009, Winterer &
Weinberger, 2003; Winterer et al., 2000, 2004; Yang et al., 2014), likely under-
lie some of the disruptions in brain function (e.g., abnormal perceptual experi-
ences) observed in both cases.
It has been proposed that CB1 receptors located on the axon terminals of 
cholecystokinin (CCK)-expressing GABAergic interneurons in the cerebral 
cortex and hippocampus are part of a noise filter-like mechanism that enhances 
the signal-to-noise ratio of neural networks (Bartos & Elgueta, 2012; Csicsvari, 
Jamieson, Wise, & Buzsáki, 2003; Tukker, Fuentealba, Hartwich, Somogyi, & 
Klausberger, 2007). This mechanism relies on the physiologic, space-localized, 
on demand, brief activation of CB1 receptors by endocannabinoids released by 
active pyramidal cells. Thus, the nonphysiologic, global, long-lasting activa-
tion of CB1 receptors by exogenous cannabinoids such as THC could disrupt 
the CB1 receptor-mediated noise filter mechanism, reducing the signal-to-noise 
ratio of the system. This transient change in the dynamics of neural networks in-
duced by exogenous cannabinoids has been proposed to mimic some important 
aspects of the long-lasting abnormalities in the dynamics of neural networks 
present in schizophrenia (Cortes-Briones, Skosnik, et al., 2015; Cortes-Briones, 
Cahill, et al., 2015b).
Event-Related Potentials
Event-related potentials (ERPs) are transient changes in the electric potential (volt-
ages) recorded at the scalp with EEG in response and time-locked to the presenta-
tion of stimuli. Numerous ERPs have been studied, with each thought to correspond 
to varying aspects of neural processing (e.g., early sensory processing, attention, 
and language processing) (Luck & Kappenman, 2012). Depending on the specific 
kind of stimuli used to elicit them, ERPs have either a positive (denoted with a “P”) 
or a negative (denoted with an “N”) polarity that peaks at a specific poststimulus 
latency (e.g., 300 ms). This is reflected on the names of ERPs (e.g., N100 indicates 
a negative response peaking 100 ms after the onset of the stimuli).
The P300 is a positive voltage response peaking around 300 ms after stimu-
lus presentation, elicited by novel (P3a) and target deviant (P3b) stimuli (visual 
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or auditory) presented with a low probability (~10%–20% of all stimuli) within 
a sequence of repetitive, highly probable stimuli (~80%–90% of all stimuli). 
P300 is thought to be related to directed attention, contextual updating of work-
ing memory, and the attribution of salience to novel and deviant stimuli (Polich 
& Criado, 2006). P300, particularly the P3b component, is thought to result 
from the activity of a distributed neural network including the thalamus, hip-
pocampus, inferior parietal lobe, superior temporal gyrus, and frontal cortex 
(Kiehl, Laurens, Duty, Forster, & Liddle, 2001). Deficits in P300 amplitude and 
latency have been demonstrated in patients with schizophrenia (Bramon, Rabe-
Hesketh, Sham, Murray, & Frangou, 2004; Bramon et al., 2005; Jeon & Polich, 
2003; Solowij & Michie, 2007; Turetsky et al., 2007). Interestingly, studies have 
shown that both oral and smoked THC acutely reduces P300 amplitude (Ilan 
et  al., 2005; Roser et  al., 2008). P300 amplitude reductions have even been 
observed in heavy cannabis users after smoking THC, indicating that the acute 
deficits in P300 amplitude induced by THC may be resistant to the effects of tol-
erance (Theunissen et al., 2012). In a double-blind, placebo-controlled, counter-
balanced, and crossover study using IV administration of THC, D'Souza et al. 
(2012a, 2012b) demonstrated that both P3a and P3b amplitudes were disrupted 
by THC in a dose-dependent manner (D'Souza et  al., 2012b). These deficits 
were not observed during early sensory-related ERPs (N100), suggesting that 
THC-induced deficits are greater in late processes involving novelty, saliency, 
and working memory context updating. Furthermore, the reductions in P3b am-
plitude were correlated with the psychotomimetic effects of THC.
Mismatch negativity (MMN) is a negative voltage response peaking around 
100–200 ms after stimulus presentation, elicited by auditory stimuli that devi-
ate in frequency or duration from a sequence of standard auditory stimuli. It is 
thought to be an index of basic auditory processing and sensory memory that 
is relatively independent of attention. Its neural sources have been localized in 
the superior temporal and prefrontal cortex (Naatanen & Alho, 1995; Rinne, 
Alho, Ilmoniemi, Virtanen, & Naatanen, 2000), which is consistent with an in-
dex of early auditory processing. Regarding the acute effect of cannabinoids on 
MMN, Juckel, Roser, Nadulski, Stadelmann, and Gallinat (2007) examined the 
effects of oral THC and THC plus CBD. They found that oral THC had no effect 
on MMN amplitude compared to placebo (Juckel et  al., 2007). Interestingly, 
THC + CBD was found to increase the amplitude of the MMN, which the au-
thors interpreted as a result of the antipsychotic effects of CBD. The lack of 
effect on MMN amplitude with THC alone could be related to the low dose of 
THC chosen (10 mg orally), or due to the inter- and intraindividual variability 
associated with oral routes of administration.
Neural Oscillations: Steady-State Response
Reduced gamma-band (~40 Hz) auditory steady-state response (ASSR) has 
been observed in first episode and chronic schizophrenia (Krishnan et al., 
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2009; Kwon et al., 1999; Light et al., 2006; Spencer, Salisbury, Shenton, & 
McCarley, 2008a). Furthermore, this deficit has been associated with some 
characteristic abnormalities of the disorder (e.g., positive symptoms and 
working memory deficits) (Light et al., 2006; Spencer, Salisbury, Shenton, 
& McCarley, 2008b). Cortical θ and γ oscillations are dependent on peri-
somatic inhibition of pyramidal neurons from basket cells expressing cho-
lecystokinin (CCK(b) cells) and parvalbumin [PV(b) cells], respectively. 
Alterations in basket cells may underlie the cortical oscillation deficits in 
schizophrenia. CB1 receptors are located at the terminals of CCK-containing 
GABAergic interneurons. In preclinical studies, cannabinoids have been 
shown to reduce γ oscillations in hippocampal slice preparations. Despite
these findings, so far there has been only one study examining the acute 
effects of cannabinoids on the ASSR and the relationship between these 
effects and the psychotomimetic effects of THC. In a double-blind, ran-
domized, crossover, and counterbalanced study in which subjects received 
IV THC (placebo, 0.015 and 0.03 mg/kg), Cortes-Briones, Skosnik, et  al. 
(2015), Cortes-Briones, Cahill, et  al. (2015a), and Cortes-Briones, Cahill, 
et al. (2015b) showed, for the first time in humans, that THC acutely disrupts 
gamma-band (40 Hz) oscillations using an ASSR paradigm (Cortes-Briones, 
Skosnik, et  al., 2015). Specifically, this study showed a dose-dependent 
reduction of intertrial coherence (ITC) (a measure of the consistency of 
the brain's response across trials) for 40 Hz stimulation. Furthermore, the 
authors showed that the higher dose of THC (0.03 mg/kg) reduced evoked 
power during 40 Hz stimulation at a trend level, and that the effects of THC 
on ITC and evoked power were reduced in subjects with a recent use of 
cannabis. No significant effects were found for the 20 or 30 Hz ASSRs, sug-
gesting a selective effect of cannabinoids on evoked gamma-band activity. 
Interestingly, an inverse relationship between ITC and the schizophrenia-
like effects of THC was found, suggesting that some of the psychotomimetic 
effects of cannabinoids may be related to their capacity to disrupt gamma-
band oscillations. Considering that ITC measures reflect the consistency 
(nonrandomness) of the brain's response to different occurrences (trials) of a 
stimulus/event, the authors hypothesized that these findings suggest that the 
schizophrenia-like effects of THC may be related to an increased variability 
(randomness) in the brain's response to stimulation.
Neural Noise
There is growing evidence supporting the idea that neural noise, that is, 
the randomness of neural activity, is increased in patients with schizophre-
nia (Diez et  al., 2013; Díez et  al., 2014; Winterer & Weinberger, 2003, 
Winterer et al., 2000, 2004). Several studies have shown increased trial-to-
trial (random) variability of evoked EEG responses in schizophrenia (Diez 
et  al., 2013; Díez et  al., 2014; Ford, White, Lim, & Pfefferbaum, 1994, 
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Winterer et al., 2000, 2004). Furthermore, nonlinear measures of uncertainty 
 (entropy) or randomness have shown increased randomness in the EEG and 
Magnetoencephalography (MEG) signals of patients with schizophrenia (Li 
et al., 2008; Takahashi et al., 2010; Fernández, Gómez, Hornero, & López-
Ibor, 2013), which are higher during periods of psychotic decompensation 
(Takahashi et al., 2010).
So far, only one study has investigated the effect of cannabinoids on neu-
ral noise in humans, and the relationship between this effect and behavior. In 
a recent study, Cortes-Briones et  al. used Lempel-Ziv complexity (LZC), a 
measure from information theory first developed to characterize the random-
ness of signals, to test the hypothesis that THC increases neural noise (Cortes-
Briones, Cahill, et  al., 2015a). Furthermore, they tested the hypothesis that 
there is a positive relationship between neural noise and the schizophrenia-
like effects of THC that is independent of the effect of THC on signal power. 
Using a double-blind, randomized, crossover, and counterbalanced design in 
which subjects received IV THC (placebo, 0.015 and 0.03 mg/kg), the authors 
measured LZC in the baseline period of an oddball task. The results showed 
that THC increased neural noise in a dose dependent manner, and that there 
was a strong positive relationship between neural noise and the psychosis-
like positive (β = 0.685) and disorganization (β = 0.754) symptoms induced 
by THC. Interestingly, no relationship between neural noise and negative-
like symptoms was found. Importantly, these relationships were independent 
of the changes in signal power induced by THC. Considering the idea that 
random noise can interfere with and distort the information circulating be-
tween the nodes of a network, the authors hypothesized that by increasing 
neural noise THC may be inducing a dysconnectivity (aberrant connections) 
(Stephan, Friston, & Frith, 2009) between the nodes of the brain's networks, 
and that this effect could be responsible for some of the psychotomimetic ef-
fects of THC.
Neuroreceptor Imaging
In addition to EEG, other neuroimaging modalities have been utilized to identify 
more proximate markers of the neural changes resulting from THC administra-
tion and, in some instances, correlated with the psychotomimetic and cognitive 
effects (summarized in Table 2).
The results of neuroreceptor imaging to study the ability of THC to in-
crease striatal dopamine (Barkus et al., 2011; Bossong et al., 2009; Kuepper 
et al., 2013b; Stokes et al., 2009) are mixed. Although there is some evidence 
of displacement of [11C]raclopride in the ventral striatum following THC ad-
ministration, the relationship with psychotomimetic effects has not been well 
established.
Kuepper et  al. studied striatal dopamine release following vaporized 
THC (8 mg) and placebo and showed that compared with healthy controls, 
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both patients and relatives of those with psychosis showed significant dis-
placement of the ligand ([F-18]fallypride) in striatal subregions, indicative 
of dopamine release with the biggest effect in the caudate nucleus (Kuepper 
et al., 2013a).
Functional Imaging
In a large study of cannabis users using PET and O15 H2O, Mathew et al. 
demonstrated an association between decreased cerebellar blood flow and 
THC-induced timing deficits (Mathew et  al., 1998). The effects of THC 
have also been studied using fMRI. THC and CBD appear to have oppos-
ing effects on BOLD signal (Bhattacharyya et  al., 2010; Winton-Brown 
et  al., 2011). Notably, a few studies show correlations between psychoto-
mimetic (but not yet cognitive) effects and perturbation in BOLD signal. 
Bhattacharya et al. reported an increased BOLD activation in the parahip-
pocampal gyrus and attenuation in the ventral striatum, correlated with psy-
chotomimetic symptoms (Bhattacharyya et  al., 2009). In a further study, 
attenuated task-related activation of the right caudate was inversely cor-
related with severity of symptoms. In a preliminary study, Bhattacharyya 
et al. have also suggested that, in individuals with specific polymorphisms 
of both the ATK1 and DAT1 genes, THC-induced psychotomimetic effects 
could be mediated by attenuation of activity in the striatum and midbrain 
(Bhattacharyya, Atakan, et al., 2012b).
As discussed earlier, cannabinoids produce robust impairments of learning 
and memory. Bhattacharyya et al. reported that oral THC (10 mg) altered me-
dial temporal activation during the encoding phase of a verbal paired associate 
learning task in healthy males (n = 15) (Bhattacharyya et al., 2009). THC also 
attenuated striatal activation during recall that was correlated with the positive 
symptoms of psychosis.
The effects of oral THC on response inhibition have been studied using a go/
no-go task (Bhattacharyya et al., 2015; Borgwardt et al., 2008). THC attenuated 
activation in the inferior frontal, anterior cingulate, and precuneal cortices, and 
augmented activation in the medial temporal cortex and caudate. Bhattacharrya 
et al. further reported that the effect of THC on inferior frontal activation cor-
related with the severity of the positive psychotic symptoms. Of note, patients 
with psychosis show altered striatal and prefrontal activation during inhibition 
tasks (Kaladjian et al., 2007; Rubia et al., 2001).
THC has also been reported to attenuate amygdalal, hippocampal, parietal, 
and prefrontal activation to fearful faces, and augment activation of these re-
gions to happy faces (Bossong et  al., 2013). THC has also been reported to 
reduce the amygdalal response to threat-related faces (Phan et al., 2008) and 
may increase functional connectivity between frontal regions and amygdalal 
subnuclei (Gorka et al., 2015).
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CONCLUSIONS
HLS using THC have reliably demonstrated an array of dose-dependent psy-
chotomimetic and cognitive effects in healthy humans, as well as in individu-
als with cannabis use disorder, increased risk of psychosis, and schizophrenia. 
Broadly, deficits are observed in domains most relevant to schizophrenia: posi-
tive, negative, dissociative, and disorganization cluster symptoms and impair-
ment in working and verbal memory. Laboratory models of psychosis may 
enrich our understanding of psychotic disorders such as schizophrenia, offer-
ing methodological advantages. The ability to extrapolate the results of HLS in 
healthy THC users to clinical psychosis is supported by the fact that these ef-
fects are intensified in individuals who are diagnosed with or at risk for schizo-
phrenia. A range of more proximate markers of neuronal function have been 
discovered, some highly associated with clinical effects. Genetic variations and 
the presence of other drugs may modulate the effects.
HLS have demonstrated value in the immediate study of acute, 
 intoxication-related, cannabis-induced psychosis, in addition to providing in-
sights into mechanisms underlying the shared phenomenology observed with 
schizophrenia. Already, for example, HLS comparing the interactive effects of 
THC and CBD have lent support for completed and ongoing clinical trials of the 
latter for schizophrenia. Furthermore, novel biomarkers of psychosis, designed 
and refined within laboratory settings, are being tested in clinical populations with 
great potential relevance for screening, prediction of relapse, and monitoring of 
treatment response. A further novel use of laboratory-based cannabinoid chal-
lenges as a neuropsychiatric “stress test” has been proposed (Gupta, Ranganathan, 
& D'Souza, 2016a). As a screening test, akin to cardiac stress testing for coronary 
ischemia, THC may be administered within safe, controlled parameters to those 
suspected to be at risk of schizophrenia in order to ascertain clinical or subclinical 
(e.g., electrophysiological) changes, further quantifying risk and informing the 
utility of new or established interventions for primary or secondary prevention.
HLS provide a vital complement to other study designs within the field by 
allowing for more controlled confirmation and elucidation of mechanisms and 
more direct inference of causality. The ecological relevance of the numerous 
HLS using oral THC is increasing as “edibles” grow in popularity. Responding 
to changing content of the cannabis available in society, HLS may need to fur-
ther explore higher doses of THC and the interactive effects of CBD. Similarly, 
HLS utilizing vaporized THC may become more prevalent. Capitalizing on es-
tablished genetic, electrophysiological, biochemical, and neuroimaging-based 
correlates of psychosis, multimodal HLS in healthy cannabis users (perhaps in 
concert with other psychotomimetic drugs and individuals with schizophrenia) 
may further illuminate the degree of overlap between laboratory models and 
clinical psychotic states. The cross pollination resulting from the continued clo-
sure of the gap between the laboratory and the clinic can only serve to propel 
the field forward.
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Key Chapter Points
●	 HLS using THC have reliably demonstrated a range of transient, dose-
dependent psychotomimetic and deleterious cognitive effects in healthy in-
dividuals, as well as in those with cannabis use disorder, increased risk of
psychosis, and schizophrenia.
●	 This type of study design complements more naturalistic or observational ap-
proaches by allowing for more controlled confirmation and elucidation of
mechanisms as well as more direct inference of causality.
●	 Psychophysiological correlates of THC-induced psychosis-like states have
been characterized, most notably in the EEG. These may have wider clinical
potential as biomarkers of psychosis.
●	 Genetic variations (in COMT, DAT1, and ATK1 genes) and the presence of
other drugs (such as haloperidol, iomazenil, and CBD) may modulate the
effects.
●	 Future priorities for HLS include the further exploration of higher doses of
THC, vaporized THC, and the interactive effects of CBD.
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ABSTRACT
BACKGROUND: Drugs that induce psychosis may do so by increasing the level of task-irrelevant random neural
activity or neural noise. Increased levels of neural noise have been demonstrated in psychotic disorders. We tested
the hypothesis that neural noise could also be involved in the psychotomimetic effects of delta-9-
tetrahydrocannabinol (Δ9-THC), the principal active constituent of cannabis.
METHODS: Neural noise was indexed by measuring the level of randomness in the electroencephalogram during the
prestimulus baseline period of an oddball task using Lempel-Ziv complexity, a nonlinear measure of signal
randomness. The acute, dose-related effects of Δ9-THC on Lempel-Ziv complexity and signal power were studied
in humans (n 5 24) who completed 3 test days during which they received intravenous Δ9-THC (placebo, .015 and
.03 mg/kg) in a double-blind, randomized, crossover, and counterbalanced design.
RESULTS: Δ9-THC increased neural noise in a dose-related manner. Furthermore, there was a strong positive
relationship between neural noise and the psychosis-like positive and disorganization symptoms induced by Δ9-
THC, which was independent of total signal power. Instead, there was no relationship between noise and negative-
like symptoms. In addition, Δ9-THC reduced total signal power during both active drug conditions compared with
placebo, but no relationship was detected between signal power and psychosis-like symptoms.
CONCLUSIONS: At doses that produced psychosis-like effects, Δ9-THC increased neural noise in humans in a
dose-dependent manner. Furthermore, increases in neural noise were related with increases in Δ9-THC-induced
psychosis-like symptoms but not negative-like symptoms. These ﬁndings suggest that increases in neural noise may
contribute to the psychotomimetic effects of Δ9-THC.
Keywords: Cannabinoids, Electroencephalogram, Neural noise, Nonlinear analysis, Psychosis, Tetrahydrocannabinol
http://dx.doi.org/10.1016/j.biopsych.2015.03.023
Complex mental processes such as perception, language,
emotion, and memory rely on the integrity of long-range
functional networks formed by ensembles of brain areas
(nodes) processing information in a coordinated manner
(1,2). Alterations in these networks and their information
processing capabilities may contribute to the emergence of
some core symptoms of psychosis such as hallucinations,
delusions, and thought disorganization. Consistent with this
view, converging lines of evidence from structural (diffusion
tensor imaging) and functional (functional magnetic resonance
imaging [fMRI], electroencephalogram [EEG], and magneto-
encephalogram [MEG]) studies have shown abnormal neural
connectivity in schizophrenia, which has been related to the
presence and intensity of psychotic symptoms (3–9).
Concepts used to characterize the functioning of real-world
complex networks (e.g., the internet) may provide valuable
insights into the abnormalities underlying some psychotic
symptoms. A network can be characterized as a set of
interconnected nodes that exchange and process information
in a coordinated manner. Information is transmitted from one
node to another through a medium (e.g., a cable) as part of a
signal (e.g., an electromagnetic wave), which is composed by
information and random noise. The latter is a sum of random
activity and interference caused by other signals travelling
through the same medium. According to information theory,
the upper limit of the total amount of undistorted (error-free)
information per unit of time that can be carried by a signal is
limited by: 1) the bandwidth (in Hz), 2) the total power, and 3) the
amount of random activity or noise of the signal (10–13). Thus,
keeping the bandwidth and the total power of a signal constant,
the higher the level of noise, the lower the amount of information
that can be carried by the signal without distortion. Increased
noise may, therefore, disrupt the coordinated activity between
nodes, resulting in the disruption of information processing.
There is growing evidence from EEG, MEG, and neuro-
imaging studies suggesting increased randomness/noise in
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the brain activity of schizophrenia patients (14–19). A number
of studies have shown increased intertrial (random) variability
in the latency and amplitude of evoked responses measured in
the EEG of schizophrenia patients (14,16–18,20). Furthermore,
measures developed to characterize the uncertainty (entropy)
or randomness of signals have revealed increased levels of
randomness in the EEG and MEG of schizophrenia patients
(21–23), which are higher during periods of exacerbation of
psychosis (22). While there may be limitations to the existing
EEG and MEG literature, recent fMRI data provide further
support to the hypothesis that noise is increased in schizo-
phrenia (19).
A number of drugs, including ketamine, delta-9-
tetrahydrocannabinol (Δ9-THC), psilocybin, and amphetamine,
have been used in the laboratory to study psychotic states
and to understand the contributions of neurotransmitter
systems to the pathophysiology of psychosis. The acute
administration of Δ9-THC, the primary psychoactive constitu-
ent in cannabis, and other agonists of brain cannabinoid
receptors (type 1 cannabinoid receptor [CB1R]) have been
shown to induce transient psychosis-like effects and psycho-
physiological abnormalities in healthy control subjects that
share some similarities to those observed in schizophrenia
[reviewed in (24–26)]. Furthermore, Δ9-THC has been shown to
increase psychotic symptoms transiently in stable schizophre-
nia patients (27). Studies in rats have shown that CB1R
agonists acutely reduce the spectral power of local ﬁeld
potential (LFP) oscillations in a number of frequency bands
within the hippocampus and entorhinal cortex (28,29). Impor-
tantly, this effect was not a consequence of a reduction in the
individual neurons’ activity but was related to an increase in
the randomness/noise (decrease in the synchronization) of the
neurons’ activity (28,29). Considering that, as mentioned
above, neural noise may be involved in the pathophysiology
and phenomenology of schizophrenia, these ﬁndings raise the
intriguing possibility that neural noise could also be involved in
the acute psychotomimetic effects of Δ9-THC and other CB1R
agonists. To our knowledge, no studies in humans have tested
this hypothesis.
Lempel-Ziv complexity (LZC) is a nonlinear measure ﬁrst
developed to characterize the level of randomness (30) or
noise of signals. It is a measure of the minimum number of
different terms (e.g., words) necessary to fully reconstruct a
signal (e.g., sentence) without losing information. Applying this
to EEG, LZC measures the minimum number of distinct
patterns of activity that are necessary to characterize the
behavior of a signal (Figure S1 in Supplement 1). The higher
the randomness of a signal (e.g., the volume of the back-
ground babble of a crowded room), the larger is the minimum
number of different terms (word fragments) necessary to
reconstruct the signal and hence, the higher is LZC. For
inﬁnite random signals, which lack regular recurrent terms
(e.g., white noise), the normalized value of LZC approaches 1,
while for inﬁnite regular (periodic) signals, it approaches 0
(31,32). LZC has been increasingly theoretically and empiri-
cally validated in the study of electrophysiological signals
[reviewed in (21,33–38)].
Traditional measures of neural noise used to study the EEG
and MEG of schizophrenia patients (14–18,39) have charac-
terized noise as brain responses that are not time-locked to
the stimuli in the context of time-locked paradigms (e.g.,
event-related potential). In this sense, neural noise refers to
the random variation of the brain’s response across the
different trials of a task (i.e., intertrial variability). Thus, this
conceptualization of noise provides information about the
capacity of the brain to produce consistent patterns of activity
in response to repeated presentations of a stimulus. In
contrast to these measures, LZC provides direct information
about the level of randomness of EEG signals (30), which
makes it especially suited for detecting cannabinoid-induced
changes in the randomness (noise) of the brain’s electrical
activity (28,29).
Until recently, brain activity during the baseline or presti-
mulation period received little attention. However, evidence
from both animals and humans suggests that this period plays
a key role in the brain’s response to tasks. The characteristics
(e.g., phase, randomness) of prestimulation brain activity are
known to modulate the electrical and behavioral responses to
tasks (40,41). More importantly, evidence for an interaction
between aberrant (increased) baseline brain activity and a
reduction of task-related poststimulus activity measured by
both EEG (14) and fMRI (42) has been observed in schizo-
phrenia patients. Furthermore, schizophrenia patients show
increased baseline activity, especially in the gamma band, and
an inverse relationship between prestimulation and poststi-
mulation gamma activity (43). These ﬁndings suggest that at
least part of the task-related abnormalities observed in
schizophrenia may be associated with the presence of aber-
rant brain activity during the prestimulation period.
This study was part of a larger project that aimed to assess
the dose-related effects of Δ9-THC on several electrophysio-
logical indices of information processing relevant to schizo-
phrenia [e.g., P300 (44), oscillations, and neural noise] and to
determine the relationship between the electrophysiological
and behavioral effects of Δ9-THC. Δ9-THC was hypothesized
to increase neural noise (LZC) during the prestimulation period
of an oddball task and psychosis-like effects. Furthermore, we
hypothesized that there would be a positive relationship
between neural noise and the psychosis-like effects induced
by Δ9-THC and that this relationship would be independent of
changes in signal power.
METHODS AND MATERIALS
A complete description of subjects, regulatory approvals, and
general study procedures is included in Supplement 1 (see
text and Table S1 in Supplement 1). In brief, in this 3 test day,
randomized, double-blind, placebo-controlled, crossover
study, subjects received Δ9-THC (vehicle [ethanol], .015 mg/
kg or .03 mg/kg) over 10minutes by intravenous route. The
sample included subjects with and without recent cannabis
exposure (within the last 30 days) and excluded cannabis-
naïve and cannabis-dependent subjects.
EEG Paradigm and Data Acquisition
A detailed account of the EEG paradigm and data acquisition
procedure is provided in Supplement 1. Brieﬂy, 22-electrode
EEG data were recorded (sampling rate 1000 Hz) while
subjects performed an auditory oddball task described else-
where (44).
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General EEG Preprocessing
A detailed description of the EEG preprocessing is provided in
Supplement 1. Brieﬂy, EEG data were bandpass ﬁltered (.5–100
Hz; bandwidth 5 99.5 Hz), and power line, muscle, eye move-
ment, and blink artifacts were removed using multitapering (45),
blind source separation (46), and adaptive ﬁltering techniques (47),
respectively. The data were segmented in 1150-ms epochs time-
locked to stimulus onset with a 250-ms prestimulus segment. To
minimize the confounding effect that muscle activity could have
on measuring neural noise, only midline electrodes were used for
statistical analyses, given that they tend to be less contaminated
by muscle activity than the rest (48).
EEG Measures
Lempel-Ziv Complexity. A detailed description of the
calculation of LZC is provided in Supplement 1. For each
subject and electrode, LZC was calculated on the prestimula-
tion segment (2250 to 21 msec) of each trial and then
averaged across trials. Finally, a single LZC value was calcu-
lated for each subject by averaging LZC across electrodes.
Signal Power. For each subject, the signal power of each
electrode was obtained by calculating the root-mean-square
power (average of the squared amplitudes) of each trial’s
prestimulation interval (2250 to 21 msec) and then averaging
across trials. Finally, for each subject, a single signal power
measure was obtained by averaging across electrodes.
Behavioral Measures
The positive, disorganization, and negative symptom subscales
from a ﬁve-factor model of the Positive and Negative Syndrome
Scale (PANSS) (49) were used to measure psychosis-like and
negative-like symptoms. This model was selected for its
stability and for not excluding items from the ﬁnal solution
(50). By characterizing positive and disorganization symptoms,
this ﬁve-factor model was hypothesized to more completely
capture the range of psychosis-like effects induced by Δ9-THC
than the usual three-factor model of the PANSS.
Statistical Analysis
Data were examined descriptively using means, standard
deviations, and distribution plots. In addition, each outcome
was assessed for normality using the Kolmogorov-Smirnov
test in each drug condition separately. Unless speciﬁed,
statistical analyses were conducted using SPSS 21 (IBM
Corporation, Armonk, New York).
Effect of Drug Condition on EEG Measures. The effect
of drug condition (placebo, .015 mg/kg, and .03 mg/kg) on
EEG measures was assessed using generalized estimating
equations (GEEs) (51,52) with an unstructured working corre-
lation matrix. GEE modeling is a robust method that corrects
for correlated samples, handles missing data, and has been
shown to be more powerful than typical repeated measures
analysis of variance for small/medium-size samples (51–53).
Independent GEE models were ﬁtted for LZC with and without
signal power as a covariate and p values were adjusted for two
comparisons with the Holm-Bonferroni (HB) method. Pairwise
comparisons (three per model) were conducted and p values
were HB-adjusted for six comparisons. In addition, independ-
ent GEE models were ﬁtted for signal power with and without
LZC as a covariate and p values were HB-adjusted for two
comparisons; pairwise comparisons were performed and
p values were HB-adjusted.
To examine the relationship between LZC and signal power,
the standardized regression coefﬁcient was obtained for the
longitudinal regression of LZC on signal power. The regression
was done by ﬁtting a GEE model with an unstructured working
correlation matrix to the data of the three drug conditions
transformed into composite Z scores.
Effect of Drug Condition on Behavioral Measures.
Each PANSS factor score exhibited ﬂoor effects and positive
skewness in the placebo condition. Thus, a nonparametric
method was used (54) and the resulting p values were HB-
adjusted for three comparisons (one per PANSS factor). For
this method, the data were ranked and ﬁtted with a mixed
effects model using dose as within-subject factor and an
unstructured variance-covariance matrix; p values were
adjusted for analysis of variance type statistics. Pairwise
comparisons (three per measure) were performed and p values
were HB-adjusted for nine comparisons. These analyses were
performed with the nparLD package (55) for R 2.14.2 (R
Foundation for Statistical Computing, Vienna, Austria) (56).
Relationship Between EEG and Behavioral Meas-
ures. To characterize the relationship between Δ9-THC-
induced changes in EEG measures (LZC and signal power) and
PANSS factors, standardized regression coefﬁcients (bs) were
obtained for the longitudinal regression across both Δ9-THC-
active conditions of each PANSS factor score on each EEG
measure (controlling and not controlling for the other EEG
measure) with a signiﬁcant main effect of drug (three coefﬁcients
per EEG measure). The p values of the regression coefﬁcients
were HB-adjusted for nine comparisons (Supplement 1).
RESULTS
Demographic information is reported in Table 1. Of the 56
subjects who were consented, 10 failed the screening proc-
ess, 8 never initiated, 8 dropped out before completing, and
30 completed all 3 test days. Due to technical difﬁculties
during EEG acquisition, six completers were excluded from
the analyses; in addition, one subject from the .015 mg/kg
condition and one subject from the .03 mg/kg condition were
excluded from analysis due to artifactual contamination in the
preprocessed EEG data. Thus, a total of 24 subjects in the
placebo condition and 23 subjects in both the .015 mg/kg and
.03 mg/kg conditions were included in the analyses. As
reported elsewhere, ﬁve nonserious and no serious adverse
events occurred on test days (44). For parsimony, statistics are
reported either in the text or tables but not both.
Effect of Drug Condition on EEG Measures
Lempel-Ziv Complexity. There was a signiﬁcant effect of
drug condition on LZC (Wald w22 5 42.696, pAdj , .001) that
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remained signiﬁcant (Wald w22 5 36.319, pAdj , .001) after
controlling for signal power. These ﬁndings persisted des-
pite HB-adjustment for two comparisons. The six HB-adjusted
pairwise comparisons performed before and after controll-
ing for signal power (three comparisons each) revealed
signiﬁcantly higher LZC for the .03 mg/kg (both pAdj , .001)
and .015 mg/kg (pAdj , .001 and pAdj 5 .002, respectively)
doses compared with placebo and for the .03 mg/kg dose
compared with the .015 mg/kg dose (both pAdj , .001)
(Figure 1; Table 2).
Signal Power. There was a signiﬁcant effect of drug con-
dition on signal power (Wald w22 5 8.004, pAdj 5 .036), which
disappeared after controlling for LZC (Wald w22 5 2.236, pAdj .
.1). Three HB-adjusted pairwise comparisons performed on the
data before controlling for LZC revealed signiﬁcantly lower
power for the .03 mg/kg and .015 mg/kg doses compared with
placebo (both pAdj 5 .029) but no difference between the
.03 mg/kg and .015 mg/kg doses (pAdj . .1) (Figure 2; Table 2).
Relationship Between LZC and Signal Power. The
regression of LZC on signal power revealed a signiﬁcant
inverse relationship between both variables (b 5 2.544, Wald
w21 5 42.229, p , .001).
Effect of Drug Condition on Behavioral Measures
The nonparametric analyses HB-adjusted for three compar-
isons revealed a signiﬁcant effect of drug condition for the
PANSS positive (analysis of variance type statistic [ATS]
[1.864] 5 28.147, pAdj , .001), disorganization (ATS [1.660] 5
26.555, pAdj , .001), and negative (ATS [1.914] 5 12.608, pAdj
, .001) symptoms factors. The nine HB-adjusted pairwise
comparisons showed signiﬁcantly higher scores for the .03
mg/kg and .015 mg/kg doses compared with placebo (all pAdj ,
.001 except pAdj 5 .031 for the .015 mg/kg dose versus
placebo comparison of the negative factor) and for the .03
mg/kg dose compared with the .015 mg/kg dose (all pAdj , .02)
(Table 2).
Relationship Between EEG and Behavioral Measures
The regressions of the PANSS factor scores on LZC revealed
signiﬁcant HB-corrected (nine comparisons) coefﬁcients for
the positive symptoms factor before (b 5 .442, Wald w21 5
9.114, pAdj 5 .015) (Figure S2A in Supplement 1) and after
(b 5 .685, Wald w21 5 39.419, pAdj , .001) (Figure 3A)
controlling for signal power and for the disorganization
symptoms factor before (b 5 .646, Wald w21 5 15.819, pAdj
, .001) (Figure S2A in Supplement 1) and after (b 5 .754, Wald
Table 1. Sample Demographics
General Characteristics
Number male (female) 17 (7)
Age, mean (SD) 26.208 (8.108)
Handedness 1 left-handed
Years of education, mean (SD) 15.167 (2.014)
Estimated IQ, mean (SD) 115.750 (4.416)
Cannabis Exposure
Age of ﬁrst cannabis use 17.000 (2.523)
Days since last use/last exposure, mean (SD) range 445.688 (846.645),
1–3650
Total years of use, mean (SD) range 7.094 (4.486), 1–15
Frequency of cannabis use within past 30 days Number of Subjects
0 days 12
1–3 days 4
4–8 days 3
9–15 days 3
16–29 days 2
Lifetime cannabis use (total number of exposures) Number of Subjects
1–10 4
11–50 8
51–200 3
201–500 3
501–1000 3
.1000 3
Cannabis exposure during heaviest use (number
of exposures)
Number of Subjects
,1 to 1 per year 6
1 per 3-6 months 4
1-3 per month 3
1-2 per week 2
3-6 per week 5
7 per week 4
Other Drug Exposure
Daily cigarette smokers (number of subjects) 2
Average number of alcoholic drinks per week,
mean (SD)
6.01 (6.06)
Previous recreational exposure to illicit drugs other
than cannabis
Number of Subjects
None 11
Hallucinogens 12
Stimulants 10
Opiates 3
Inhalants 2
None of the subjects met criteria for abuse or dependence of the
above illicit substances.
0.38
0.39
0.4
0.41
0.42
0.43
0.44
Placebo 0.015 mg/kg 0.03 mg/kg
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Figure 1. Lempel-Ziv complexity per drug condition. The graph shows
the mean and standard error bars of Lempel-Ziv complexity (raw values,
not corrected for signal power) per drug condition. Signiﬁcant differences
(p , .001) between conditions are indicated with **.
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w21 5 25.861, pAdj , .001) (Figure 3B) controlling for signal
power. No signiﬁcant coefﬁcients were found for the regres-
sion of the negative symptoms factor on LZC (all pAdj . .1). In
contrast to LZC, no coefﬁcient reached signiﬁcance for signal
power after HB correction (pAdj . .1).
Exploratory analysis to determine whether recent (30-day)
cannabis exposure inﬂuenced the effects of Δ9-THC on LZC
revealed no signiﬁcant effects of cannabis exposure
(Supplement 1). Finally, plasma levels of Δ9-THC and its
metabolite Δ9-THC-COOH were sampled periodically
(Supplement 1), showing a dose-dependent increase as
reported previously (44).
DISCUSSION
To our knowledge, this is the ﬁrst study to demonstrate an
increase in neural noise, deﬁned as the randomness of EEG
signals, induced by a psychotomimetic drug in humans. More
speciﬁcally, this study showed for the ﬁrst time that Δ9-THC
increased neural noise indexed by LZC in a dose-related
manner. As expected [reviewed in (24–26)], Δ9-THC increased
positive, disorganization, and negative symptoms. Further-
more, there was a strong positive relationship between neural
noise and the psychosis-like effects induced by Δ9-THC,
which was independent of the changes in total signal power.
In contrast, there was no relationship between noise and
negative-like symptoms. This suggests a speciﬁc relationship
between neural noise and Δ9-THC induced psychosis-like
effects, raising the intriguing possibility that neural noise may
be involved in other forms of psychosis as well. In addition,
Δ9-THC reduced total signal power during both active drug
conditions compared with placebo, but this effect disappeared
after controlling for LZC. No relationship was detected
between signal power and psychosis-like symptoms. Finally,
an inverse relationship between LZC and signal power was
observed.
Noise and Signal Power
As described above, LZC is a nonlinear measure of the
randomness (noise) of time series (30). While Δ9-THC
increased noise in a dose-dependent manner, the signal did
not become completely random, a state that would be
associated with an LZC value of 1. Note that the LZC value
associated with a perfectly regular (periodic) or predictable
signal would approach 0 (31,32). What the associated LZC
value is for optimal brain function remains unknown and is
likely an intermediate value between 0 and 1.
Animal studies have revealed that cannabinoids acutely
reduce the spectral power of LFP oscillations by increasing the
randomness (reducing the synchronization) of the activity of
populations of neurons rather than reducing the activity of
individual neurons (28,29). The increased randomness would
reduce the neurons’ capacity to form temporally coordinated
ensembles, leading to a reduction of LFP spectral power (28).
Consistent with these ﬁndings, our results showed that Δ9-
THC reduced signal power and increased randomness and
that there was an inverse relationship between signal power
and randomness.
Relationship Between Noise, Connectivity, and
Behavior
As discussed above, keeping the bandwidth and total power
of a signal constant, the higher the level of random noise, the
lower the amount of information that can be carried by a signal
without distortion. Considering that our ﬁndings were inde-
pendent of total signal power and that the bandwidth of the
signals was kept constant (99.5 Hz) across conditions by
ﬁltering, we speculate that our ﬁndings could reﬂect a negative
relationship between the amount of error-free information
capable of being carried by the brain signals and the
psychosis-like effect induced by Δ9-THC. Furthermore, we
hypothesize this may affect the capacity of different brain
areas (nodes) to process information coordinately. This would,
of course, apply only to the brain sources captured by the
midline electrodes used in our analyses. However, if the
Table 2. Δ9-THC Effects on Electroencephalographic and Behavioral Measures
Measure Placebo Mean (SD) .015 mg/kg Mean (SD) .03 mg/kg Mean (SD)
Lempel-Ziv Complexity .395 (.021) .408 (.023) .420 (.025)
Total Signal Power 64.391 (32.448) 55.088 (23.082) 54.507 (21.643)
PANSS Positive Factor 6.833 (2.334) 9.435 (2.936) 11.217 (2.999)
PANSS Disorganization Factor 11.667 (2.353) 14.304 (3.183) 16.739 (4.223)
PANSS Negative Factor 7.208 (2.395) 8.870 (3.348) 11.826 (4.579)
Δ9-THC, delta-9-tetrahydrocannabinol; PANSS, Positive and Negative Syndrome Scale.
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Figure 2. Baseline signal power per drug condition. The graph shows the
mean and standard error bars of baseline signal power (raw values, not
corrected for Lempel-Ziv complexity) per drug condition. Signiﬁcant differ-
ences (p , .05) between conditions are indicated with *.
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activity captured by these electrodes is representative of the
activity within larger brain areas, then one might speculate that
the results of this study may be informative about brain
function in general. If so, these results would be aligned with
some theoretical models proposing an aberrant connectivity
(dysconnection) between brain areas as the underlying mech-
anism of psychotic symptoms in schizophrenia (57–59). Fur-
thermore, we speculate that LZC will be inversely correlated to
electrophysiological indices of connectivity such as phase lag
index (60) and inter-electrode coherence (61).
Mechanism of Noise
While it is beyond the scope of this study to determine the
mechanism by which Δ9-THC increased noise, it is tempting to
speculate on some explanations. In the cerebral cortex and
hippocampus, CB1Rs are located on the axon terminals of
cholecystokinin-expressing gamma-aminobutyric acidergic
interneurons (62). While parvalbumin-expressing gamma-ami-
nobutyric acidergic interneurons seem to have the main role in
the generation of regular oscillatory activity (nonrandom
recurrent patterns), it has been proposed that cholecystokinin
cells enhance the signal-to-noise ratio of neural oscilla-
tions (like a noise ﬁlter) through a CB1R-mediated mechanism
(63–65). Thus, it may be the case that the observation that
Δ9-THC increased LZC resulted from a disruption of this noise
ﬁlter mechanism by the nonphysiologic activation of CB1Rs by
Δ9-THC. While the manner in which this abnormality would
affect neural computations is far from being clear, it is
interesting to note that increased levels of LZC and similar
measures have been reported in schizophrenia and have been
related to periods of symptomatic exacerbation (21–23).
LZC Complements Traditional Measures of Brain
Activity
Event-related potentials are one of the EEG measures most
widely used in current studies of psychoses. Event-related
potentials provide valuable information about the consistency
and strength of the brain’s time-locked response to different
presentations of a stimulus. Using this approach we showed
that Δ9-THC reduced the amplitude of the P300 (44). LZC
complements these measures by capturing a different aspect
(randomness) of the neural dysfunction underlying Δ9-THC-
induced psychosis-like symptoms. Interestingly, exploratory
analyses revealed medium-sized (β  2.4) negative relation-
ships between LZC and the amplitudes of P3a and P3b. Of
note, while P3a or P3b amplitudes were not related to
symptoms measured either by the three-factor (44) or ﬁve-
factor (current) solution of the PANSS, LZC was related
(Supplement 1). Furthermore, we explored the relationship
between baseline power (an index of brain activity not evoked
by a task) in the traditional frequency bands and psychosis-
like symptoms. Similar to the Spencer (43) study on schizo-
phrenia patients, we found no relationship between baseline
power and psychosis-like symptoms in any frequency band
(Supplement 1). Taken together, these ﬁndings suggest that
LZC may be more sensitive to the pathophysiology underlying
positive symptoms than some traditional EEG measures.
Thus, LZC may be able to provide information about the
pathophysiology of positive symptoms that has been over-
looked by studies using these measures.
Strengths and Limitations
Unlike other measures of noise (e.g., intertrial variability,
increased task-unrelated activity) (14–18,39,43), LZC provides
direct information about the level of randomness of the EEG
signals (30), which makes it more suitable for quantifying the
noise of brain activity. The obvious differences between these
measures limit any direct comparisons between the results of
this study and those previously obtained in schizophrenia.
In contrast to previous evoked-response studies (14–18,
39), in this study, data captured immediately before the onset
of the stimulation period were analyzed. Despite the fact that
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Figure 3. Delta-9-tetrahydrocannabinol induced positive and disorganization symptoms versus Lempel-Ziv complexity (LZC) corrected for signal power.
The ﬁgure shows the regression lines and standardized coefﬁcients of the regressions of positive (A) and disorganization (B) symptom factors of the Positive
and Negative Syndrome Scale on LZC corrected for signal power. Positive and Negative Syndrome Scale scores and LZC values are presented in Z scores.
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the prestimulation period does not capture evoked activity, it is
not true resting state activity due to the anticipation elicited by
recurring events (i.e., auditory click trains) and the expectation
associated with task-related stimuli (i.e., P3b). Thus, whether
our ﬁndings apply to resting state activity or to activity
associated with expectancy during the prestimulation will need
to be determined in future studies.
In this study, continuous EEG data were transformed into
binary symbolic sequences using the threshold-crossing
approach (Methods and Materials) before calculating LZC.
While this approach is associated with some loss of informa-
tion (66,67) about the ﬁne-grained dynamics of the system
generating the signals (e.g., the brain), it is capable of
providing an accurate representation of the macroscopic-
level dynamics of the system (67). Furthermore, a conse-
quence of using the median as the threshold is that low-range
frequencies are preferentially represented in the resulting
binary data (Supplement 1). Even though the median-
crossing approach is widely used, alternate approaches
[e.g., (68)] that better represent the entire frequency spectrum
should be explored. The loss of some information notwith-
standing, LZC based on this approach has been informative
about the brain in health and disease (34,35,37,38).
Conclusions
At doses that produced increases in psychosis-like effects,
Δ9-THC increased neural noise (LZC) measured in the EEG of
humans in a dose-dependent manner. Furthermore, increases
in neural noise were positively related with Δ9-THC-induced
psychosis-like, but not negative-like, effects. These ﬁndings
suggest that neural noise may contribute to the psychotomi-
metic effects of Δ9-THC. Further replication of these ﬁndings
is warranted as are studies into the mechanisms underlying
the increases in neural noise (e.g., studying the intracortical
correlates of these surface recordings in animals). It would be
interesting to determine whether these ﬁndings are exclusive
to Δ9-THC or whether other drugs known to produce
psychosis-like effects (e.g., ketamine [NMDA receptor antag-
onist] and psilocybin [serotonin 2A receptor agonist]) increase
LZC and whether the drug-induced increases in LZC correlate
with psychosis-like effects. While LZC is increased during
decompensation (22), to our knowledge, whether LZC is
correlated with psychotic symptoms in schizophrenia patients
has not been studied. If conﬁrmed, LZC may have signiﬁcant
utility as a novel biomarker for the functional deﬁcits under-
lying psychotic symptoms. Finally, while admittedly specula-
tive, if psychotic symptoms are a result of brain
dysconnectivity related to an abnormal increase of neural
noise, interventions directed toward reducing noise may have
therapeutic potential.
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As an example of this sort of analysis, Fig. 3 shows the results of
MSI performed on 4 separate spikes, each differing slightly in
terms of topography or amplitude. Despite the high goodness-of-
ﬁt values for each of the source solutions, the dipole localizations
are scattered rather unpredictably within the temporal lobe.
It is perhaps a testament to how far the ﬁeld has advanced that
we are able to solve the inverse problem with even this degree of
lobar accuracy. But it is not unreasonable to attempt to achieve
even better, more consistent, localization results. Rigorous studies
comparing dipole source solutions with their actual intracranial
ﬁelds represent a logical and necessary progression in electromag-
netic source imaging research. Recent advances facilitating the
simultaneous recording of MEG and intracranial EEG promise even
greater insights into the nature of dipole variability in MEG/MSI.
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Testing differences in the activity of event-related
potential sources: Important implications
for clinical researchers
Source analysis of electroencephalographic (EEG) data is an
increasingly popular tool that allows investigators to estimate
the location, direction, and strength of the electric currents within
the brain. Clinical researchers have increasingly exploited
user-friendly Linear Distributed Source Model (LDSM) software
packages (such as sLORETA-KEY) to extend classical event-related
potential (ERP) experiments. However, methodological biases and
inferential errors may have occurred. Spatial solutions tend to be
accurately reported, but, use of standard methods to quantify
source activity can introduce error into group/condition compari-
sons of ‘‘ERP generators’’, especially when the experimental effect
is hypothesized to alter ERP peak amplitude or latency. Since 2010
alone, this journal has published a number of clinical studies
reporting source localization of ERPs in which one cannot exclude
one or more of these methodological or inferential issues (outlined
in Table 1). We illustrate the potential pitfalls with proposed
solutions.
In LDSMs-based analyses, either cortical grey matter is divided
into a number of voxels or cortical surface is modeled as a mesh
with a number of vertices, each of which is assigned a three dimen-
sional vector representing electric activity (EAV), a current density
vector in the ﬁrst case, or an electric dipole in the second. The
length (norm) and orientation of an EAV correspond, respectively,
to the magnitude and direction of ﬂow of the reconstructed current
(Pascual-Marqui, 2002). Grossly, positive scalp potentials would
result from currents ﬂowing towards scalp sensors, whereas nega-
tive scalp potentials would result from currents ﬂowing away from
these sensors.
As EEG signals are purported to result from the summed ﬁeld
potentials generated by cortical neurons whose dendritic trees
are perpendicular to the cortical surface, EAVs are frequently con-
strained to be oriented in this direction (Grech et al., 2008). To
facilitate statistical comparison and graphical representation, it is
common to then reduce each EAV (possessing three values per
voxel or vertex) to its norm (|x|, a single positive number). Conse-
quently, information about the direction of ﬂow of current is lost.
The norm solution, favored by popular software packages, is there-
fore not a complete reconstruction of the activity underlying the
signals recorded at the scalp; instead, it only yields the magnitude
of the activity. Although a perfectly valid measure in itself, source
magnitude may be insensitive to some facets of underlying neural
processes and cannot be directly related to the scalp ERPs.
A temporal window centered on the peak of the scalp ERP is de-
ﬁned. Sources at each time point within this window are recon-
structed and averaged across time to yield what is interpreted as
the ‘ERP source’.
1. Issue 1: Testing differences in ERP peak amplitude and
source activity
A group/condition difference in the norm solution informs us
that cortical areas coincidently active with the ERP peak have dif-
ferent magnitude. However, this does not prove a difference in cor-
tical activity ‘underlying’ or ‘generating’ the ERP directly. If aiming
to draw inferences about cortical activity that directly contributes
to the ERP, the use of the norm solution is analogous to comparing
scalp-ERPs using the absolute value of their peak amplitude
(Fig. 1A).
A rich literature describes a range of clinical states in which the
amplitude of ERPs is diminished (Folmer et al., 2011; Polich and
Criado, 2006; Thaker, 2008; Turetsky et al., 2007). ERP amplitudes
are commonly utilized as dependent measures in studies
examining the neural basis of cognitive function (Bartholow,
2010; Kotchoubey, 2006; van Veen and Carter, 2002). Under cer-
tain experimental conditions, amplitude perturbation may impede
an individual’s ERP from even crossing the temporal axis (Fig. 1A).
Thus, the value of that ERP peak, and hence source activity, would
possess an opposite sign than characteristically expected. If the
norm solution is then taken, the amplitude perturbation is
erroneously diminished and some variance perhaps attributable
to an experimental effect is lost, even when a robust difference
in ERP peak amplitude exists at the scalp and the sources
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Table 1
Clinical studies reporting source localization of ERPs which may be prone to methodological or inferential issues.
References Potential problems due to. . .
Issue 1 Issue 2 Inferential language
Babiloni et al. (2009) Yes – "amplitude of prefrontal P300 sources..."
Doege et al. (2010) Yes – "ERP components and their source localisation"
Jung et al. (2010) Yes – "current density of P200 component was signiﬁcantly reduced..."
Babiloni et al. (2011) Yes – "...P300 sources..."
Fisher et al. (2011) Yes Yes –
Tanaka et al. (2012) Yes Yes ‘‘N1 source’’
De Pascalis et al. (2013) Yes Yes –
Annic et al. (2014) Yes – "...cortical generators of the N100 and P200 components..."
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Fig. 1. (A) This ﬁgure shows the P3b ERPs at electrode CPz of a representative subject from our lab receiving either placebo (blue curve) or an active drug (red curve), and the
absolute value of the ERP of the active drug condition (red dashed curve) (for the methods, see (D’Souza et al., 2012)). It illustrates the case when the reduction of an ERP’s
amplitude impedes it from having its expected polarity. This abnormality is reﬂected in the comparison of the peak amplitudes as a large voltage difference between the
conditions (DV1). Instead, a comparison based on the absolute value of the voltage is not able to capture it: it reduces the difference between these highly dissimilar ERPs to a
small ‘ordinary’ value (DV2). This is analogous to the case when the sources of the different conditions are compared using the norm solution instead of the vector solution
(B). Processing and source analyses of the data shown in all the ﬁgures were done using custom scripts and the Brainstorm toolbox (Tadel et al., 2011) for Matlab
(MathWorks). (B) The ﬁgure shows the time course of the magnitude of a current dipole (CD) perpendicular to the cortex of a point located in the temporo-parietal area (one
of the generators of the P3b (Polich, 2007)) during the occurrence of ERPs depicted in (A); it also shows the norm solution of the ERP of the active condition (red dashed
curve). Analogous to what occurs with the EEG signals (A), the activity of the placebo (blue curve) and the active (red curve) conditions have different polarities during the
occurrence of the ERP. In the comparison of the peaks this abnormality is reﬂected as a large difference between the magnitude of the current dipoles of the conditions
(DCD1); instead, under the norm solution the difference between these highly dissimilar conditions appears to be small (DCD2).
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(Fig. 1A and B). Analyzed within a dataset, such data-points may
theoretically increase the risk of missing empirically relevant dif-
ferences between the sources’ activity of the groups/conditions.
Furthermore, the loss of variance may also theoretically increase
the risk of ﬁnding differences that may have little to do with the
between-group/-condition differences of ERPs. All studies utilizing
these methods, published and unpublished, must discuss or avoid
this potential bias.
In an attempt to make group/condition comparisons of the
norm solution, some investigators localize the between groups/
conditions ERP difference wave. This raises its own inferential
challenges, beyond the scope of this letter.
The norm solution treats source current moving towards and
away from the scalp as equal. Although theoretically valid, the
description of sources as ERP ‘‘generators’’ or ‘‘contributors’’ loses
meaning when they are described in terms of the norm solution
alone. Such terms imply a direct relationship, whereas, given a de-
crease in ERP peak amplitude, the norm solution of an individual’s
source may decrease, increase, or stay the same.
2. Issue 2: Studies where differences in ERP Peak Latency may
exist
Shifts in the latency of certain ERPs are known to occur in
several neuropsychiatric disorders (e.g. schizophrenia patients)
and with drug administration (e.g. benzodiazepines or nicotine)
(Jeon and Polich, 2003; Lucchesi et al., 2005; Pritchard et al.,
2004; Urata et al., 1996). When comparing the magnitude of
source activity, many investigators account for ERP latency
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Fig. 2. (A) The ﬁgure shows two identical P3b ERP curves at CPz one of which has been shifted ‘s’ milliseconds in time. It represents the scenario when comparing groups/
conditions in which one has a peak latency shift compared to the other. The same ERP curves were used for both cases to highlight the consequences resulting only from the
time shift without the intervention of other variables (see (B)). Blue curve: P3b ERP at electrode CPz of a representative subject from our lab obtained by averaging across
trials (methods describes in (D’Souza et al., 2012)). Red dashed curve: the same ERP but shifted in time. ‘w’: length of the common interval used to capture the ERP’s peak in
both conditions. (B) The ﬁgure shows the time course of the magnitude of a current dipole (CD) perpendicular to the cortex of a point located in the temporo-parietal area
(one of the generators of the P3b (Polich, 2007)) during the occurrence of the shifted (red curve) and non-shifted (blue curve) ERPs depicted in (A). The hatched area shows
the difference between the activities of both conditions during the common analysis interval ‘w’. The shift introduces a difference between the conditions that is not coming
from the magnitude of the sources’ activity (both sources have the same curve) but from the peak latency difference existing between them.
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variation by deﬁning temporal windows centered on the ERP peak
for each individual, in each condition/group. Issues may arise how-
ever when the same temporal window is applied to all groups/
conditions.
Due to latency shifts, the neural sources of individuals belong-
ing to different groups/conditions obtained with the averaged-
interval technique may reﬂect very different moments of the ERP
waveform (Fig. 2A). This may generate between-group/-condition
differences in the magnitude of the reconstructed sources’ activity
that disappear after correcting for the latency shift effect (Fig. 2B).
Furthermore, signiﬁcant differences in source magnitude that oc-
cur between groups/conditions, within classical ERP temporal win-
dows, are not necessary relatable to neural processes that underlie
the coincident ERP.
In summary, LDSM software packages offer valuable and
increasingly accessible tools for localization of the electrical activ-
ity associated with ERPs. These techniques promise to expand our
understanding of ERPs. However, caution must be exercised when
attempting to integrate ERP source activity ﬁndings into classical
ERP approaches. We highlight a set of potential issues, now emerg-
ing with the expanding use of these techniques, particularly in
clinical research. Investigators should be mindful of the distinction
between source magnitude and activity and choose the more
appropriate measure for testing their hypothesized effect.
As a general rule, when seeking to infer differences in cortical
activity related to an ERP, we suggest investigators: (1) Consider
using the vector (non-norm) solution; (2) Identify an ERP peak
window for each subject individually. If the norm solution is used,
it may be more accurate to interpret the source magnitude as coin-
cident with rather than either directly related to, or a ‘‘generator’’
of the ERP.
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Compatibility of intraoperative 3 T MR imaging
and intraoperative neurophysiological
monitoring
One of the main challenges in brain tumor surgery is achieving
the largest extent of resection (EOR) possible without causing
damage to the surrounding healthy brain parenchyma. This is
especially difﬁcult in tumors which cannot be distinguished from
normal brain reliably with the operating white light microscope
and in lesions in close proximity to eloquent areas. EOR is linked
to survival (Kreth et al., 2013) and much effort has been invested
in the development of technologies that guide tumor resections
in order to improve EOR. In daily practice, intraoperative neuro-
physiological monitoring (IONM), neuronavigation, intraoperative
magnetic resonance imaging (ioMRI), intraoperative ultrasound
(ioUS) and 5-aminolevulinic acid (5-ALA) are the most frequently
used ones. IONM helps the surgical team to monitor neural func-
tion (Macdonald et al., 2013). Neuronavigation using preoperative
contrast-enhanced MRI images helps to identify tumor, but brain
shift occurring during resection often makes the preoperative
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The	Endocannabinoid	System	and	Schizophrenia:	Links	 to	 the	Underlying	Pathophysiology	and	to	Novel	Treatment	
Approaches	
Swapnil	Gupta,	MBBS,	MD;	John	D.	Cahill,	MBBS;	Mohini	Ranganathan,	MD;	and	Christoph	U.	Correll,	MD	
Six	decades	after	 the	 introduction	of	dopamine	D2-receptor–based	antipsychotics,	 schizophrenia	 remains	one	of	 the	
most	 severe	 and	 difficult-to-treat	 mental	 disorders.	 While	 a	 range	 of	 alternative	 therapeutic	 targets,	 such	 as	 the	
glutamatergic	 system,	have	attracted	attention	 for	negative	 symptoms	and	 cognitive	dysfunction,1	novel	 treatments	
for	the	core	symptoms	of	schizophrenia	remain	unproven.2	
The	Endocannabinoid	System	
The	 endocannabinoid	 system	 (ECS)	 is	 a	 largely	 overlooked	 brain	 homeostatic	 system	 that	 is	 relevant	 to	 both	 the	
pathophysiology	and	treatment	of	schizophrenia.	It	centers	on	2	G-protein–coupled	receptors,	cannabinoid-1	receptor3	
and	cannabinoid-2	receptor4;	 lipid	 ligands	or	endocannabinoids5,6	 including	anandamide	and	2-arachidonoylglycerol;	
and	 enzymes	 involved	 in	 endocannabinoid	 biosynthesis	 (diacylglycerol	 lipase)	 and	 degradation	 (fatty	 acid	 amide	
hydrolase	 [FAAH]	and	monoacylglycerol	 lipase).7,8	Cannabinoid-1	receptors	are	highly	expressed	 in	 the	brain	regions	
implicated	in	the	putative	neural	circuitry	of	schizophrenia,	including	the	cerebral	cortex,	basal	ganglia,	hippocampus,	
anterior	 cingulate	 cortex,	 and	 cerebellum,9	 where	 they	 modulate	 presynaptic	 glutamate	 and	 GABA	 release.10,11	
Furthermore,	 endocannabinoids	 enhance	 dopaminergic	 function	 in	 the	 prefrontal	 cortex	 and	 hippocampus	 while	
providing	 inhibitory	 feedback	 on	 mesolimbic	 dopamine	 neurotransmission.12–14	 Finally,	 endocannabinoids	 are	
increased	 in	 response	 to	 stress,	 possess	 intrinsic	 antioxidant	 properties,	 and	 are	 precursors	 of	 membrane	 lipids,	
leukotrienes,	and	prostaglandins.15	
The	Endocannabinoid	System	and	Schizophrenia	
Anandamide	levels,	increased	in	acute	schizophrenia,	may	represent	a	compensatory	mechanism,	specifically	in	early	
illness.	 Cerebrospinal	 fluid	 and	 plasma	 levels	 of	 anandamide	were	 noted	 to	 be	 significantly	 increased	 in	 acutely	 ill,	
antipsychotic-naive,	 first-episode	 schizophrenia	 patients	 compared	 to	 controls.16,17	 Increased	 levels	 negatively	
correlated	 with	 psychotic	 symptoms	 and	 normalized	 with	 antipsychotic	 response.17	 Furthermore,	 in	 prodromal	
individuals,	elevated	anandamide	 levels	were	associated	with	 lower	risk	of	conversion	to	schizophrenia,18	suggesting	
that	anandamide	increases	could	be	compensatory	in	this	context.	
Studies	of	cannabinoid-1	receptor	densities	in	schizophrenia	show	mixed	results.	Postmortem	studies	of	cannabinoid-
1	receptors	in	schizophrenia	have	found	alterations	in	the	anterior19	and	posterior20	cingulate	cortices,	but	1	study21	
found	no	changes.	The	availability	of	positron	emission	tomography	(PET)	ligands	for	in	vivo	imaging	techniques	shows	
promise	for	 future	studies.22	 In	a	preliminary	PET	study	 in	schizophrenia	patients,	Wong	et	al23	found	that	elevated	
cannabinoid-1	receptor	density	in	the	frontal,	middle,	and	posterior	cingulate	regions	correlated	with	psychopathology.	
Cannabinoid-1	 receptor	gene	polymorphisms	may	be	associated	with	 schizophrenia.	 Cannabinoid-1	 receptor	 gene3	
(CNR1)	polymorphisms	have	been	associated	with	schizophrenia	 in	some	studies,24,25	but	not	 in	others.26,27	While	
this	 inconsistency	 might	 reflect	 demographic	 differences	 in	 the	 study	 populations,	 another	 possibility	 is	 the	
heterogeneity	of	the	illness.	
Exogenous	Cannabinoids	and	Schizophrenia	
Epidemiologic	 studies	 have	 linked	 both	 onset	 and	 extent	 of	 cannabis	 use	 with	 the	 development	 and	 severity	 of	
schizophrenia.	 A	 number	 of	 longitudinal	 studies	 have	 found	 that	 earlier	 onset	 of	 cannabis	 use,	 especially	 before	 18	
years	 of	 age,	 was	 associated	with	 an	 increased	 incidence	 of	 psychotic	 symptoms	 or	 disorder	 later	 in	 life.28–31	 For	
instance,	a	study	of	Swedish	military	conscripts	(N	=	45,570)	showed	a	significant	dose-response	relationship	between	
self-reported	cannabis	use	at	enrollment	and	psychiatric	hospitalization	 for	 schizophrenia	 in	 the	ensuing	15	years.28	
Heavy	cannabis	users	by	18	years	of	age	were	6.7	times	more	likely	than	nonusers	to	be	hospitalized	for	schizophrenia	
later	in	life.29	Similarly,	a	birth-cohort	study	of	1,037	people	born	in	Dunedin,	New	Zealand,30	found	that,	compared	to	
nonusers,	 individuals	 with	 cannabis	 use	 at	 ages	 15	 and	 18	 years	 had	 higher	 rates	 of	 psychotic	 symptoms	 and	
schizophreniform	disorder	at	age	26.	Consistent	with	these	studies,	a	systematic	review32	of	35	studies	demonstrated	
an	increased	risk	of	psychosis	in	individuals	who	had	ever	used	cannabis	and	the	existence	of	a	dose-response	effect,	
with	greater	risk	in	people	who	used	cannabis	most	frequently.	Meta-analyses	of	studies	of	cannabis	use	and	psychosis	
suggest	that	cannabis	is	a	component	cause	in	the	development	and	prognosis	of	psychosis33	and	that	the	age	at	onset	
of	psychosis	was	2.7	years	earlier	among	cannabis	users	compared	with	non–substance-using	controls.34	Finally,	 in	a	
recent	 nationwide	 Finnish	 study,35	 the	 8-year	 rate	 of	 ultimate	 conversion	 to	 schizophrenia	 in	 18,478	 patients	 with	
substance-induced	 psychotic	 disorders	 was	 highest	 in	 cannabis	 users	 (46%),	 followed	 by	 amphetamine	 (30%)	 and	
alcohol	(5%)	users.	Moreover,	the	risk	was	highest	in	the	first	3	years,	especially	in	cannabis	users.	
Δ9-tetrahydrocannabinol,	 a	 partial	 cannabinoid-1	 receptor	 agonist,	 produces	 psychotomimetic	 effects,	 whereas	
cannabidiol,	a	putative	FAAH	inhibitor,	may	attenuate	them.	Cannabis	contains	a	number	of	constituent	cannabinoids	
of	 which	 Δ9-tetrahydrocannabinol	 (THC)	 is	 the	 main	 psychoactive	 component.	 In	 psychopharmacologic	 challenge	
studies,	the	acute	administration	of	THC	has	been	shown	to	transiently	induce	a	range	of	positive,	negative,	cognitive,	
and	 psychophysiologic	 abnormalities	 in	 healthy	 people,	 comparable	 to	 those	 observed	 in	 schizophrenia.36	 THC	
similarly	induced	an	increase	in	psychotic	symptoms	in	stable,	antipsychotic-treated	schizophrenia	patients,	who	were	
more	sensitive	to	THC-induced	positive	symptoms	and	cognitive	deficits	as	compared	to	healthy	controls.37	
In	 contrast	 to	 THC,	 cannabidiol,	 another	 component	 of	 cannabis,	 does	 not	 appear	 to	 have	psychotomimetic	 effects,	
instead	producing	hypnotic,	anticonvulsive,	anxiolytic,	and	neuroprotective	effects.38	In	healthy	subjects,	cannabidiol	
pretreatment	 reduced	the	psychotomimetic	effects	of	THC39	and	attenuated	ketamine-induced	depersonalization.40	
Furthermore,	 chronic	 cannabis	 users	 with	 evidence	 (per	 hair	 analyses)	 of	 significant	 cannabidiol	 exposure	 showed	
lesser	positive	schizophrenia-like	symptoms	than	those	without.41	
Conversely,	 a	 subgroup	 of	 schizophrenia	 patients	 may	 derive	 benefit	 from	 exogenous	 cannabinoid-1	 receptor	
agonism.	Despite	the	above	evidence,	cannabis	continues	to	be	the	most-abused	illicit	substance	in	schizophrenia.42	In	
1	open-label	study,43	treatment	with	dronabinol	resulted	 in	symptomatic	 improvement	 in	4	of	6	treatment-resistant	
patients	who	had	a	self-reported	history	of	benefits	from	cannabis	use.	Additionally,	meta-analysis	revealed	that	 in	a	
subgroup	 of	 patients,	 cannabis	 use	 is	 associated	 with	 improved	 cognition,44	 further	 pointing	 to	 a	 significant	
heterogeneity	in	the	interaction	between	the	disease	and	cannabis.	
In	 summary,	 the	 ECS	 is	 implicated	 in	 the	 major	 pathophysiologic	 hypotheses	 for	 schizophrenia:	 mesolimbic	
hyperdopaminergia	 (and	 dopaminergic	 hypofrontality),	 glutamate/GABA	 disruptions,	 oxidative	 stress,	 deficiency	 of	
membrane	 lipids,	 and	 neuroinflammation.	 Its	 involvement	 is	 supported	 by	 alterations	 in	 the	 ECS	 in	 patients	 with	
schizophrenia	 and	 further	 by	 epidemiologic	 and	 laboratory	 data	 supporting	 the	 role	 of	 exogenous	 cannabinoids	 in	
psychosis	and	schizophrenia.	Given	the	pleiotropism	of	the	ECS	and	heterogeneity	of	the	evidence,	the	nature	of	the	
link	between	the	ECS	and	schizophrenia	is	complex,	requiring	further	study.45	
Novel	Treatment	Strategies	Based	on	the	Endocannabinoid	System	
Cannabinoid-1	receptor	antagonism	has	demonstrated	anxiolytic	but	no	clear	antipsychotic	effects.	Alternatively,	novel	
therapeutic	 targets	 focused	 on	 boosting	 endogenous	 anandamide	 levels	may	 show	 greater	 promise.46	 Such	 targets	
may	 have	 most	 utility	 in	 acute,	 early-phase	 schizophrenia	 via	 their	 ability	 to	 increase	 prefrontal	 and	 decrease	
mesolimbic	 dopamine.	 Elevating	 anandamide	 levels	 has	 been	 shown	 to	 ameliorate	 symptoms	 in	 animal	 models	 of	
schizophrenia;	 for	 example,	 hyperlocomotion	 in	 dopamine	 transporter	 knockout	 mice12	 and	 PCP-induced	 social	
withdrawal.47	Anandamide	itself	has	poor	bioavailability,	but	drugs	exist	that	reduce	its	deactivation	via	 inhibition	of	
FAAH	 and	 blocking	 reuptake	 into	 the	 neuron.48	 In	 a	 4-week	 trial	 of	 42	 acute	 schizophrenia	 patients,	 cannabidiol	
showed	 comparable	 efficacy	 to	 amisulpride	 for	 positive	 and	 negative	 symptoms,	 while	 being	 better	 tolerated.49	
Moreover,	symptom	improvement	correlated	with	increases	in	anandamide,	suggesting	that	cannabidiol	may	mediate	
its	 effect	 via	 FAAH	 inhibition.	 Synthetic	 FAAH	 inhibitors	 increase	 anandamide	over	 2-arachidonoylglycerol	 levels,	 the	
latter	 of	 which	 may	 be	 implicated	 in	 cannabinoid-1	 receptor–mediated	 psychotic	 effects.	 A	 range	 of	 synthetic	
anandamide-boosting	drugs	promise	efficacy	and	tolerability	 in	mood	and	anxiety	disorders,50,51	but	these	have	not	
yet	been	tested	in	schizophrenia.	
Future	Directions	
In	vivo	cannabinoid-1	receptor	imaging.	Availability	of	several	cannabinoid-1	receptor	PET	ligands	now	permits	in	vivo	
imaging	in	patients	at	every	stage	of	psychotic	illness.23	Future	studies	may	disambiguate	the	effects	of	antipsychotic	
medications,	 stage	 of	 illness,	 and	 cannabis	 use	 (among	 other	 factors)	 from	 schizophrenia-related	 changes	 in	
cannabinoid-1	receptor	availability.	
Preclinical	 and	 clinical	 studies	 examining	 the	 role	 of	 the	 cannabinoid-2	 receptor	 in	 schizophrenia.	 Initial	 genetic	
linkage	 studies	 associated	 cannabinoid-2	 receptor	 gene	 hypofunction	 with	 an	 increased	 risk	 of	 schizophrenia,52	
warranting	further	study	of	this	association	and	treatments	directed	at	this	receptor.	
Acute	 psychopharmacologic	 challenge	 studies	 in	 healthy	 humans.	 The	 controlled,	 acute	 administration	 of	 THC	 in	 a	
laboratory	 serves	 to	probe	 the	ECS	and	characterize	 its	 role	 in	psychosis.	 Further,	putative	 therapeutic	drugs	 can	be	
tested	 against	 THC	 in	 this	 laboratory	 model.	 Finally,	 characterizing	 the	 relative	 contributions	 of	 the	 principal	
constituents	of	cannabis	on	psychotomimetic	effects	may	have	important	public	health	implications.	
Clinical	 trials	 of	 novel	 ECS	 agents	 in	 schizophrenia.	Novel	 antipsychotic	 drugs	 targeting	 the	 ECS	may	 best	 focus	 on	
early-phase	schizophrenia	given	a	preponderance	of	clinical	evidence	in	this	population.	On	the	basis	of	the	hypothesis	
that	 the	 ECS	 (perhaps	 via	 increases	 in	 anandamide)	 plays	 a	 compensatory	 role	 in	 early	 psychosis,	 treatment	with	 a	
FAAH	inhibitor	could	decrease	conversion	to	schizophrenia	in	prodromal	patients	or	improve	prognosis	in	first-episode	
psychosis	patients.	
Conclusions	
There	 are	 substantial	 preclinical,	 clinical,	 and	 epidemiologic	 data	 supporting	 the	 involvement	 of	 the	 ECS	 in	
schizophrenia.	The	ECS	hypothesis	unifies	other	major	pathophysiologic	hypotheses	of	schizophrenia.	Further	studies	
are	warranted	 to	 further	 probe	 the	 exact	 nature	 of	 ECS	 abnormalities	 in	 schizophrenia.	 Consideration	 of	 stage	 and	
heterogeneity	of	the	illness	is	vital.	Further	exploration	of	the	potential	benefit	of	cannabidiol	and	other	anandamide-
boosting	agents	may	lead	to	novel	treatments.	
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A Prescription for “Deprescribing” in Psychiatry
Swapnil Gupta, M.B.B.S., M.D., and John Daniel Cahill, M.B.B.S., B.Med.Sci.
The term “deprescribing,” initially coined in geriatric medicine,
describes a process of pharmacologic regimen optimization
through reduction or cessation of medications for which
beneﬁts no longer outweigh risks. Burgeoning rates of poly-
pharmacy, growing appreciation of long-term adverse ef-
fects, and a focus on patient-centered practice present
speciﬁc indications for deprescribing in psychiatry. A strong
therapeutic alliance, appropriate timing, and consideration of
the meaning of medication for the patient must accompany
the following established elements: review of all medications,
identiﬁcationofmedications that could be ceasedor reduced,
collaborative planning of the deprescribing regimen, and
provision of review and support to the patient and caregivers.
The authors discuss how deprescribing might be adapted for
and implemented in psychiatry, identify potential barriers, and
make recommendations for future directions.
Psychiatric Services 2016; 67:904–907; doi: 10.1176/appi.ps.201500359
A term now established in geriatric medicine, “deprescribing”
has been deﬁned as the systematic process of identifying and
reducing or discontinuing drugs in instances in which existing
or potential harms outweigh existing or potential beneﬁts, taking
into account the patient’s medical status, current level of
functioning, and values and preferences (1). The end goal of
deprescribing is not necessarily the complete cessation of med-
ications but rather their parsimonious use. Despite a scattered
and disparate literature examining dose reduction or discontin-
uation of maintenance regimens (mostly notably antipsychotics
and benzodiazepines), only recently in psychiatry’s history have
general, structured, multidimensional approaches to medication
discontinuation gathered momentum. Similarly, the ﬁeld of
cardiology is questioning the need for long-termmedications by
critically reexamining the evidence base and developing strate-
gies for repeated risk-beneﬁt analyses over time (2).
Changing systems of care, lack of diagnostic and therapeutic
precision, and a focus on symptomatic rather than functional
outcomes have conspired with a relative lack of clinical evi-
dence for (or experience with) medication discontinuation to
increase rates of “prescribing inertia” and polypharmacy.
Furthermore, many psychosocial factors, along with comorbid
general medical and substance use disorders and the high
importance given to the subjective experiences of patients,
yield a particularly complex risk-beneﬁt analysis for psycho-
tropic medications. In this Open Forum, we describe how the
process of deprescribing might be implemented in psychiatry,
alongwith potential beneﬁts, challenges, and future directions.
Indications for Deprescribing in Psychiatry
Changing Risk-Beneﬁt Ratio. Biological, psychological, and
social factors must align to produce a favorable risk-beneﬁt
ratio such that a medication regimen becomes established
for a patient. Over time, this risk-beneﬁt ratio can change,
providing an indication for deprescribing. Certain adverse
effects may develop only after longer-term use—for example,
tardive dyskinesia with antipsychotics and renal impairment
with lithium.Normal aging alters both the pharmacodynamics
and the kinetics of medications, increasing vulnerability to
side effects. Pregnancy, the development of general medical
comorbidities, new medication interactions, and substance
abuse raise similar issues. Psychological factors, such as
patients’ choice, their understanding of illness andmedication,
and their coping strategies, may evolve over time, shifting
their individual risk-beneﬁt ratio. Social factors, such as
geographical relocation, changes in ﬁnancial and insurance
status, and changes in religion, may prompt a reappraisal. The
growth of the recovery movement and patient-centered care
in psychiatry, including in pharmacological management,
further necessitates the development of deprescribing skills.
Nonadherence and Treatment Alliance. Medication non-
adherence is a signiﬁcant and underappreciated issue in all
of medicine. Abrupt, unsupervised discontinuation of certain
medications riskswithdrawal syndromes, rebound effects, and
relapse of the underlying condition. Although research has
attributed nonadherence to a range of pragmatic as well as
treatment-speciﬁc factors, the lack of communication between
the patient and the prescriber when the patient unilaterally
decides to discontinue a medication raises questions of dis-
connect in the patient-prescriber relationship that are par-
ticularly pertinent in psychiatry. Perhaps by showing expertise
in collaboration—and awillingness to collaborate—in regard to
medication discontinuation from the outset, prescribers may
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reduce the chances of this disconnect and improve the alli-
ance. Ambivalence about diagnosis and treatment is prevalent
in psychiatry, attributable to the relative proximity of disor-
ders to the core sense of self or to direct effects on insight and
judgment. Due to the stigma associated with mental illness,
which is often heightened by news media coverage, and an
initial treatment focus on remission, a patient’s ﬁrst impres-
sion of the psychiatrist may be that of a “pill pusher.” Alter-
natively, a patient may desire to please the prescriber through
continued adherence, which might also generate conﬂict in
regard to treatment. An initial discussion that gives equal
weight to deprescribing (when appropriate) as well as pre-
scribing may serve to counter such conﬂict.
Furthermore, guided by the patient’s preference, collab-
oration about a trial reduction or discontinuation of a med-
ication, even if unsuccessful, might enhance the therapeutic
relationship and the patient’s understanding of the illness
and ownership of the medication regimen.
Polypharmacy. Practice guidelines recommend adequate
trials of single medications before the addition of a second,
but real-world practice differs (3). Medicaid claims data
have shown that psychotropic polypharmacy has risen con-
sistently over the past two decades in various states (4,5).
Although certain combinations of psychotropics have been
shown to be beneﬁcial in “treatment resistant” psychiatric
disorders, the stability of the treatment-resistant label over
time is unknown. In fact, Stahl and Grady (6) found in their
review that most practitioners do not try to discontinue one
of the drugs after a combination proves beneﬁcial, even
though such discontinuation would establish the true need
for the combination. Meanwhile, the risks, especially with
increasing age and general medical comorbidities, render
the risk-beneﬁt ratio even more disproportionate.
Implementing Deprescribing in Psychiatry
It is imperative that every psychiatrist be able to provide an
individualized risk-beneﬁt analysis of each medication for a
given patient at a given time point, keeping in mind general
medical comorbidities and psychosocial circumstances.
Woodward (7) proposed the following ﬁve principles of
deprescribing in geriatric medicine: review all current medi-
cations, identify medications to be targeted for reduction or
cessation, plan a deprescribing regimen, plan in partnership
with patients and caregivers, and provide frequent review and
support. A review of more than ten studies of deprescribing
found concordance in these ﬁve principles as the crucial
elements of the process (8).
Further key considerations for psychiatry may be the
timing and context of the change, the patient’s alternative
coping strategies, the meaning of the change for the patient,
the strength of the treatment alliance, the level of risk, and
whether the patient is receiving mandated treatment (see
box). Environmental factors that could trigger relapse, in-
cluding changes in housing, employment, ﬁnances, signiﬁcant
relationships, and even season, may need to be considered,
along with holidays and anniversaries, in decisions about
the timing of a deprescribing intervention. Furthermore, be-
cause risk behaviors vary widely among patients, the level of
risk should be carefully considered in evaluating a patient for
deprescribing. Accordingly, for patients with a history of sui-
cide or homicide attempts, multiple hospitalizations in the
recent past, severe relapses after dose reduction, or poor social
support, deprescribing should be considered more cautiously
(9). In all cases, one would also need to consider whether the
patient is under mandated treatment and any expressed wish
by the patient to reduce or discontinue medication.
Obtaining a complete list of the patient’s medications and
discussing the perceived risks and beneﬁts of each medica-
tion should be the next step. As noted in geriatric medicine
(10), barriers to obtaining a complete medication list include
fragmentation of care and a failure to communicate the
treatment rationale to the patient. Coordination with the
patient’s primary care physician may involve frequent oral
communication and sharing of medical records. In gener-
ating a priority list of medications to consider for depres-
cribing, it is essential to ensure that all stakeholders are
apprised of the evidence in regard to the risks and beneﬁts of
a medication. A medication with a high potential risk and
low potential beneﬁt would typically top the priority list.
However, with psychotropicmedications, wemay encounter
instances when the ratio is skewed in a particular direction
because of a very high or low potential risk or beneﬁt. For
instance, although the risk of continuing benztropine in
combination with haloperidol for ﬁve years might be consid-
ered low, the potential beneﬁt is also low (perhaps lower than
the risk for a given patient). For patientswithmultiple general
medical comorbidities, a pharmacist’s input on drug interac-
tions and drug prescribing cascades might be invaluable.
Once the medication and tapering have been planned, the
decision needs to be discussed with the patient’s treatment
team, including visiting nurses, social workers, case man-
agers, and therapists. The patient’s family, if involved, may
be a valuable support for the patient. Patients may inter-
nalize anxiety experienced by their care providers, and this
in itself could trigger psychological symptoms (11). Buy-in by
family members and other care providers is therefore cru-
cial, not only to minimize this effect but also to ensure early
identiﬁcation of relapse and avert hospitalization. The pre-
scriber should also consider an additional risk—namely, the
patient may interpret the proposal to deprescribe as a mes-
sage that no treatment is warranted. Before the initiation
of a taper, it may be worthwhile to spend several visits
exploring the potential meaning of the change and develop-
ing an action plan in case symptoms recur and to manage
withdrawal symptoms. The plan might include several non-
pharmacological measures, such as increasing the frequency
of visits to a therapist, developing a Wellness Recovery
Action Plan (12), connecting with peer support, and teaching
the patient and caregivers to identify early warning signs of
illness relapse.
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Symptoms of withdrawal from antidepressants, antipsy-
chotics, and anticholinergic agents have been well described
in the literature. In psychotic disorders, delineating with-
drawal psychoses from a true relapse may be challenging.
Similarly, in depressive disorders, many symptoms of with-
drawal from selective serotonin reuptake inhibitors can be
misinterpreted as symptoms of a depressive relapse. As with
standard practice in prescribing a new medication, frequent
visits during tapering of a medication are advisable. The rate
of taper may need to be adjusted depending on the patient’s
experience, withdrawal symptoms, recurrence of symptoms,
and interim stressors.
Potential Challenges
Arguably, the manner in which a medication is prescribed
will determine the ease withwhich it may be deprescribed, if
appropriate. As medication visits become briefer, the focus
can potentially shift towards symptoms rather than a deeper,
holistic exploration of the illness, whichmay breed superﬁcial
prescribing (that is, transactions of symptom andmedication).
Many factors can contribute to anxiety about and resistance
toward reducing or discontinuing a psychotropic medication for
the psychiatrist, family members, and the patient, including a
belief thatmental illnesses require lifelongmedication treatment
Deprescribing psychotropic medicationsa
Step 1: Choose the right time
• Avoid times of crisis or acute phase of illness
• Ensure that the treatment alliance is well established
• Use caution when the patient is actively abusing substances
Step 2: Compile a list of all the patient’s medications
• Document dose, route, expected duration, and original indication
• Document current therapeutic and adverse effects
• Estimate potential drug-drug interactions and future risk-beneﬁt ratio
Step 3: Initiate the discussion with the patient
• What is the patient’s knowledge and attitudes about the medications?
• What is the patient’s perception regarding the beneﬁts and risks of each?
• Explore the meaning of medication(s) to the patient
Step 4: Introduce deprescribing to the patient
• Inform the patient about potential indications for and the process of deprescribing
• Solicit ideas, concerns, and expectations
• Address any anxieties on the part of the prescriber, patient, family, or clinical care team
• Get family and caregiver buy-in
Step 5: Identify which medication would be most appropriate for a taper
• Collaboratively weigh pros and cons of deprescribing each medication
• Solicit the patient’s preferences
Step 6: Develop a plan
• Set a start date and rate of taper
• Is a switch to another medication or formulation indicated?
• Reinforce alternative biopsychosocial strategies for addressing symptoms
• Inform the patient about expected and possible discontinuation effects and their timing
• Agree on a monitoring and follow-up schedule and crisis plan
Step 7: Monitor and adapt, if necessary
• Adjust rate of taper
• Treat discontinuation syndrome or relapse
• Abort or defer deprescribing
aAlthough the entire array of medications taken by a patient needs to be considered for deprescribing, psychiatrists may focus on psychotropic
medications and provide the impetus for deprescribing of other medications through coordination with primary care physicians and
pharmacists.
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and distress related to both signs and symptoms. The prescriber
may desire to maintain the status quo once stability has been
achieved and may be reluctant to change medications. Further-
more, many long-term side effects are not immediately visible
(for example, renal impairment) and may not be accompanied
by subjective distress (for example, tardive dyskinesia), and the
prescriber may not ask about certain side effects at every visit
(for example, sexual side effects). It is not surprising that there
is a wealth of clinical evidence for initiating psychiatric medi-
cations and little evidence for discontinuing them. Even if psy-
chiatrists wish to deprescribe, the lack of guidelines and data on
discontinuation of medications serves as a barrier.
Future Directions
As in the study by Farrell and colleagues (13), discussion by a
panel of psychiatrists, primary care physicians, pharmacists,
social workers, therapists, and patients may help formulate a
consensus hierarchy of medications for deprescribing in psy-
chiatry. Within individual systems of care, multidisciplinary
“deprescribing committees” could be modeled on a traditional
consultation service. The committees could prepare a report
for patients and prescribers that includes a hierarchy of med-
ications that could be reduced or discontinued and a plan to
manage emerging issues. It will be essential to develop strate-
gies for closer coordination with primary care physicians so as
to implement deprescribing as a general medical strategy (in-
cluding all the medications that a patient takes) rather than
restricting it to psychiatric medications.
Introducing the concept of deprescribing in psychiat-
ric training and generating guidelines based on existing
literature are important ﬁrst steps. Although discontinuation
trials exist in psychiatry, further research is indicated to
reﬁne the parameters of “good deprescribing” in the bi-
ological, psychological, and social domains. Rossello and
colleagues (2) have called for a reexamination of long-term
prescriptions of many cardiovascular drugs. Similarly,
existing data on long-term medication management in psy-
chiatric disorders may need to be reexamined critically with
a view to identifying patients for whom deprescribing might
be successful. Studies of receptor changes and their corre-
lation with withdrawal symptoms could provide useful data
on managing and preventing withdrawal syndromes. The
Patient Attitudes Towards Deprescribing Questionnaire (14)
has been used in geriatric medicine and could be adapted for
psychiatry to measure the acceptability of deprescribing.
Conclusions
In response to a growing awareness of adverse medication
effects, the impacts of patients’ changing physiology and
psychosocial context, and the beneﬁts of patient-centered
practice, the intervention of deprescribing has much to offer
psychiatry. For patients who choose to manage their psy-
chiatric illness with fewer or no medications, psychiatrists
must be equipped to collaborate in analyzing potential risks
and beneﬁts and developing a plan for managing withdrawal
symptoms and relapses. Critical review of the existing lit-
erature and new research on deprescribing interventions in
psychiatry are needed.
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Abstract
Objective Traditional, lecture-based methods of teaching
pharmacology may not translate into the skills needed to com-
municate effectively with patients about medications. In re-
sponse, the authors developed an interactive course for third-
year psychiatry residents to reinforce prescribing skills.
Methods Residents participate in a facilitated group discus-
sion combined with a role-play exercise where they mock-
prescribe medication to their peers. Each session is focused
on one medication or class of medications with an emphasis
on various aspects of informed consent (such as describing the
indication, dosing, expected benefits, potential side effects,
and necessary work-up and follow up). In the process of
implementing the course at a second site, the original format
was modified to include self-assessment measures and video
examples of experienced faculty members prescribing to a
simulated patient.
Results The course was initially developed at one site and has
since been disseminated to a number of other institutions.
Between 2010 and 2016, 144 residents participated in the
course at the authors’ two institutions. Based upon pre/post
surveys conducted with a subset of residents, the course sig-
nificantly improved comfort with various aspects of prescrib-
ing. Although residents may also gain comfort in prescribing
with experience (as the course coincides with the major out-
patient clinical training year), improvement in comfort-level
was also noted for medications that residents had relatively
little experience initiating. At the end of the year, half of the
residents indicated the course was one of their top three pre-
ferred methods for learning psychopharmacology in addition
to direct clinical experience and supervision (with none listing
didactics).
Conclusion An interactive prescribing workshop can improve
resident comfort with prescribing and may be preferred over a
traditional, lecture-based approach. The course may be partic-
ularly helpful for those medications that are less commonly
used. Based upon our experience, this approach can be easily
implemented across institutions..
Keywords Residents . Psychopharmacology . Teaching
methods
There is no consensus about the best way to teach psycho-
pharmacology to psychiatry residents. Historically, psycho-
pharmacology has been taught in a passive way with residents
attending lectures where each class of medication is reviewed
[1, 2]. Residents are often presented with a large amount of
information about each medication and are faced with the
challenge of integrating multiple resources, including expert
guidelines and clinical trials [3]. Expecting residents to mem-
orize the amount of material presented to them during these
lectures is unrealistic. It is also not clear how well this ap-
proach translates into the actual skills required to prescribe
these medications to patients [2].
The act of good prescribing requires more than acquired
knowledge—psychiatrists must draw upon a combination of
communication skills, ethics, therapeutic process, and profes-
sional identity. Residents need to be able to present material
clearly and obtain informed consent, all while remaining
attuned to psychological factors within the doctor-patient
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relationship that plays a role in medication response [4, 5].
Translating knowledge about medications in a way that is easy
for patients to understand is not a skill that is usually taught in
a classroom. For example, residents may learn in a classroom
that lamotrigine has a rare but serious side effect of Stevens-
Johnson Syndrome, but may not know how to discuss this risk
with a patient without generating excessive anxiety.
These skills are also challenging to teach in modern treat-
ment settings. The “see-one, do-one, teach one” model of
adult learning assumes these types of conversations are
modeled by supervisors and that residents have clinical expe-
rience with all of the medications that have been discussed in
the classroom. However, this is frequently not the case.
Training in psychopharmacology is often highly variable, de-
pending on the expertise of the faculty supervisor and the
unique caseload of patients that each resident sees. In treating
individual patients, residents often have guidance in terms of
medication choice and dosage but not necessarily explicit ad-
vice about how to talk to patients, especially during their
Postgraduate Year 3 (PGY3) where direct supervision in out-
patient care is limited [6]. In addition, not every supervisor
emphasizes how these conversations might be customized to
address individual factors unique to the patient but highly
relevant to treatment decisions [4, 7]. Furthermore, residents
may get considerable experience using first line agents (such
as a selective serotonin reuptake inhibitor, or SSRI, for depres-
sion) but may not get any practice prescribing third line agents
(such as a monoamine oxidase inhibitor, or MAOI), further
limiting their clinical educational experience.
To address these gaps in the clinical experience, psycho-
pharmacology curricula in residency have started to include
more interactive options. While these strategies (such as
problem-based learning and interactive games) have beenwell
received and cover basic facts about medications in an inter-
active manner, they do not address the question of what the
physician actually says to patients about medications [8, 9].
At the same time, the milestones initiative within residency
training requires programs to perform more objective assess-
ments of residents’ patient care, medical knowledge, and com-
munication skills [10]. The ability to communicate clearly and
discuss treatment options with patients cuts across all of these
domains and is an important skill set to assess during residen-
cy training.
Here, we present the development, adaptation, and evalua-
tion of a prescribing workshop course that reinforces acquisi-
tion of medical knowledge related to psychopharmacology
and addresses the communication skills needed to effectively
prescribe medications. Our goal was to create a new frame-
work for teaching psychopharmacology that gives residents
prescribing experience in a structured classroom setting and
to provide a model for teaching psychopharmacology that
translates directly to clinical practice.We hoped the interactive
format of this course would be engaging for residents and
would improve resident comfort with the various elements
that go into prescribing. These include discussing with pa-
tients; recommended treatment options; how to take specific
medications; benefits and potential limitations (including ad-
verse effects); mechanisms of action; relevant work up; and
other considerations.
Course Development
The course was developed for third year (PGY3) psychiatry
residents. We felt PGY3 residents were an appropriate audi-
ence for this course as they are transitioning to a more auton-
omous role in the outpatient setting, often without direct su-
pervision. Therefore, their motivation to learn the various
skills of prescribing in the outpatient setting is very high.
The organizing principle of the course was straightforward:
we want to ensure that residents will be safe and effective
prescribers of psychotropic medications. To this end, we de-
signed a course frame that focuses on this explicit behavioral
skill: each session centers on a resident having the opportunity
to role play prescribing a medication in a safe setting and with
the opportunity for structured feedback. Each “prescriber’s
workshop” is devoted to a designated medication class or
clinical concept (such as augmenting agents). Residents are
expected to prepare basic information about the specified
medication before each session in a flipped classroom model
using a standard template and be ready to apply this basic
information to a clinical scenario. (A copy of the template is
available upon request.)
Structure of the Yale Workshop
The original workshop developed at Yale in 2010 is a 75-min
workshop with approximately 20 sessions over the first
6 months of the PGY3 year. Each session is divided into three
equal parts designed to address knowledge, skills, and pro-
cess. The first 15–20 min of each workshop is a review of
the information entered into the template to consolidate
knowledge, allow for questions, and ensure that each resident
is comfortable with the core content. The next 30 min of the
workshop is devoted to a role-play exercise. During this sec-
tion, residents break up into groups of three: one resident plays
the role of prescriber, another plays the role of the patient, and
the third acts as observer (faculty members also circulate to
offer additional feedback). Following the encounter, the small
group has time to discuss the role play. The residents then
rotate so that each resident has an opportunity to play each
role. For some sessions, faculty demonstrates an example of
what theymight say to a patient while prescribing the assigned
medication. The final 25 min of each workshop is designated
for group reflection and discussion of the processes that
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occurred during the role-play (such as things that worked well
or were more challenging).
Several challenges arose after the start of this course. In the
first year of the workshop, different expert psychopharmacol-
ogists taught individual sessions, each on the area of his or her
expertise. This led to variability in class frame, with some
sessions deviating from the intended structure. At the begin-
ning of the course, the initial review of medication facts at
times devolved into discussions of esoteric details rather than
practical prescribing information. Furthermore, role-play ex-
ercises were initially limited by mutual anxiety: residents
would be anxious to prescribe a medication in front of peers
and supervisors; expert faculty—often participating in one or
two sessions only—at times felt uncomfortable engaging in a
teaching format with which they had no experience. As a
result, residents and faculty could together collude to avoid
the role-play exercise.
To address these challenges, two faculty members were
recruited in the second year to co-direct the course. One fac-
ulty member had relative strength for general psychopharma-
cology knowledge and the other had relative expertise in ther-
apeutic communication and in managing group process.
Having the same two individuals run all sessions dramatically
enhanced group comfort with the exercise and ensured con-
sistency in the workshop frame throughout the course.
Adaptations at Columbia
Using the general framework developed at Yale, Columbia
decided to implement a similar course for PGY3 residents
starting in 2013. The course started out as a year-long monthly
60-min workshop and was expanded during the second year
of implementation to twice a month for 75 min each.
Adaptations included (1) addition of an educational video-
series demonstrating how a panel of expert psychopharmacol-
ogists discuss various medications with patients; (2) the inclu-
sion of additional preceptors (faculty and PGY4 volunteers,
instead of peers) to observe, assess, and provide feedback for
residents working in pairs; and (3) administration of pre and
post workshop self-assessments measuring resident comfort
level in the different tasks of prescribing.
In order to build in time for the expert videos and the
discussions that follow, there is no review of the medication
information template in class. Each workshop begins with the
presentation of a brief clinical scenario (e.g., “Patient is a 24-
year-old man presenting with his first major depressive epi-
sode, you will now discuss starting citalopram”). Participants
then divide into groups of three consisting of two PGY3 res-
idents and one preceptor (either a faculty member or a PGY4
resident volunteer). Following each role-play, preceptors help
to facilitate discussion and provide feedback.
Educational Videos Since PGY3 residents almost never
observe experienced psychopharmacologists start medica-
tions with outpatients, we felt it would be educational for
residents to have a chance to see how experienced fac-
ulty members discuss medications with their patients.
Residents tend to feel more confident when they have
one-to-one supervision with a senior clinician, and vid-
eotapes are a method for making this experience acces-
sible to more residents (especially considering the time
constraints faced by senior clinicians). A library of
videos was created of expert psychopharmacologists
role-playing how they talk to patients about specific
medications. As an example of content, one video is of
a psychopharmacologist who specializes in affective dis-
orders prescribing lithium to a fictionalized patient. In
addition to the demonstration, these videos often include
“clinical pearls” at the end.
The video corresponding to the designated medication was
played at the end of each workshop so residents could observe
a particular prescribing style after they all had a chance to
complete the role-play exercise. This was meant to encourage
residents to think through the material themselves and not feel
as though there is only one correct way to discuss a medication
with a patient.
Course Preceptors There is a core group of faculty and
PGY4 preceptors with up to four present at each workshop
(in addition to the course directors: a psychopharmcology ex-
pert and the director of the outpatient clinic) to observe the
role-plays. The goal of involving PGY4 residents as precep-
tors was that theywould help PGY3 residents feel comfortable
while demonstrating the remarkable growth in knowledge and
skill the residents will acquire by the end of their third year. Of
note, many PGY4 residents have volunteered to participate as
it gives them an opportunity to teach and consolidate their
own learning. Preceptors and faculty were provided with
checklists of elements of prescribing to guide their listening
and discussion during the role-play exercise and to remind
them of teaching points.
Course Assessments At Columbia, self-assessment tools
were added to see whether the goals of learning were met.
The Institutional Review Board (IRB) of the New York
State’s Psychiatric Institute determined that this study was
not human subject’s research and was therefore not subject
to IRB review. Residents were surveyed in two ways: 1) pre
and post surveys within each workshop focusing on the
comfort level discussing various factors of a specific med-
ication with patients, to measure the impact of the class
itself and 2) pre and post course surveys about actual clini-
cal experiences and comfort with prescribing various med-
ications, to measure the impact of the course as a whole
versus other methods of teaching psychopharmacology
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(i.e., direct supervision, online resources, traditional didac-
tics). Both types of surveys used a 5-point Likert-type scale.
Individual workshop data was collected and analyzed for
participants at Columbia during the inaugural year of the
course in 2013–2014. Data were collected before and after
individual workshops on SSRIs, MAOIs, tricyclic antide-
pressants (TCAs), stimulants, valproic acid, lithium, and
lamotrigine. Outcome data were analyzed using a paired t
test of pre and post assessments.
Since this course coincided with the residents’ major
outpatient clinical year, we sought to understand the poten-
tial value of the course while taking into account the fact
that our main outcome (comfort level in prescribing) would
likely increase based upon experience alone (which includ-
ed weekly supervision in psychopharmacology and experi-
ence prescribing medications in managing outpatient case-
loads). Based upon one of the original goals of the course,
we hypothesized that the course would be particularly ben-
eficial for learning how to prescribe those medications that
were less commonly used in clinical practice. For each
medication (or medication class), we calculated the per-
centage of residents who reported initiating treatment more
than two times by the end of the year. We specifically fo-
cused on resident experience of initiating treatment (as op-
posed to prescription renewal) since this was the focus of
the workshop. We then looked at gains in comfort level
across medications taught in the course that were common-
ly initiated by residents in comparison to those that were
not commonly initiated. As a control, we also assessed
resident comfort level in initially prescribing medications
that were not commonly used nor taught in prescribing
workshop course.
Results
Between 2010 and 2016, 144 psychiatry residents have
participated in the prescribing workshop across both
PRE     
PRE     
PRE     
PRE     
POST    
POST    
POST    
POST    
1. Establishing a treatment alliance -2.044 11 .066
-4.236 11 .001
-8.476 11 <0.001
-7.988 11 <0.001
-5.876 11 <0.001
-8.460 11 <0.001
-9.588 11 <0.001
-9.409 11 <0.001
-7.113 11 <0.001
PRE     
1 2 3 4 5 t df p-value
POST    
PRE     
POST    
PRE     
PRE     
POST    
PRE     
POST    
POST    
2. Discussing with patients the recommended 
treatment options for the presenting symptoms
3. Discussing with patients how medication works
4. Discussing with patients how to take medication
5. Discussing with patients the benefits of 
taking medication
6. Discussing side effects of taking medication
7. Discussing the possibility of any serious adverse 
events that may come up when taking medication
8. Discussing any relevant workup necessary when 
using medication
9. Discussing the plan for appropriate follow up when 
using medication
Fig. 1 Boxplots of pre–post workshop assessments for each of the nine comfort questions with individual paired t tests. Vertical lines represent the mean,
with the surrounding box representing the 25th and 75th percentiles and the whiskers representing the 5th and 95th percentiles
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institutions (108 from Yale and 36 from Columbia). In
order to determine the overall impact of the course, data
from each workshop at Columbia held between 2013 and
14 were combined and a paired t test was performed on
pre/post assessments (58 total paired entries from 12 par-
ticipating residents). As displayed in Fig. 1, residents re-
ported significant improvement for every question
assessing comfort, with the exception of the one focusing
on “establishing a treatment alliance” which was relative-
ly high at baseline.
In the inaugural year of the workshop at Columbia, 11
participants also completed assessments at the beginning and
end of the year. As shown in Table 1, more than 50% of
residents reported relatively limited experience in prescribing
a subset of medications (e.g., TCAs, lamotrigine, and stimu-
lants). Despite this limited experience, residents showed
sustained significant improvement in comfort prescribing
these medications at the end of the year (p< .05). As a com-
parison, for less commonly prescribed medications where
there was no corresponding workshop (e.g., disulfiram,
buprenorphine, clozapine), residents did not show significant
improvement over the course of the year in terms of comfort
prescribing. For more commonly prescribed medications for
which there was also a workshop (e.g., SSRIs and second
generation antipsychotics), there was no significant improve-
ment in comfort over the course of the year and the initial
comfort in prescribing these medications at the beginning of
the year started at a higher baseline (>3.5). For commonly
prescribed medications where initial comfort started at a base-
line of <3 (e.g., valproic acid and lithium), there was still a
significant improvement in comfort after the year (p< .05),
though it is unclear if this is related to this course or clinical
experience.
Residents in the first year of the workshop were asked to
list their top three preferred methods for learning psychophar-
macology during their PGY3 year.While none of the residents
listed traditional didactics, 50% of residents indicated that the
prescriber workshop was one of their preferred methods of
learning. All residents listed clinical experience as their num-
ber one method for learning psychopharmacology.
Discussion
These data support the value of a prescriber’s workshop for
improving resident comfort with various aspects of pre-
scribing and suggest that residents see the course as a useful
method for learning psychopharmacology. The data also
indicate that residents prefer this workshop-format over a
traditional, lecture-based approach. The pre- and post-
course data collected in the first year at Columbia suggests
that this course can lead to significant improvement in
Table 1 Resident comfort level with initiating treatment for various medications (or classes of medications) at the beginning and end of the year-long
course based upon a 5-point Likert-type scale
Medication Percentage
with substantial
experience*
(n = 11)
Pre mean Pre SD Post mean Post SD Corresponding
workshop
Paired t test
(p value)**
Buprenorphine 0% 1.45 0.69 1.82 0.75 No NS
Disulfiram 0% 1.55 0.69 2.00 0.63 No NS
Clozapine 27% 2.27 0.79 3.09 0.94 No NS
TCA 0% 2.09 0.54 3.64 0.92 Yes 0.001
Lamotrigine 18% 2.45 1.21 3.82 0.75 Yes 0.016
Stimulants 36% 2.18 0.75 3.82 0.60 Yes 0.000
Lithium 82% 2.82 0.98 4.09 0.94 Yes 0.014
Depakote 100% 2.91 1.04 4.18 0.60 Yes 0.008
SSRI 100% 4.09 1.04 4.82 0.60 Yes NS
Atypical Antipsychotic 100% 3.64 1.21 4.36 0.67 Yes NS
The Likert scale included the following anchors:
(1) Would not prescribe this medication on my own to a patient today
(2) Would not prescribe without having the opportunity to read/learn more before sitting with patient
(3) Would prescribe if necessary and might want to consult a resource before prescribing
(4) Likely would prescribe this medication on my own but might double check something afterwards
(5) Totally comfortable prescribing this medication and would do so without hesitation
*Substantial experience was defined as initiating treatment more than twice by the end of the outpatient clinical year
**Significance at the p< .05 level
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comfort with prescribing medications even with little to no
corresponding clinical experience, which may help resi-
dents feel more comfortable in considering these medica-
tions as treatment options for their patients in the future.
This is especially encouraging in that an original goal of the
course was to address a frequent complaint of graduating
residents that they never prescribed certain rare medica-
tions (e.g., an MAOi or TCA)—following this course, res-
idents will have prescribed all of these agents at least once
with supervision (albeit in a mock setting).
These workshops do not significantly improve residents’
comfort with establishing a treatment alliance, which is not
surprising as baseline comfort level was reported to be high.
This is likely because building an alliance is a skill that is
emphasized in all areas of clinical care during residency, in-
cluding psychotherapy training, and is usually taught much
earlier.
Limitations of this study include the fact that although there
were a large number of participants across both sites, the sub-
set of residents who completed assessments is relatively small.
Furthermore, while these assessments focused on resident
comfort with prescribing before and after each workshop,
we did not assess actual prescribing practices after the com-
pletion of the course.
Despite these limitations, the course has consistently re-
ceived positive feedback across both institutions. At
Columbia, 10 out of 24 participants in the first 2 years of the
course have returned to serve as preceptors during their PGY4
year, which may have helped to provide them with repeat
exposure to this intervention and consolidate gains. The addi-
tion of a library of videos of psychopharmacology experts not
only addresses the challenge of limited time and access to
expert psychopharmacologists but also makes the workshops
easier to implement. Because of these videos, the faculty and
PGY4 preceptors present during the workshop do not need to
be experts in the assigned medication being discussed. Both
versions of the course have been implemented at other pro-
grams and have received consistently positive feedback. The
Columbia group is working to make their videotapes available
through a protected residency-wide wiki page so that residents
can access them after the course (particularly for those they
miss) and, ideally, so that they can ultimately be made acces-
sible to other academic institutions for training purposes.
Teaching psychopharmacology in residency has historical-
ly been challenging, as the act of prescribing draws upon
many factors and depends upon the integration of many
sources of information. Using an interactive practice-based
approach can help residents master not only the details of
medications, but also how to think critically to present the
material to patients clearly and improve their comfort as pre-
scribers. It is encouraging that these skills, traditionally felt to
be gained only through clinical experience, can be strength-
ened in a formal and standardized classroom setting.
Compliance with Ethical Standards
Disclosures On behalf of all authors, the corresponding author states
that there is no conflict of interest.
References
1. Glick ID, Zisook S. The challenge of teaching psychopharmacolo-
gy in the new millennium: the role of curricula. Acad Psychiatry.
2005;29(2):134–40.
2. Glick ID, Salzman C, Cohen BM, Klein DF, Moutier C, Nasrallah
HA, et al. Improving the pedagogy associated with the teaching of
psychopharmacology. Acad Psychiatry. 2007;31(3):211–7.
3. Salzman C. The limited role of expert guidelines in teaching psy-
chopharmacology. Acad Psychiatry. 2005;29(2):176–9.
4. Mintz DL. Teaching the prescriber’s role: the psychology of psy-
chopharmacology. Acad Psychiatry. 2005;29(2):187–94.
5. Mallo C, Mintz DL, Lewis KC. Integrating psychosocial concepts
into psychopharmacology training: a survey study of program di-
rectors and chief residents. Psychodyn Psychiatry. 2014;42(2):243–
54.
6. Dubovsky SL.Who is teaching psychopharmacology?Who should
be teaching psychopharmacology? Acad Psychiatry. 2005;29(2):
155–61.
7. Salzman C, Glick ID. Teaching the teachers of clinical psychophar-
macology. Acad Psychiatry. 2015;29(4):475–81.
8. Zisook S, Balon R, Benjamin S, Beresin E, Goldberg DA, Jibson
MD, et al. Psychopharmacology curriculum field test. Acad
Psychiatry. 2009;33(5):358–63.
9. Zisook S, Benjamin S, Balon R, Glick I, Louie A, Moutier C, et al.
Alternate methods of teaching psychopharmacology. Acad
Psychiatry. 2005;29(2):141–54.
10. The Accreditation Council for Graduate Medical Education and
The American Board of Psychiatry and Neurology. The
Psychiatry Milestone Project. July 2015. https://acgme.
org/acgmeweb/Portals/0/PDFs/Milestones/PsychiatryMilestones.
pdf. Accessed 21 Nov 2016.
Acad Psychiatry (2017) 41:491–496
John	D.	Cahill,	September	2017	
	 	 	 146	
WORK	8																						
WORK	8																															
Send Orders for Reprints to reprints@benthamscience.ae 
Current Psychiatry Reviews, 2016, 12, 000-000 
REVIEW ARTICLE 
1573-4005/16 $58.00+.00 © 2016 Bentham Science Publishers 
Building Early Intervention Services for Psychotic Disorders: A Primer for 
Early Adopters in the U.S. 
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Abstract: Recent developments in the U.S. healthcare policy signal a growing commitment to early 
intervention for psychotic disorders. A growing international and U.S. research database supports the 
effectiveness of specialty team-based models adapted to care for young individuals with recent onset 
psychosis. The RAISE (Recovery After an Initial Schizophrenia Episode) initiative, sponsored by the 
NIMH (National Institute of Mental Health), has defined such Coordinated Specialty Care (CSC) services 
as a new benchmark for care across the U.S., and published a variety of resources to support 
dissemination. Funding initiatives led by the center for Substance Abuse and Mental Health Services 
(SAMHSA), and support from other national organizations, have catalyzed interest in community 
agencies across the country. We offer guidance to such early adopters and supplement extant resources 
with a focus on the process of setting up such programs. Adopters have numerous decisions to make. These 
include determining admission criteria, structuring care processes to maximize impact, choosing from 
several empirically based interventions, and resourcing workforce development. We provide a guide to 
salient resources, and lessons learned from a decade old CSC, to aid in these complex decisions. We end 
with a discussion of limitations in the current knowledge base, and the need for responsive research. Early 
intervention services can engender application of demonstrably effective treatment, while also providing 
platforms for research to improve and develop new treatments. Collaborations between a wide variety of 
government, academic and commercial stakeholders will be essential to realize the transformative public 
health impact of early intervention for psychotic disorders. 
Keywords: Psychosis, early intervention, first episode, schizophrenia, coordinated specialty care. 
1. INTRODUCTION
 The U.S. may be in the midst of a transformation in the 
delivery of services to individuals and families confronting 
the recent onset of a psychotic illness. While the intuitive 
notion of early intervention is likely at least as old as the 
recognition of these disorders, the past two decades have 
seen this idea made operational in effective service models 
across several countries. Several pragmatic randomized trials 
of comprehensive team based care have been accompanied by 
national policies supporting systematic implementation [1]. 
Until recently however, the reality for patients in the U.S. 
has presented a paradox: while seminal research has emerged 
from this country, few systematic efforts had been mounted 
to disseminate services that can deliver empirically based 
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interventions. In 2015, the publication of the first U.S. 
randomized trial demonstrated the effectiveness of a real-
world public sector based service in Connecticut [2]; this was 
followed by a large cluster randomized trial demonstrating 
feasibility in community sites across 21 states [3]. This 
actionable evidence generated with funding from the National 
Institute of Mental Health (NIMH) has been accompanied by 
federal funding initiatives. The Substance Abuse and Mental 
Health Services Administration (SAMHSA) beginning in 
2014, has directed that at least 10% of its Mental Health Block 
Grant (MHBG) to State Mental Health Agencies (SMHA), 
be dedicated toward early intervention services. As we have 
argued previously [4], SMHAs are a de facto national public 
mental health system, and have a strong incentive to invest in 
approaches to reduce the long-term morbidity of psychotic 
illnesses. The growth of new early intervention services 
across the U.S., in both public and private settings, spurred 
in part by this federal initiative, is a welcome development. 
This paper is targeted at such ‘early adopters’ in the U.S. 
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2. BUILDING AN EARLY INTERVENTION SERVICE
IN THE U.S.: WHERE TO BEGIN? 
A map is not the territory ... 
—  Alfred Korzybski (1933, p. 58) [5] 
 Unlike previous pioneers in Australia, Canada, Northern 
Europe and the U.K., developers of new services in the U.S. 
can draw from a rich array of resources. Aside from 
informative reviews of international implementations [6], the 
RAISE project has assembled a vast online portal to support 
implementation of what the NIMH has usefully termed 
Coordinated Specialty Care (CSC). This label applies to a 
variety of services that share a comprehensive team based 
approach for new onset psychosis [7]. The web site includes 
links to empirical papers, manuals and webinars addressing a 
broad range of critical issues. Program developers can thus 
find detailed and essential ‘maps’ to guide their journey 
through the fragmented U.S. healthcare system. CSC based 
services can play a critical role in integrating local networks 
of healthcare providers towards the complex needs of these 
patients and their families. In keeping with the spirit of the 
epigraph, however, these maps cannot be expected to address 
all - or even the most salient - challenges that will arise for such 
early adopters. Also, while highlighting multiple destinations 
(e.g. infrastructure needs, workforce development, funding 
models, specific treatments), these maps can be intimidating 
to planners new to the needs of this population. 
 In what follows, we emphasize selected aspects of the 
work of a CSC, drawing from the evolving experiences of a 
decade old service (Specialized Treatment Early in 
Psychosis; STEP) [4], that can help guide the difficult 
decisions involved in setting up new services. This is 
intended to supplement, not replace the resources above, and 
far from being prescriptive, aims to clarify the many 
reasonable choices developers can make in the face of 
complex decisions. Perhaps more nebulous, but important, is 
our aim to elucidate a culture [8] of practice wherein the 
espoused values of early intervention are most likely to be 
actually experienced by patients, families, referrers and 
others in the community who have a stake in the health of 
emerging adults with new onset psychotic disorders. 
2.1. Outreach: Acknowledging Local Pathways to Care 
 New programs might organize their thinking around the 
sequence of events in a putative pathway to care. Much has 
usually transpired before a patient becomes visible to most 
clinics, and developers might draw on their knowledge and 
experiences of local pathways to better curate entry into their 
services. Some CSCs use separate outreach teams who 
screen and evaluate patients at the point of referral and, if 
appropriate, connect them to the ongoing treatment team. 
Other clinics assign a clinician to be designated as the outreach 
and engagement coordinator. In either case, staff might 
endeavor an assertive, yet flexible, stance toward patients 
who may be reluctant because of prior aversive treatment 
experiences. Others may lack insight, suffer disorganization, 
or be otherwise unwilling to seek treatment despite concern 
from others. Critically important to the “front door” of a CSC 
is its network of referral sources: mental health professionals, 
schools and universities, law enforcement and other 
emergency personnel, youth organizations, members of the 
clergy, and community leaders. Ideally, these community 
stakeholders are familiar with the CSC team, the importance 
of early identification and referral, and will facilitate 
engagement. Fledgling CSCs would do well to invest in 
relationships with key members of these local networks, 
make the referral process as simple and rapid as possible, 
and provide education and consultation to ensure patients 
will be directed to CSCs in a timely and effective manner. 
2.2. Screening: Admission Criteria 
 Patients’ first contact with STEP begins with screening 
for program eligibility (see Table 1 for our current criteria). 
Programs can use conceptual and pragmatic considerations 
to develop their own criteria. Barriers, such as the divide that 
exists in some states between separate systems that serve 
those under and over age18, or with private or public health 
insurance, or residence in certain catchment areas, may need 
to be addressed [4]. In addition to catchment area restrictions 
that may exist within their organization, implementers 
should consider travel time and what they consider a safe 
distance for managing clinical crises if they plan to offer 
mobile or home based services, as well as population size 
needed to recruit a sample large enough to justify a specialty 
clinic while maintaining reasonable staff:client ratios and a 
strong referral network. Depending on program priorities and 
clinical capacity, implementers will need to define the target 
sample, and can draw on various, defensible precedents [9]. 
Some combination of time since illness onset (e.g. within the 
first 3-5 years since frank psychosis) and age range (e.g. 16-
35yo) will help delimit a population around which to organize 
a coherent, developmentally appropriate model of care. 
While programs may wish to target their services to those in 
the earliest stages of psychosis or have patients within a 
narrower phase of development, criteria that are too restrictive 
may confuse referrers and delay access. Most early inter- 
vention programs around the world have focused on the 
treatment of primary psychotic disorders, and though co-
morbidities are expected, primary affective disorders; 
Table 1. STEP inclusion and exclusion criteria. 
Domain STEP’s Criteria 
Age 16-35 y.o. 
Diagnoses Excluded for: Psychosis confirmed to be 
secondary to substance use or a medical 
condition; Bipolar or depressive disorder 
with psychotic features; Autism spectrum 
disorder with new onset psychosis. 
Estimated illness duration <3 year since onset of psychosis 
Treatment history No exclusions for past treatment 
Insurance status No exclusions  
Town of Residence 10 surrounding towns 
Estimated Cognitive 
Ability 
Exclude for IQ below 70 or eligibility for 
State DDS 
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substance-induced psychosis; psychoses secondary to some 
medical conditions; autistic spectrum disorders and severe 
intellectual disabilities are examples of disorders for which 
patients may be better served elsewhere. Regardless of which 
criteria are selected, the screening process should allow for 
prompt determination of eligibility so as not to contribute to 
referrer burden, delay access, or complicate pathways to 
care. There is considerable ambiguity in early presentations 
of these illnesses, and programs will have to determine to 
what degree they will err on the side of inclusion versus 
exclusion. For example, a policy of including individuals 
with a high suspicion of Bipolar Disorder that is only 
confirmed on follow-up will require that the service be able 
to care for a wider range of pathology, but will protect it 
from inappropriate exclusion of primary psychotic illnesses 
that present with affective symptoms. 
2.3. Diagnostic Evaluation 
 CSC services are designed to assertively engage and treat 
primary psychotic disorders in the phase of emerging 
adulthood. Although recognizable by characteristic syndromal 
presentations and longitudinal course, these are diagnoses of 
exclusion. A multitude of medical conditions and drug-
induced states can mimic primary psychoses. Patients with 
psychotic symptoms that are secondary to an identifiable 
cause often require distinct treatment and referral away 
from a CSC. Professionals working in a CSC may be the 
first to conduct a diagnostic assessment for rare secondary 
causes [10]. Careful history taking, physical and laboratory 
examination, targeted follow-up for unusual presentations or 
treatment resistance and continued vigilance for the 
emergence of signs or symptoms suggestive of ‘medical 
mimics’ of primary psychotic disorders can reduce the risk 
of misdiagnosis. After careful exclusion of secondary causes, 
considerable ambiguity is to be expected in classifying early-
course primary psychosis. For example, the variability in 
expression of symptoms and lack of an extended or reliable 
longitudinal history in young patients can make it difficult to 
distinguish between depressive or bipolar disorder with 
psychotic features and schizophrenia spectrum disorders. It 
is helpful to avoid premature closure on a diagnosis and to 
encourage patients and their families to exercise the same 
caution while focusing on symptom control, rehabilitation of 
functional disabilities, and continued longitudinal evaluation. 
2.4. Engagement Into Care 
 Inability or unwillingness to acknowledge having a 
serious mental illness is a common challenge to effective 
engagement. Patients may be reluctant to agree that treatment 
is important but will often readily identify the need for 
assistance in getting a job, going to school, improving social 
relationships, or improving difficulties with thinking. A 
responsive ‘menu’ of interventions that includes structured 
supports for finding employment or resuming high school, 
college or vocational training and approaches to improve 
social skills and cognition can help improve engagement [11] 
and offers the possibility of mutually reinforcing effects on 
functional outcomes. 
 Just as important as what is how services are offered. The 
culture and values of CSC teams are essential. It is important 
to maintain optimism, a focus on recovery toward personal 
goals, and a collaborative therapeutic alliance. Often, 
patients may not believe that they are in need of mental 
health treatment, thus making engagement one of the most 
critical elements of care. Patience and flexibility can help 
avert power struggles. It can be useful to connect with 
patients around their interests, understand what trajectory of 
wishes or plans were interrupted by the illness, [11] and 
explicitly recognize and value their goals, even when this 
might conflict with those of the family or treatment team. 
Clinicians should emphasize what the program or clinic can 
offer to match the patients’ priorities and be prepared to 
address confusion, stigma, or pessimism about the causes or 
treatment of mental illness amongst patients, families or 
referrers. Flexibility whenever possible around length and 
scheduling of appointments is encouraged. 
 An initial detailed assessment can facilitate engagement 
by expanding the discussion beyond symptoms to include 
social and vocational goals that are often most important to 
patients, and communicating (verbally and nonverbally) 
comfort with discussing unusual or bizarre material. Patients 
may present with disorganization or agitation that clinicians 
would do well to respond to with patience and validation of 
what that experience is like rather than immediately debating 
the content or explanation of those experiences. Despite 
initial resistance and limited or absent insight, many patients 
respond well if given an opportunity to feel heard and if the 
clinician’s perspective is only offered after careful 
assessment and, preferably, with the patient’s permission. 
 Inclusion of family members and other naturalistic 
supports is an essential component of CSC. Families, in 
addition to their vital role in patients’ lives, can provide 
invaluable historical information for diagnosis and treatment 
selection, collaborate in monitoring for safety, and report 
early warning signs of psychotic relapse. The emotional 
environment they provide the patient is one of the strongest 
predictors of psychiatric relapse and hospitalization. Enabling 
families to recognize and reduce high levels of “expressed 
emotion”—criticism, lack of warmth, hostility, and emotional 
over-involvement—is likely to have tremendous benefit. 
Families should be treated as allies and members of the 
treatment team. They may present with incorrect attributions 
regarding illness, be frightened by aggressive or disorganized 
behavior, need to grieve the loss of the future they had 
envisioned for their child, or express frustration at clinical 
staff after experiencing convoluted pathways through care. It 
is important to keep in mind that initial meetings with families 
may come at what is the worst time for them. Many may have 
recently had a frustrating experience seeking help for their ill 
relative. Empathic and patient responses to their initial requests 
can go a long way. Reassurance, education, and communication 
of optimism from the clinician are useful and appropriate. 
2.5. Putting Together and Delivering a Package of Care 
 A broad menu of interventions will allow flexible matching 
and refinement to dynamic patient priorities. Implementers 
should start from within a range of empirically supported 
treatments used in CSCs around the world [6] or SAMHSA’s 
Inventory and Environmental Scan of Evidence-Based Practices 
for Treating Persons in Early Stages of Serious Mental 
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Disorders [12], before mounting de novo approaches. 
Participation rates in group-based interventions in early-
psychosis samples can be low, and given many patients will 
be attending work or school, attendance in all interventions 
offered within a CSC may not be realistic or desirable. Given 
limited resources, hard choices will need to be made on what 
to include in a package of care while keeping in mind that 
engagement and retention can be enhanced for this very 
heterogeneous population by offering a wider menu. 
 Many CSCs provide treatment in the community, similar 
to or following an Assertive Community Treatment (ACT) 
model of care. Patients are treated primarily in settings 
outside the clinician’s office. Implementers of new CSC will 
need to determine what (if any) of their services can be 
resourced for delivery in the community and what crisis 
coverage will be available outside of usual clinic hours. 
For office-based services, an open access or partially open 
access model should be considered. Many patients, due to 
disorganization, reluctance or paranoia, have difficulty 
consistently attending scheduled appointments. In our CSC 
(STEP), we offer scheduled appointments later in the day but 
patients who are unable or unwilling to adhere to them are 
encouraged to “drop by anytime” early in the day. The team-
based approach described below ensures that any of the CSC 
staff will be familiar enough with the patient to engage with 
them should their primary clinician not be available. 
 Consistent across CSCs is the use of interdisciplinary 
teams. Various disciplines bring diverse perspectives to 
understanding and treating patients that can be leveraged  
in a pluralistic model of care. This includes psychiatry, 
psychology, social work, nursing, occupational therapy, and 
persons with lived experience of a mental illness. Roles can 
be assigned based on aptitude and skill rather than merely 
along disciplinary lines. For example, any of the clinical 
disciplines can serve in the essential role of primary clinician 
(i.e. the point person who coordinates and tailors CSC care 
for their assigned patients). Alternative or additional roles  
for the same clinician can include education and support  
of the family or therapy for patients in an individual or group 
modality. However, the supported employment and education 
role requires significant time in the community to develop 
relationships with employers and areas colleges and to assist 
patients on site. This role is thus less likely to be inter- 
changeable among the clinicians. Psychiatrists or advanced 
practice nurses typically provide medication management, 
coordinate with primary care, and play a pivotal role in 
differential diagnosis, physical health monitoring and inter- 
vention. A designated team leader (again, drawn from any of 
the clinical disciplines) can coordinate clinic activities, lead 
team meetings, provide supervision, oversee development 
and implementation of services, ensure adherence to 
treatment philosophies, and even carry a caseload as primary 
clinician. 
 Weekly interdisciplinary team meetings and frequent 
communication ensure fidelity to treatment principles, 
facilitate morale, and encourage high-quality service 
delivery. Care should be taken not to fall into a pattern of 
focusing only on crises or negative outcomes in young 
patients, whose setbacks can be felt deeply by clinicians. 
Periodic signposting of meaningful improvements at a 
patient level (e.g. interviewing for a job or more consistently 
attending appointments) and population level (e.g. % 
employed or in school, % with positive symptom remission) 
can contextualize an inevitable focus in clinical meetings on 
the highest need patients. Periodic thorough case reviews can 
be used to illustrate values and practice ethos, troubleshoot 
treatment challenges and also effectively reveal training 
needs [13]. 
 A practice these authors have found useful, is a daily 
morning ‘huddle.’ This is a brief daily meeting amongst the 
team leader and primary clinicians to triage new referrals, 
trouble-shoot emerging crises, coordinate simultaneous care 
to patients and families, and plan coverage for unforeseen 
staff absences. 
 While this may improve as CSCs become more 
prevalent, new programs will likely recruit staff without 
prior experience of this model of care. Training clinicians 
with structured treatment manuals can ensure that adequate 
background knowledge is communicated, even as defined 
skills are developed. Another important aspect of on-
boarding many clinicians is to help them develop confidence 
in adapting their existing clinical skills to an early psychosis 
population. While specialized knowledge of early stage 
psychosis is valuable, techniques used in various CSC 
interventions are within the skill set of most experienced 
clinicians. Just as crucial as training on specific interventions 
is building a culture of practice. Ongoing supervision and 
continuing education can reinforce core values of flexibility, 
teamwork, optimism, respect for patients’ rights and 
autonomy, and toleration of uncertainty and risk. 
 Work in a CSC is aided by knowledge of common 
problems encountered in early-course psychotic disorders 
but also a more general understanding of the developmental 
psychology of adolescence and young adulthood. Also 
relevant, depending on the population under care, is 
knowledge of the impact of immigration and trauma or the 
interacting co-morbidities of substance use, suicidality, 
anxiety, and obsessive compulsive disorder (OCD). Patients 
and their families will likely have questions regarding 
substance use and its relationship to psychosis risk; providers 
would do well to become familiar with the literature on 
cannabis use in particular. Substance use in recent onset 
psychosis is associated with higher rates of relapse, poorer 
social functioning, and more severe psychopathology [14, 
15]. 
 In addition to elevated rates of trauma and stressful life 
events among recent onset psychosis populations, the 
experience of becoming psychotic is often frightening. Entry 
into treatment can involve aversive experiences including 
interactions with police, physical restraint, and involuntary 
hospitalizations. Assessing for and attempting to alleviate 
fears about treatment through reassurance, education, and a 
patient, therapeutic stance is essential. For example, a patient 
may be reluctant to engage and particularly guarded due to 
anxiety regarding involuntary hospitalization, but may be 
forthcoming if the criteria for emergency commitment are 
provided along with reassurance from the professional that 
this is a last resort. As always, careful consideration must be 
given when considering involuntary commitment. 
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 Reducing immediate threats to physical safety (the 
patient’s and others’) while always a priority, must be 
managed with a view to long term, sustained reduction of this 
risk. The latter is threatened by the loss of the therapeutic 
alliance and departure from treatment. If hospitalization is 
necessary, clinicians can mitigate this risk of disengagement 
by effecting procedural justice for each patient (e.g., being 
treated fairly and respectfully, feeling heard, getting a chance 
to tell one’s side of the story, being included in the decision 
process) and following up with the treatment team and 
patient during the ensuing hospitalization. As described 
earlier, engagement is a significant challenge in treating 
recent onset psychosis, and it is vital to proactively address 
fears or misunderstandings that can threaten a trusting 
therapeutic relationship. 
 Paranoia and persecutory delusions may also increase 
risk for aggressive behavior because patients may believe 
they are acting in self-defense. Although the majority of 
those in the early stages of psychosis will not be violent, they 
may still come into contact with the criminal justice system 
for illness related behaviors, such as trespassing or disorderly 
conduct. Professionals working within CSCs will likely find 
themselves interacting with the legal system regarding their 
patients. Understanding the local criminal justice system, as 
well as the ethical considerations of working with patients with 
legal charges or court-mandated treatment will prove useful. 
 Although positive symptoms often respond adequately to 
antipsychotic medication, the symptoms that can have the 
greatest impact on functional recovery—negative and 
cognitive symptoms—typically do not. Distinguishing and 
reducing the impact of depression, medication side effects or 
social isolation [16] can help many with negative symptoms, 
but research has yet to deliver effective treatments of any 
remaining deficit symptoms. Cognitive remediation programs 
have shown promise in reducing the intellectual deficits that 
typically develop in schizophrenia and, in combination 
with other approaches, like supported employment, might 
have particular promise in improving functional outcomes. 
Professionals working within CSC should familiarize 
themselves with the common cognitive symptoms associated 
with psychosis, such as executive functioning deficits, and 
consider referral for neuropsychological assessment. Such an 
assessment can evaluate the extent of dysfunction compared 
to population norms, monitor for changes over time, and 
suggest strategies to reduce their impact on school and work 
function. 
 Individuals with chronic psychotic disorders are well 
known to suffer premature mortality, mostly from cardio- 
vascular diseases. Key risk factors that emerge in early 
psychosis populations are obesity and smoking [17]. Positive 
and adverse health behaviors may be consolidated during 
early illness and predict long-term behavior. CSCs thus 
might have a window of opportunity to modify lifestyle 
habits that can have a pervasive impact well into adulthood 
[17]. Strategies to optimize cardiovascular health within a 
CSC can mirror the overall ethos of maintaining a patient-
centered and flexible approach. Biological (e.g. antipsychotic 
induced weight gain, familial hyperlipidemia), psychological 
(e.g. maladaptive health beliefs, lack of education) and social 
(lack of access to healthy foods or gyms, family norms) 
factors, potentially contributing to cardiovascular health, 
must all be addressed. Many patients may be interacting with 
healthcare providers for the first time as adults. Others may 
come from a culture of seeking primary care via ad hoc 
emergency room visits only. Therefore patients must be 
empowered with education and resources, whilst potentially 
shifting attitudes towards health and healthcare. It may be 
developmentally unrealistic to expect younger patients to 
expend significant effort to avoid the cardiovascular 
morbidity of middle age and beyond. However, this can be 
tackled therapeutically in the same way as acceptance of 
illness, prognosis and chronicity of maintenance phase 
treatment. If a patient does not shop and cook for 
themselves, the involvement of the family may be necessary 
to address diet, portion sizes and access to healthy snacks. 
 The importance of cardiovascular health and monitoring 
for metabolic side effects of treatment should be addressed 
early in the course of care, not only to reduce long-term risk, 
but also to preserve and strengthen the treatment alliance as 
problems such as weight gain emerge. STEP’s approach is to 
instigate a ‘wellness visit’ with a nurse within 2 weeks of 
admission. During this visit admission laboratory testing is 
reviewed or ordered for fasting glucose and lipids, electro- 
cardiogram, urine toxicology and pregnancy tests are obtained 
and vital signs and weight are recorded. Past medical history 
(and family history) is reviewed, paying particular attention 
to the client’s diet and exercise practices and attitudes to 
health and wellness in order to identify potential areas of 
education and development. Counseling may be provided 
around contraception and seeking routine health surveillance 
via primary care or gynecology. If necessary, patients are 
engaged around a primary care referral; otherwise releases of 
information and records are obtained from other providers (if 
they have not been already). A monitoring schedule for those 
taking antipsychotic medications can be drawn from extant 
guidelines [18]. 
 If smoking is identified, counseling is provided and 
motivation to quit is assessed within a motivational inter- 
viewing stance. If appropriate, goals for harm reduction or a 
quit date is set. Conventional therapeutic and medication 
strategies to support abstinence are offered. These may include 
motivational interviewing, cognitive behavioral therapy 
based groups, nicotine replacement therapy, bupropion and 
varenicline. 
2.6. Evolution and Refinement of Services 
 Early adopters can assure themselves that though 
several decisions are necessary in the implementation and 
development of a CSC, few, if any, of these decisions should 
be considered final. Our package of care in STEP has changed 
in numerous ways over the course of our first decade, with 
interventions, strategies, and inclusion criteria being modified 
or replaced to better fit the needs of our patient population, 
resources, and local community. We recommend choosing 
empirically supported treatments that can then be adapted 
based on patient preferences, a reflection of program values; 
utilization, in consideration of economic resources; and 
outcomes. This approach provides a framework for training 
clinicians on structured interventions that they can then 
flexibly implement individually with patients and families. 
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 A few examples from STEP of how we have changed 
inclusion criteria, interventions, and service delivery 
structure may illustrate. When we begin recruiting, our 
criteria included ‘early in treatment’ as defined by less than 
12 weeks lifetime antipsychotic use. As this excluded many 
individuals who were recent onset, we later removed the 
weeks of antipsychotic use limit. Our initial set of 
interventions included Multifamily Group Psychoeducation 
and Support (MFG) [19] and provided an opportunity for 
clinicians to learn about the impact of expressed emotion and 
delivery of psychoeducation and problem solving 
techniques; however, participation rates were low and family 
members were more likely to attend single family sessions. 
Thus, we later implemented Family Focused Therapy (FFT) 
[20] which accommodated this apparent preference, reduced 
delays in offering the intervention as waiting for a group 
cohort to accumulate was no longer necessary, and added 
explicit teaching of communication and problem solving 
skills to the clinicians’ skill set. Similarly, a Cognitive 
Behavioral Group (CBT) offered early on in STEP’s 
development [21] provided an excellent opportunity for 
public mental health clinicians to hone their CBT skills to 
this population but was poorly attended. We later adopted 
the Social Cognition and Interaction Training (SCIT) group, 
which is engaging and interactive and with an explicit 
emphasis on socialization that appeals to our age group. Now 
that STEP clinicians have been trained and supervised on 
this model, they are able to incorporate SCIT techniques into 
the individual sessions of patients who are not willing or able 
to attend group. Due to resource limitations, in our first 
clinical trial, primary clinicians assisted patients in obtaining 
work or returning to school. We learned through patient 
feedback that emphasis on work and school were key to 
engagement. Increased resources from the State of 
Connecticut included dedicated Supported Employment and 
Supported Education staff. We suspect having designated 
staff who focus on vocational outcomes improves our appeal 
to our young adult clients and these roles allow for 
strengthening ties with potential employers, colleges and 
universities as well as provide valuable observations on how 
the patient is functioning in the community. Regarding 
service structure, we have changed from a combined 
clinician/outreach staffing to separate personnel dedicated to 
outreach and engagement. We have found that these tasks 
require extensive time in the community not typically 
practical for a clinician schedule in order to develop our 
referral network and strengthen ties with stakeholders who 
can facilitate hastening young people into care. 
2.7. Justifying Services 
 Early adopters and more established programs may have 
concerns about funding and stakeholder commitment to CSC. 
Whatever processes and service delivery structures they chose, 
we encourage programs to orient their processes toward 
population health and invest in outcomes monitoring in 
support of demonstrating value to their funders [22]. For 
example, reducing hospitalizations and improving vocational 
engagement in STEP has helped justify committing financial 
resources. 
3. CONCLUSION
 Managers of resources in U.S. healthcare agencies are 
wise to consider implementing early intervention services for 
psychotic illnesses. Empirical evidence supports a clear 
benefit for comprehensive models of care in reducing distress, 
disability, and cost. This is reflected in ongoing national 
funding initiatives to support service implementation and 
pending legislation in the U.S. congress recognizing the 
importance of early intervention for psychotic illnesses. 
While there is much to celebrate in these developments, there 
is also much work to do. While CSCs have demonstrated 
unambiguous impact, they are insufficient to transform the 
trajectories of illnesses that have often begun long before and 
will persist long after the relatively brief period within a 
CSC. In many cases, disability has accrued well before the 
onset of reliably recognizable symptoms. The goal of early 
recognition at a prodromal or even premorbid phase remains 
an active aspiration for research that deserves vigorous 
support. Also, the impact of CSCs may not be sustained in 
the years after transition to usual care services [23] and new 
approaches are needed to sustain the positive effects of these 
services. Finally, while CSCs do include elements of 
community outreach, their focus is on the care of those who 
are able to respond to minimal efforts at early detection of 
incident cases. Focused efforts are required and underway to 
learn how to reduce the duration of untreated psychosis 
(DUP) [24]. The landmark Scandinavian TIPS study [25] 
was the first to demonstrate successful reduction of DUP, 
and notably this appeared to have a durable impact on 
outcome [26]. The development and testing of approaches to 
reduce DUP in the U.S. context, is the focus of several 
ongoing NIMH funded research efforts [24]. The ability to 
advance knowledge and practice in all these areas will be 
accelerated by the implementation of CSCs across the U.S. 
that can provide best practice care while also serving as 
necessary platforms for research that can our knowledge of 
the causes and physiology of psychotic illnesses and inform 
the next generation of interventions. 
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SUPPLEMENTARY	WORK	S1		
Results: Controls showed a lesser fronto-central pre-stimulus theta
power (−2.512, p=0.012), which was negatively correlated with
parietal beta ITC following target response (−0.679, p=0.001). This
relationship was absent in patients (−0.165, p=0.462) and correlation
difference (pb0.05). There was, however, no group difference in beta
ITC (−0.439, p=0.639).
Conclusions: We present this relationship as a correlate of sensory–
motor transformation, disrupted in schizophrenia without a manifest
effect on beta ITC. Excess task-irrelevant activity (perhaps secondary
to dopaminergic neuron-modulation of GABA and NMDA networks)
could be causative.
doi:10.1016/j.schres.2007.12.128
62 – IMPAIRED SYNCHRONIZATION OF NEURAL
OSCILLATIONS IMMEDIATELY FOLLOWING AUDITORY
STIMULI REPRESENTS A PERVASIVE DEFICIT IN BRAIN
RECRUITMENT IN SCHIZOPHRENIA
J.D. Cahill1, M. Groom1, A.T. Bates2, C. Hollis1, P.F. Liddle1.
1Division of Psychiatry, University of Nottingham, UK
2Department of Psychiatry, University of British Columbia, Canada
Presenting Author details: johncahill@doctors.org.uk
Division of Psychiatry, QMC, NG7 2UH Nottingham,
United Kingdom,
Tel.: +44 7855366491.
Background: Abnormal coordination of EEG oscillations has been
associated with a range of psychopathology in schizophrenia. This
could stem from a fundamental neuronal impairment, manifesting at a
basic level of stimulus-assimilation. Post stimulus responses can be
characterized by their phase relationship to stimulus onset; either
generated from ongoing pre-stimulus activity or de novo. Winterer
implicates an excess ‘broadband noise’ in behavioral impairments in
patients. We propose that schizophrenia involves a deficit in neural
recruitment, associated with increased pre-stimulus activity.
Methods: One hundred and twenty-eight channel EEG was recorded
from 22 patients with DSM-IV criteria adolescent-onset schizophrenia
and 22 age- and sex-matched controls undertaking a frequency deviant
auditory oddball task. Data were segmented into 3-s epochs
surrounding the non-target stimulus. Artefact was corrected using
ICA before special-decomposition into the 5 bands (delta to gamma)
using discrete windowed Fourier transforms. Inter-trial phase
coherence and event-related spectral power (both stimulus-locked
and non-locked) were derived. Fronto-central signal was examined in
3 windows: pre-stimulus (−525 to −275 ms), post-stimulus 0–250 ms
and 250–500 ms.
Results: Patients showed a pan-spectral impairment in post-stimulus
recruitment: a lesser percentage power increase, greatest in theta
(−3.873, p=0.000); a significantly reduced consistency of phase
organization across trials (−3.450, p=0.001); plus increased theta/
delta pre-stimulus activity (−2.512, p=0.012/−2.30, p=0.026). The
extent of stimulus-locked theta activity showed a strong positive
correlation with pre-stimulus power in controls (0.589, p=0.004),
which is disrupted in patients (0.200, p=0.371).
Conclusions: This study represents the first, such comprehen-
sive demonstration of the impaired recruitment of oscillations in
schizophrenia; an impairment, perhaps related to maladaptive pre-
stimulus (structural or neuromodulatory via prefrontal dopamine)
compensation.
doi:10.1016/j.schres.2007.12.129
63 – INFLUENCE OF METAGLOSSOTHERAPY ON THE
COGNITIVE EVENT-RELATED POTENTIALS OF
SCHIZOPHRENIC PATIENTS
K. Dapsys1,2, V. Maciulis1, S. Marceniene1, V. Banaitis1,
J. Utkuviene1.
1Republican Vilnius Psychiatric Hospital/Vilinius, Lithuania
2Vilnius University/Vilnius, Lithuania
Presenting Author details: k.dapsys@rvpl.lt
Parko 15, LT-11205 Vilnius, Lithuania,
Tel.: +370 5 2670070; fax: +370 5 2671503.
Background: Metaglossotherapy (MGT) is a method of treating
schizophrenic patients based on teaching them a new foreign language.
The method was proposed by Dr. A. Matulis (1977, USA). During
MGT the patient would once again initiate an activity of labeling,
adopting to a “new” reality only with different foreign names. Besides
the communicative amelioration, the new foreign language can
contribute notably to the stabilization and clarification of the
schizophrenic patient's self-concept and have an overall positive
influence on schizophrenic patient's cognitive functions. Our goal was
to evaluate the influence of MGT on the cognitive event-related
potentials of treated schizophrenic patients.
Methods: A sample size of 11 long-stay male chronic schizophrenic
patients took part in the program. The selected patients were assigned
into two groups. One group was learning English, another group –
Esperanto. The program lasted 3 months, 3 lessons a week. Auditory
event-related potential (ERPs) were recorded at baseline and after
3 months of MGT. The ERPs were recorded with the digital EEG
device from Fz, Cz and Pz sites. ERPs were acquired during active
auditory oddball paradigm. Comparisons of peak latencies and
amplitudes of ERPs N200, P300 components before MGT and after
3 months of therapy were performed.
Results: The amplitudes of both components slightly increased after
3 months of MGT. However, the differences were statistically not
significant. The latencies of P300 component have significantly
(p=0.02) shortened (for Cz electrode from 379.5 ms to 347.6 ms after
MGT).
Conclusions: The tendency of shortening of P300 latency can be
indicator of improvement in cognitive function, but it is necessary to
measure ERPs for larger number of patients.
doi:10.1016/j.schres.2007.12.130
64 – NEUROPSYCHOLOGICAL CORRELATES OF N400
ANOMALIES IN PATIENTS WITH SCHIZOPHRENIA
W.H. Jung1, K.S. Shin1, D.H. Kang2, Y.Y. Kim3, J.S. Kwon1,2,3.
ABSTRACTS / Schizophrenia Research 98 (2008) 3–199
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SUPPLEMENTARY	WORK	S2		
well. Progress in social cognitive measures, in particular emotional
face recognition, is supported by evoked potential response that shows
an activation of medio-frontal areas (typically involved in emotional
stimuli processing) and this suggests that the core circuitry for
imitation might interact with the limbic system during social mirroring.
Conclusions: These preliminary results need confirmation from the
larger ongoing study rehabilitation treatment for schizophrenics based
on imitation of social cognition skills. However, if the preliminary
results are confirmed, action observation and imitation could be
regarded as a new frontier in rehabilitation, easy to implement and with
a well-founded neurophysiologic basis.
Reference:
Mazza, Costagliola, Roncone, Casacchia, Galzio. Deficit of social
cognition in subjects with surgically treated frontal lobe lesions and in
subjects affected by schizophrenia. Eur Arch Psychiatry Clin Neurosci.
2007 February; 257(1): 12–22.
doi:10.1016/j.schres.2007.12.126
EEG Studies
60 – CORRELATION BETWEEN THE EFFECTS OF SECOND
GENERATION ANTIPSYCHOTIC DRUGS AN THE
EVENT-RELATED POTENTIALS (ERPS) P300, P50 AND PANSS
NEGATIVE SCORE: A PRELIMINARY STUDY
A. Boxus1.
1AASM, Limoux, France
Presenting Author details: albert.boxus@wanadoo.fr
Place du 22 September, 11300 LIMOUX, France,
Tel.: +33 4 68746450; fax: +33 4 68746251.
Background: The P300 component of the ERP reflects the capacity of
self-organisation and self-regulation of the central nervous system. The
P50 suppression reflects the capacity to interpret a stimulus as
negligible.
Methods: Fifty-five individuals (32 males and 23 females; mean
age=35.9 years [SD=13.8]) meeting DSM-IV criteria for schizo-
phrenia, admitted for an acute relapse, were included in the study and
observed within the 8-month period from 2005/10 to 2006/07. They
were treated with the following antipsychotics (mean daily dosage):
aripiprazole (13.75 mg), risperidone (5.06 mg), olanzapine (14.12 mg),
amisulpride (1000 mg) and clozapine (150 mg). The other psycho-
tropic drugs were prohibited except for cyamemazine (100 mg/day
during the first week), benzodiazepines, zolpidem and anticholinergic
medications. Clinical and electrophysiological evaluations were
performed before the start of treatment (T1) and after remission (T2).
Psychopathology was measured by the Positive and Negative
Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS).
Results: After treatment, P300 latency was not significantly improved
but we observed a significant increase in P300 amplitude (pb0.02).
P50 suppression deficit, which was present in 49 subjects at T1, was
observed in only 44 patients at T2 (pb0.003). This improvement
occurred particularly in patients receiving aripiprazole or risperidone.
PANSS and BPRS decreased respectively from 100±12 and 85±8 at
T1 to 53±11 and 38±6 at T2 (pb0.01) .This study will analyze these
results with the items of the negative scale of the PANSS and try to
show the difference between each treatment for positives effects on
specific cognitive functions.
Conclusions: Correlation between PANSS and ERP evaluation may
suggest that clinical cognitive symptomatology relies to electrophysio-
logical measurement. The negative scale of the PANSS decreased with
the treatment but is not able to value differences for each treatment and
for specific cognitive functions. ERP evaluation may help psychiatrists
in the choice of the optimal drug to treat schizophrenic patients. We need
another evaluation than the negative scale of the PANSS to measure the
improvement on specific cognitive functions.
References:
[1] Application of electroencephalography to the study of cognitive
and brain functions in schizophrenia. Schizophrenia Bulletin. 2007;
Mar 15.
[2] Topographic abnormalities of P3 in schizotypal disorder.
Biological Psychiatry, Volume 40, Issue 3, Pages 165–172.
[3] D. Salisbury, M. Volgmaier, L.Seidman, R. McCarley. Alteration of
event related potentials in siblings discordant for schizophrenia.
Schizophrenia Research. 2000 Jan 21; 41(2):325–34.
doi:10.1016/j.schres.2007.12.127
61 – PRE-STIMULUS THETA POWER PREDICTS THE
SUPPRESSION OF BETA SYNCHRONIZATION DURING
MOTOR RESPONSE: DOES A DISRUPTED EFFECT IN
SCHIZOPHRENIA REFLECT PATHOLOGICAL BASELINE
THETA ACTIVITY?
J.D. Cahill1, M. Groom1, A.T. Bates2, C. Hollis1, P.F. Liddle1.
1Division of Psychiatry, University of Nottingham, UK
2Department of Psychiatry, University of British Columbia, Canada
Presenting Author details: johncahill@doctors.org.uk
Division of Psychiatry, QMC, NG7 2UH Nottingham, United Kingdom,
Tel.: +44 7855366491.
Background: Although aberrant non-stimulus locked background
activity has been demonstrated in schizophrenia, the significance of
pre-stimulus EEG remains unknown. A disrupted relationship between
pre- and post-stimulus oscillationsmight reflect poor cerebral recruitment
in schizophrenia. Excess low frequency activity has already been
demonstrated at rest and preceding stimulus processing. Beta power is
negatively related to motor events. Imperative stimuli may suppress the
initial, indiscriminate, post-stimulus beta phase synchronization via
parieto-dependant motor networks. Theta activity associated with
attention andworkingmemory tasksmay facilitate stimulus-assimilation.
It is hypothesized that the extent of pre-stimulus theta will negatively
predict the extent of parietal beta inter-trial phase coherence (ITC) around
response. This relationship will be disrupted in schizophrenia.
Methods: One hundred and twenty-eight channel EEG was recorded in
22 patients with DSM-IV criteria adolescent-onset schizophrenia and 22
age/sex-matched controls whilst undertaking a frequency deviant
auditory oddball task necessitating a button press. Data were segmented
into 3-s epochs around the stimuli. Artefact was corrected using ICA
before decomposition into theta (4–8 Hz) and beta (13–30 Hz) bands
using discrete Fourier transforms. ITC and total power were calculated
for fronto-central and midline-parietal regions: pre-stimulus window
(−525 to −275 ms) and response window (250–500 ms).
ABSTRACTS / Schizophrenia Research 98 (2008) 3–199
Results: Controls showed a lesser fronto-central pre-stimulus theta
power (−2.512, p=0.012), which was negatively correlated with
parietal beta ITC following target response (−0.679, p=0.001). This
relationship was absent in patients (−0.165, p=0.462) and correlation
difference (pb0.05). There was, however, no group difference in beta
ITC (−0.439, p=0.639).
Conclusions: We present this relationship as a correlate of sensory–
motor transformation, disrupted in schizophrenia without a manifest
effect on beta ITC. Excess task-irrelevant activity (perhaps secondary
to dopaminergic neuron-modulation of GABA and NMDA networks)
could be causative.
doi:10.1016/j.schres.2007.12.128
62 – IMPAIRED SYNCHRONIZATION OF NEURAL
OSCILLATIONS IMMEDIATELY FOLLOWING AUDITORY
STIMULI REPRESENTS A PERVASIVE DEFICIT IN BRAIN
RECRUITMENT IN SCHIZOPHRENIA
J.D. Cahill1, M. Groom1, A.T. Bates2, C. Hollis1, P.F. Liddle1.
1Division of Psychiatry, University of Nottingham, UK
2Department of Psychiatry, University of British Columbia, Canada
Presenting Author details: johncahill@doctors.org.uk
Division of Psychiatry, QMC, NG7 2UH Nottingham,
United Kingdom,
Tel.: +44 7855366491.
Background: Abnormal coordination of EEG oscillations has been
associated with a range of psychopathology in schizophrenia. This
could stem from a fundamental neuronal impairment, manifesting at a
basic level of stimulus-assimilation. Post stimulus responses can be
characterized by their phase relationship to stimulus onset; either
generated from ongoing pre-stimulus activity or de novo. Winterer
implicates an excess ‘broadband noise’ in behavioral impairments in
patients. We propose that schizophrenia involves a deficit in neural
recruitment, associated with increased pre-stimulus activity.
Methods: One hundred and twenty-eight channel EEG was recorded
from 22 patients with DSM-IV criteria adolescent-onset schizophrenia
and 22 age- and sex-matched controls undertaking a frequency deviant
auditory oddball task. Data were segmented into 3-s epochs
surrounding the non-target stimulus. Artefact was corrected using
ICA before special-decomposition into the 5 bands (delta to gamma)
using discrete windowed Fourier transforms. Inter-trial phase
coherence and event-related spectral power (both stimulus-locked
and non-locked) were derived. Fronto-central signal was examined in
3 windows: pre-stimulus (−525 to −275 ms), post-stimulus 0–250 ms
and 250–500 ms.
Results: Patients showed a pan-spectral impairment in post-stimulus
recruitment: a lesser percentage power increase, greatest in theta
(−3.873, p=0.000); a significantly reduced consistency of phase
organization across trials (−3.450, p=0.001); plus increased theta/
delta pre-stimulus activity (−2.512, p=0.012/−2.30, p=0.026). The
extent of stimulus-locked theta activity showed a strong positive
correlation with pre-stimulus power in controls (0.589, p=0.004),
which is disrupted in patients (0.200, p=0.371).
Conclusions: This study represents the first, such comprehen-
sive demonstration of the impaired recruitment of oscillations in
schizophrenia; an impairment, perhaps related to maladaptive pre-
stimulus (structural or neuromodulatory via prefrontal dopamine)
compensation.
doi:10.1016/j.schres.2007.12.129
63 – INFLUENCE OF METAGLOSSOTHERAPY ON THE
COGNITIVE EVENT-RELATED POTENTIALS OF
SCHIZOPHRENIC PATIENTS
K. Dapsys1,2, V. Maciulis1, S. Marceniene1, V. Banaitis1,
J. Utkuviene1.
1Republican Vilnius Psychiatric Hospital/Vilinius, Lithuania
2Vilnius University/Vilnius, Lithuania
Presenting Author details: k.dapsys@rvpl.lt
Parko 15, LT-11205 Vilnius, Lithuania,
Tel.: +370 5 2670070; fax: +370 5 2671503.
Background: Metaglossotherapy (MGT) is a method of treating
schizophrenic patients based on teaching them a new foreign language.
The method was proposed by Dr. A. Matulis (1977, USA). During
MGT the patient would once again initiate an activity of labeling,
adopting to a “new” reality only with different foreign names. Besides
the communicative amelioration, the new foreign language can
contribute notably to the stabilization and clarification of the
schizophrenic patient's self-concept and have an overall positive
influence on schizophrenic patient's cognitive functions. Our goal was
to evaluate the influence of MGT on the cognitive event-related
potentials of treated schizophrenic patients.
Methods: A sample size of 11 long-stay male chronic schizophrenic
patients took part in the program. The selected patients were assigned
into two groups. One group was learning English, another group –
Esperanto. The program lasted 3 months, 3 lessons a week. Auditory
event-related potential (ERPs) were recorded at baseline and after
3 months of MGT. The ERPs were recorded with the digital EEG
device from Fz, Cz and Pz sites. ERPs were acquired during active
auditory oddball paradigm. Comparisons of peak latencies and
amplitudes of ERPs N200, P300 components before MGT and after
3 months of therapy were performed.
Results: The amplitudes of both components slightly increased after
3 months of MGT. However, the differences were statistically not
significant. The latencies of P300 component have significantly
(p=0.02) shortened (for Cz electrode from 379.5 ms to 347.6 ms after
MGT).
Conclusions: The tendency of shortening of P300 latency can be
indicator of improvement in cognitive function, but it is necessary to
measure ERPs for larger number of patients.
doi:10.1016/j.schres.2007.12.130
64 – NEUROPSYCHOLOGICAL CORRELATES OF N400
ANOMALIES IN PATIENTS WITH SCHIZOPHRENIA
W.H. Jung1, K.S. Shin1, D.H. Kang2, Y.Y. Kim3, J.S. Kwon1,2,3.
ABSTRACTS / Schizophrenia Research 98 (2008) 3–199
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Topic one: Psychiatry (582000)  
Topic two: Pharmacology/pharmacy/antibiotics (613000) 
Ketamine and depression 
The world of medicine has long known ketamine hydrochloride to be a dissociative anesthetic 
agent, typically used intravenously for pediatric surgical procedures. Ketamine’s principal action 
in the brain is on N-methyl-D-aspartate (NMDA) receptors, where it blocks the action of the 
brain’s principal excitatory neurotransmitter, glutamate.  
As a derivative of phencyclidine (PCP), ketamine (Fig. 1) shares some notoriety as a 
commonly abused club drug, going under the street names K and Special K. It is a schedule III 
controlled substance in the United States. At lower, so-called subanesthetic doses (at which 
consciousness is largely preserved), ketamine produces dissociative (out-of-body) and 
hallucinogenic effects. These effects led to its early study in psychiatric research, as a 
pharmacological model of psychosis.  
Depression, antidepressants, and treatment resistance. 
Major depressive disorder is defined as a depressed mood or a loss of pleasure in daily 
activities consistently for at least a two-week period. There is a decline in social, occupational, or 
educational functioning. Depression remains one of the most significant causes of disability and 
lost productivity worldwide.  
Medications, neuromodulatory treatments, psychotherapy, and social interventions 
potentially play an important role in the treatment of depression. Nevertheless, it is estimated that 
more than one-third of patients treated for depression will not adequately improve. Treatment 
resistant depression (TRD) is generally diagnosed when a patient has not derived significant 
clinical benefit from two or more adequate trials of conventional antidepressant medications.  
When selecting any psychiatric medication, patients and their prescribers must weigh the 
potential benefits versus risks. The great suffering of people with TRD can justify the use of 
more efficacious treatments that carry greater risk. Lesser-used antidepressants and combinations 
of medications may be employed. Electroconvulsive therapy (ECT) is currently the most 
effective, validated treatment for TRD.  
A paradigm shift. 
Since the 1950s, when the serendipitous finding of the antidepressant effects of 
antituberculous drugs prompted a focus on the monoamine neurotransmitters, serotonin and 
norepinephrine, the formulary (list of prescribed drugs) for depression has steadily grown. 
However, until recently, novel antidepressant agents continued to focus on monoamine 
neurotransmitter systems without a significantly increased efficacy (albeit there was improved 
tolerability). Ketamine has now significantly broken that mold, leading to new frontiers in both 
the pathophysiology and treatment of depression.  
At the end of the twentieth century, growing laboratory evidence for the role of NMDA 
receptor antagonists in depression began to coincide with serendipitous observations that 
subanesthetic ketamine (given as an anesthetic or analgesic) reduced comorbid depressive 
symptoms in patients. The first systematic, placebo-controlled clinical trial of ketamine for major 
depression was conducted at Yale University School of Medicine (New Haven, CT) in 2000.  
Ketamine has distinguished itself from conventional antidepressants through its rapid 
effect (4 hours versus 2 weeks), its efficacy (2 out of 3 patients respond versus 1 out of 2), and its 
hypothetical mechanism of action (glutamatergic systems versus monoaminergic systems). 
Unfortunately, the benefits are transient, tending to last less than a week. There is also the 
potential for its abuse and for a range of adverse effects. Therefore, clinical trials of ketamine 
have tended to study subjects with TRD; who have a favorable risk/benefit ratio.  
Clinical trials. 
Until recently, the evidence for ketamine’s antidepressant effect in humans has primarily 
consisted of case reports or non-placebo-controlled (open-label) studies, which are potentially 
subject to bias. It is only in the past few years that research groups (including those from the 
National Institute of Mental Health and Mount Sinai School of Medicine) have added a handful 
of placebo-controlled trials, which more strongly support the clinical effects of ketamine.  
There is a range of clinical evidence in humans to date; the majority of patients studied 
since 2011. A dozen case studies, totaling 16 patients, report a rapid antidepressant response with 
regimens ranging from one to six ketamine infusions. Durations of response range from a 
day to several weeks. Open-label studies more systematically illustrate the effect of ketamine, 
but lack a placebo/control comparison. A dozen such studies, involving 120, mostly un-
medicated, treatment resistant depressed patients, most clearly support a rapid, transient response 
in approximately 40-60% of patients, at four hours after a single 0.5mg/kg intravenous infusion. 
Two further open-label studies have tested repeated dose regimens in a total of 34 subjects, 
showing a response rate of 50 to 71% and an extended median duration of effect of 18 days (after 
last infusion). Controlled-trials in this field have also been supportive of an effect, commonly 
comparing the response of ketamine and a non-psychoactive, saline placebo within each subject. 
There have been 6 such trials published, involving 81 depressed patients (including bipolar 
depression), showing a peak response rate ranging from 40 to 79% within 72 hours of a single IV 
administration. Finding a rigorous control condition is a challenge with ketamine - which has 
both an immediate intoxicating and downstream antidepressant effect. Results of ongoing trials 
using a psychoactive control, midazolam should be informative. 
These trials have focused on a single, intravenous infusion (lasting 40 minutes) of 
racemic ketamine hydrochloride (at a dose of 0.5 mg per kg body weight). Clinical targets have 
mainly been subjects suffering from TRD (including those unresponsive to ECT), bipolar 
depression (major depression in the context of bipolar disorder), and suicidal ideation.  
Attempts to extend the fleeting benefits of single-dose ketamine with an oral NMDA 
receptor antagonist, riluzole, proved ineffective. However, there is hope of sustaining ketamine’s 
effect through repeated intravenous dosing regimens, which would be similar to the way that 
ECT is administered (three treatments per week with tapering frequency). Alternative routes of 
administration, particularly intramuscular, may also be of interest.  
Another conceptually appealing application has been the use of ketamine as the 
anesthetic agent for ECT treatments. This, in fact, has been long practiced when struggling to 
induce therapeutic seizures in a patient. Ketamine will not increase the seizure threshold as much 
as conventional anesthetics. Sadly, the evidence for a cumulative benefit of ECT and ketamine is 
not compelling. The mechanism of interaction of these two treatments remains unclear, and it is 
likely that ketamine’s antidepressant effect is particular to the lower, subanesthetic dose range.  
Although a compelling novel mechanism for treating depression with ketamine is 
elucidated, practicality and safety may constrain the clinical utility of ketamine to a jump start 
for other biological, psychological, and social interventions.  
Mechanism of action. 
Recent investigations into the potential mechanism of action of ketamine have brought 
about a breakthrough, extending our understanding of the pathophysiology of depression as a 
whole. It has long been thought that chronic stress, associated with depression, may damage 
neurons (especially in the hippocampus and the rest of the limbic system), reducing the number 
of connections (synapses) between them. Laboratory studies in rodent models of depression 
show that a single ketamine dose induces a rapid behavioral response (equivalent to an 
antidepressant response), which is correlated with a rapid increase in the protein building blocks, 
number, and function of the synaptic connections in the prefrontal cortex (a brain region 
associated with mood and higher cognitive function) [Fig. 2].  
By consolidating these various findings, investigators have proposed a model in which 
ketamine transiently reverses the synaptic deficits in the prefrontal cortex (Fig. 3). Brain-derived 
neurotrophic factor (BDNF) is a protein secreted to promote the normal growth of neurons and 
the formation of synapses (synaptogenesis). It is an important player for maintaining the balance 
of neurochemical factors necessary for synaptic function and regular mood (synaptic 
homeostasis). A component of this healthy equilibrium is the cycling of glutamate A1 (GluA1) 
receptors to and from the synapse, making the receptors functionally available. The depression 
state is characterized by a disruption of the equilibrium (synaptic destabilization), and GluA1 
receptors are internalized and become unavailable at the synapse. Furthermore, BDNF levels 
were shown to be reduced in stress and depression, causing synapse loss and neuronal atrophy.  
Ketamine’s primary action is the blockade of NMDA receptors on inhibitory 
(GABAergic) interneurons, unleashing a burst of glutamate into the synapse. The glutamate acts 
on AMPA receptors (glutamate receptors that also bind the glutamate agonist AMPA) to signal a 
complex interplay of neurochemical factors (including BDNF, mTOR, TrKB, and Akt) [Fig. 3]. 
The end result is the restoration of GluA1 cycling and functional synaptic connections 
(synaptogenesis). Additionally, ketamine (through the inhibition of postsynaptic NMDA 
receptors) may deactivate an enzyme called eukaryotic elongation factor 2 kinase, disinhibiting 
the rapid production of synaptic proteins such as BDNF. BDNF levels are increased by a range 
of proven antidepressant treatments, including ketamine.  
Vitally, this model accounts for the relative rapidity of ketamine’s effects. Ketamine’s 
eventual disinhibition of BDNF release (along with other essential components for functional 
synapses) utilizes an ever-ready, efficient physiological mechanism for generating synaptic 
connections. This stands in contrast to conventional antidepressants, which are thought to rely on 
more extensive changes in the neuronal architecture.  
A word of caution. 
Reports of ketamine’s potential clinical benefits must be interpreted with the utmost 
caution. Any therapeutic use of ketamine for depression is experimental, requires hospital 
monitoring, and has not received the general approval from the U.S. Food and Drug 
Administration. Furthermore, the unsupervised, nonprescription use of this drug is extremely 
dangerous and can be fatal. Acute adverse effects include increased heart rate and blood 
pressure, dangerous behavioral changes, and disturbing perceptual changes. Chronic side effects 
include ulcerative cystitis, cognitive and memory impairments, liver damage, structural brain 
damage, and drug abuse or dependence.  
Future outlook. 
The last few years have brought a wave of laboratory studies and clinical trials that 
augment our theoretical and practical knowledge of ketamine and major depression. Work 
exploring ketamine’s potential role in the reversal of depression-related synaptic loss shows great 
promise; however, both the pathophysiology of major depression and the mechanism of 
ketamine’s action remain unconfirmed. In addition, there are a number of outstanding clinical 
questions: What is the optimal dose and route of administration? How is it possible to sustain the 
response? What are the long-term side effects of this treatment?  
More than 50 clinical trials pertaining to ketamine and depression have been registered to 
date in the United States. Novel agents with similar glutamatergic properties are also being 
developed and studied with the hope of comparable benefits and attenuated side-effect profiles. 
Whether ketamine itself becomes established in general psychiatric practice remains to be seen. 
Its reported effects, thus far, have nevertheless garnered considerable attention and are catalyzing 
a paradigm shift in our understanding of, and approach to, major depression.  
For background information see AFFECTIVE DISORDERS; BRAIN; MENTAL DISORDERS;
NERVOUS SYSTEM (VERTEBRATE); NEUROBIOLOGY; NEURON; PHARMACOLOGY; PHARMACY;
PSYCHOLOGY; PSYCHOPHARMACOLOGY; PSYCHOSOMATIC DISORDERS; PSYCHOTHERAPY; STRESS
(PSYCHOLOGY); SYNAPTIC TRANSMISSION in the McGraw-Hill Encyclopedia of Science & 
Technology.  
John Daniel Cahill 
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<legend>  
Fig. 1. The chemical structure of ketamine hydrochloride [(±)-2-(o-chlorophenyl)-2-
(methylamino)cyclohexanone hydrochloride].  
Fig 2. Two-photon microscopic images of rodent neurons after treatment with ketamine (bottom 
panel), showing increased synaptic spine density (yellow arrows), as compared to controls (top 
panel). (Figure courtesy of R. S. Duman and G. K. Aghajanian, Synaptic dysfunction in 
depression: Potential therapeutic targets, Science, 338(6103):68–72, 2012, 
DOI:10.1126/science.1222939)  
Fig. 3. The synaptogenic basis of depression and the action of ketamine. See text for more 
details. LTD, long-term depression. (Figure courtesy of R. S. Duman and G. K. Aghajanian, 
Synaptic dysfunction in depression: Potential therapeutic targets, Science, 338(6103):68–72, 
2012, DOI:10.1126/science.1222939)  
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Figure 2: 
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Cortes-Briones et al. 
The Psychosis-Like Effects of Δ9-THC Are Associated with Increased Cortical ‘Noise’ in Healthy Humans 
Supplemental Information 
Supplemental Text  
Subjects, regulatory approvals, and general study procedures 
Electroencephalographic paradigm and data acquisition 
Electroencephalographic preprocessing 
Calculation of Lempel-Ziv complexity 
Statistical analyses - relationship between EEG and behavioral measures 
Effects of recent (30 day) cannabis exposure 
Plasma samples of ∆9-THC and its metabolite ∆9-THC-COOH 
Relationship between P300 and both LZC and behavioral measures 
Spectral analysis 
Analysis comparing information contained in binarized vs. continuous (non-binarized) signals 
Supplemental Tables 
Table S1. Schedule of procedures 
Supplemental Figures 
Figure S1. Lempel-Ziv complexity in recurrent, electroencephalographic, and random signals 
Figure S2. Δ9-THC-induced positive and disorganization symptoms versus Lempel-Ziv complexity 
uncorrected for signal power 
Supplemental References 
Cortes-Briones et al. 
Subjects, Regulatory Approvals, and General Study Procedures 
The study was conducted at the Neurobiological Studies Unit of the VA Connecticut Healthcare System 
(VACHS; West Haven, CT). Subjects were recruited by advertisements and by word of mouth, and were 
paid for their participation. The study was approved by the institutional review boards of the VACHS and 
Yale University School of Medicine and was carried out in accordance with the Helsinki Declaration of 
1975. ∆9-THC was administered with the approval of the U.S. Food and Drug Administration under an 
Investigational New Drug application (51,671). Subjects were informed about the potential for adverse 
effects of Δ9-THC including psychosis, anxiety, panic and abuse liability.  
After obtaining written informed consent, subjects underwent a Structured Clinical Interview for 
DSM-IV (SCID (1)) and were carefully screened for any DSM Axis I lifetime psychiatric or substance use 
disorder (excluding tobacco and cannabis use) and family history of major Axis I disorder. Subjects were 
screened at a separate session within about 4 weeks of the first test day. Cannabis-naïve individuals 
were excluded to minimize any risk of promoting future cannabis use/abuse. Subjects with DSM-IV 
cannabis dependence based on the SCID were excluded because cannabis dependence has been 
associated with a blunted response to Δ9-THC (tolerance). The history provided by subjects was 
confirmed by a telephone interview conducted with a spouse or family member identified by the 
subject. A general physical and neurological examination, electrocardiogram and laboratory tests (serum 
electrolytes, liver function tests, complete blood count with differential, urine toxicology and urine 
pregnancy in women) were also conducted. After screening, subjects were instructed to refrain from 
alcohol, caffeinated beverages, illicit drugs (other than cannabis) or prescription drugs not approved by 
the research team for 2 weeks before the study and throughout study participation. Recent users of 
cannabis, defined as those having used within the last 30 days, were instructed to abstain from smoking 
for at least 24 hours prior to test day. Test days were rescheduled if subjects reported using cannabis 
within 24 hours of the test day. Subjects who were not categorized as recent users of cannabis were 
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reminded not to use cannabis for two weeks before testing and throughout study participation. For this 
group, abstinence was confirmed by urine drug testing on the morning of each test day. 
Electroencephalographic (EEG) Paradigm and Data Acquisition 
Multichannel EEGs were recorded from the scalp at a sampling rate of 1000 Hz using a 22 
electrode cap (Physiometrix Inc., Billerica, MA, USA) and Neuroscan Synamps amplifiers (Neuroscan 
SynAmps, Compumedics Neuroscan, Charlotte, NC, USA). Electrode impedances were maintained <10 
kΩ and a linked-ear reference was used during the recordings. Vertical and horizontal electro-oculogram 
(VEOG and HEOG) data were recorded and used for eye-artifact correction.  
Subjects sat in an acoustically and electrically shielded booth in front of a computer monitor 
with eyes open while passively listening to click trains via insert earphones (Etymotic Research, Inc., Elk 
Grove Village, IL, USA) as part of an auditory oddball task described elsewhere (2). Briefly, the task 
consisted of a series of frequent ‘standard’ click trains (20, 30, or 40 Hz), infrequent ‘target’ tones (1000 
Hz), and infrequent task-irrelevant ‘novel’ distractor sounds presented with a 1250 ms stimulus onset 
asynchrony in three separate blocks of 180 stimuli each; each block had a different frequency. Standard 
click trains were 500 ms in duration and 80 dB SPL (C weighting), target tones were 500 ms in duration 
and 80 dB SPL (C weighting), and novel distractor sounds ranged between 175 and 250 ms in duration 
and averaged 80 dB SPL (C weighting). The task was programmed in Presentation (Neurobehavioral 
Systems, Berkeley, CA, USA). Only EEG data preceding each stimulus were included in the analysis 
described in this paper. 
Electroencephalographic Preprocessing 
In order to minimize the confounding effects that muscle activity and other sources of artifactual 
contamination could have on measuring neural noise in EEG signals, raw data were cleaned and only 
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midline electrodes were used for statistical analyses, given that these electrodes tend to be less 
contaminated by muscle activity than the rest (3).  
Continuous EEG data were band-pass filtered (0.5-100 Hz) with a windowed-sinc finite impulse 
response (FIR) filter (-6 dB/Hz) (4). To avoid frequency and phase distortions induced by notch filtering, 
line noise was removed using a multi-tapering technique (5). To clean muscle artifacts, EEG data were 
decomposed into uncorrelated components using a canonical correlation analysis-based blind source 
separation (CCA-BSS) algorithm (6). Muscle-related components were identified and removed from the 
resulting decomposition, and cleaned EEG data were reconstructed using the remaining components. 
Artifactual components were selected on the basis of their power spectral density (PSD) distribution: the 
ratio between PSD under and above 15 Hz (𝑃𝑆𝐷<15Hz 𝑃𝑆𝐷>15Hz⁄ ) was calculated, and those component 
having a ratio smaller than 10 were removed (7). This criterion is based on the power law distribution of 
PSD that has been reported for the human brain (𝑃𝑆𝐷 ∝ 1 𝑓𝛼�  with 𝛼~2) (8, 9). To better capture and
remove different patterns of artifactual activity, a 2-step CCA-BSS-based procedure was used: In the first 
step, the CCA-BSS algorithm was applied to the complete continuous EEG data, and the resulting 
artifactual components were removed from the signal; while in the second step, the algorithm was 
applied independently on non-overlapping 5 trials-length successive signal segments, and the artifactual 
components of each segment were removed from the corresponding segment only.  
VEOG and HEOG channels were used to correct eye movements and blinks artifacts with an 
exponentially weighted 𝐻∞ norm-based adaptive filter algorithm (10).  Data were segmented in 1150 
ms epochs time-locked to stimulus onset, with a 250 ms pre-stimulus segment. Epochs with voltages 
exceeding a ±100 μV threshold were rejected. The CCA-BSS algorithm was used in addition to the 
standard voltage-threshold method for artifact removal, given that EEG data free of obvious artifacts 
may still have an important amount of muscular activity (11, 12). The average number of clean epochs 
per drug condition used for further analyses was 416.625 (SD = 20.667) for placebo, 420.043 (SD = 
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11.830) for the 0.015 mg/kg dose, and 419.043 (SD = 13.075) for the 0.03 mg/kg dose. No significant 
differences were found in the total number of clean epochs between drug conditions (Wald 𝜒2(2) = 
0.578, p = 0.749). EEG data from midline electrodes (Fz, Cz, and Pz) were selected for analysis given that 
they tend to be less contaminated by muscle activity (3). Finally, only data from Cz and Fz were used 
since data from Pz presented artifactual contamination in a number of subjects. 
Calculation of Lempel-Ziv Complexity (LZC) 
The first step in the calculation of the LZC of a signal is to code the signal into a symbolic sequence. In 
order to do this, the threshold-crossing approach was chosen given that it is one of the most commonly 
and successfully used methods for coding signals in fields ranging from pure physics to neuroscience (cf. 
13, 14-17). In this method, the range of voltage values of an EEG signal is partitioned in 2 intervals 
delimited by a threshold 𝑇𝑉𝑜𝑙𝑡; signal values ≥ 𝑇𝑉𝑜𝑙𝑡 are coded as 1, while signal values < 𝑇𝑉𝑜𝑙𝑡  are 
coded as 0. In this study, the threshold 𝑇𝑉𝑜𝑙𝑡  was chosen to be the median of the signal given that it has 
been shown to be more representative of the whole signal (in contrast to the midrange) and robust 
against outliers (in contrast to the mean) than other measures of central tendency frequently used as 
thresholds (18, 19).  
For each subject, electrode and trial, the signal segment preceding the onset of stimulation 
(-250 to -1 ms) was coded into a binary sequence using the threshold-crossing approach (see described 
above). The coded signal was then broken into distinct symbolic subsequences or ‘words’ using Lempel 
and Ziv’s exhaustive parsing algorithm (20). LZC was obtained by dividing (normalizing) the total number 
of distinct ‘words’ that were necessary to reconstruct the coded signal by 𝑛 log2 𝑛⁄ , the upper bound of 
the LZC of a symbolic sequence of length 𝑛 when 𝑛 tends to infinity (see Figure S1). For each electrode, a 
single LZC value was obtained by averaging the LZC of the individual trials. Finally, a single LZC value was 
calculated for each subject by averaging the LZC of the different electrodes. 
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Statistical Analyses - Relationship between EEG and Behavioral Measures 
To characterize the relationship (correlation) between ∆9-THC induced changes in EEG measures (LZC 
and signal power) and Positive and Negative Syndrome Scale (PANSS) factors, standardized regression 
coefficient (𝛽s) were obtained for the longitudinal regression across both ∆9-THC-active conditions of 
each PANSS factor score on each EEG measure with a significant main effect of drug (3 for each EEG 
measure). The resulting standardized regression coefficients were interpreted as correlation coefficients 
in which a change of 1 standard deviation in the EEG measure 𝑥 led to a change of 𝛽𝑥𝑦 standard 
deviations in the score of the PANSS factor 𝑦 during acute ∆9-THC intoxication. For each EEG measure 
and PANSS factor this was done by fitting a single generalized estimating equations (GEE) model to the 
data of both ∆9-THC-active conditions transformed into composite z scores. To preserve the relative 
differences in the values of each variable between the two ∆9-THC active conditions, composite z scores 
were calculated using the mean and standard deviation of the data of both ∆9-THC-active conditions 
pooled together. In addition, to obtain the specific relationship between LZC and the PANSS factor 
scores independently of signal power, the standardized residuals resulting from the regressions of the 
PANSS factors on signal power (i.e., the part of the variation of the psychosis-like and negative-like 
behavioral effects that was not explained by signal power) were regressed on the standardized residuals 
of the regression of LZC on signal power (i.e., the part of the variation of LZC that was independent of 
signal power) (3 coefficients). No regression was conducted to determine the specific relationship 
between signal power and the PANSS factor scores independently of LZC, given that no significant main 
effect of drug on signal power was observed after correcting for LZC (see Methods section). Thus the p-
values of the resulting regression coefficients were Holm-Bonferroni (HB)-adjusted for 9 comparisons (6 
for LZC and 3 for signal power). All the analyses of this section were done in SPSS 21 (IBM Corporation, 
Armonk, NY, USA). 
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Effects of Recent (30 Day) Cannabis Exposure 
We conducted exploratory analyses examining the differences in the effects of Δ9-THC on LZC between 
recent and not-recent users of cannabis. The LZC data from the two Δ9-THC-active conditions were fitted 
with a GEE model with an unstructured working correlation matrix. Drug condition (0.015 and 0.03 
mg/kg), cannabis use (recent and non-recent users), and an interaction term (drug condition*cannabis 
use) were included in the model as explanatory variables. As expected, the results showed a significant 
main effect of drug condition on LZC (Wald 𝜒2(1) = 19.213, p < 0.001), with the 0.03 mg/kg dose inducing 
higher LZC than the 0.015 mg/kg dose. No significant effects were observed for recent exposure to 
cannabis and the interaction between drug condition and recent exposure to cannabis (both ps > 0.1). 
These results do not support the hypothesis that recent cannabis exposure affects the effects of Δ9-THC 
on LZC.   
Plasma Samples of ∆9-THC and Its Metabolite ∆9-THC-COOH 
Plasma was sampled at several time points from the IV line from the arm opposite to the one used for 
administering the study drug for determination of 11-nor-∆9-THC-9-COOH (∆9-THC-COOH) and analyzed 
using methods previously described (21). 
Relationship between P300 and Both LZC and Behavioral Measures 
Exploratory analyses were performed in which P3a and P3b peak amplitudes and latencies were 
regressed on LZC across the three drug conditions using GEE models with unstructured working 
correlation matrices. Peak P3a and P3b amplitudes and latencies were calculated as described in (2). 
Significance levels were Holm-Bonferroni adjusted for 4 comparisons. P3a, P3b, and LZC measures were 
obtained for electrode Cz (Pz was removed during the preprocessing due to artifactual contamination). 
The results showed a significant inverse relationship between LZC and both P3a (𝛽 = -0.391, Wald 𝜒2(1) = 
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16.712, pAdj < 0.001) and P3b (𝛽 = -0.419, Wald 𝜒2(1) = 10.100, pAdj = 0.002) peak amplitudes. No 
significant relationships were found between LZC and latencies of the peaks (psAdj > 0.1). 
Event-related potentials (ERPs) have been shown to be sensitive to the acute effects of Δ9-THC 
on brain activity (2). However, it is not clear which measure is more sensitive to the pathophysiology of 
the psychosis-like effects induced by Δ9-THC. In order to compare the sensitivity of LZC and ERPs, the 
post-stimulation period of the data used for calculating LZC was used to obtain the peak amplitudes and 
latencies of the P3a and P3b ERPs at electrode Cz (Pz was excluded from analyses due to artifactual 
contamination). Specifically, to obtain the ERPs: 1) EEG data was low-pass filtered (30 Hz) with a 
windowed-sinc FIR filter (-6 dB/Hz) (4), 2) the mean voltage amplitude of the baseline period (-250 to -1 
ms) of each trial was substracted from the whole trial, 3) trials were averaged in a point-by-point 
manner, and 4) the peaks were automatically detected as the highest positive value within the post-
stimulation time interval 250-500 ms. Then, psychosis-like behavioral effects (PANSS factor scores) were 
regressed independently on the peak and amplitude of the ERPs (P3a or P3b) during the ∆9-THC-active 
conditions. Each regression was done by fitting a single GEE model with an unstructured working 
correlation matrix to the data of both ∆9-THC-active conditions transformed into composite z scores. The 
p-values of the resulting standardized regression coefficients were HB-adjusted for twelve comparisons 
(2 measures for ERP x 2 ERPs x 3 behavioral-effects).  
The analyses revealed that there were no significant coefficients for any of the regressions, 
either before or after correcting for multiple comparisons (all psAdj > 0.1). These results suggest that LZC 
is more sensitive to the pathophysiology underlying the psychosis-like effects of Δ9-THC than the P3a 
and P3b ERPs.  
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Spectral Analysis 
In order to obtain the spectral power per frequency band (band power) during the baseline period, for 
each subject, the signal of each electrode was band-pass filtered (0.5-100 Hz) with a windowed-sinc FIR 
filter (-6 dB/Hz) (4) with cutoff frequencies corresponding to the traditional frequency bands (𝛿 [1-4 Hz], 
𝜃 [4-8 Hz], 𝛼 [8-13 Hz], 𝛽 [13-30 Hz], 𝛾1 [30-55 Hz], 𝛾2 [65-100 Hz). Then, for each subject, electrode 
and frequency band, signal power was obtained by calculating the root-mean-square power (average of 
the signal’s squared amplitude) of each trial’s pre-stimulation interval (-250 to -1 ms) and then averaging 
across trials. Finally, for each subject and frequency band, a single signal power value was obtained by 
averaging across electrodes.   
The effect of drug condition (placebo, 0.015 mg/kg, and 0.03 mg/kg) on band power was 
assessed using GEEs (22, 23) with unstructured working correlation matrices. Independent GEE models 
were fitted for each frequency band and p-values were adjusted for multiple comparisons (6 
comparisons, one per frequency band) with the HB method. Post-hoc pairwise comparisons (3 per 
model) were performed for those models with a significant main effect of drug condition and the p-
values were HB-adjusted for the total number of pairwise comparisons performed across all the models 
(3 per model with a significant main effect of drug condition).  
To characterize the relationship between ∆9-THC-induced changes in band power and psychosis-
like behavioral effects, standardized regression coefficient (βs) were obtained for the longitudinal 
regression of each PANSS factor score on each band power that had a significant main effect of drug 
condition across both ∆9-THC-active conditions. p-values were HB-adjusted depending on the total 
number of comparisons (3 per model –one per behavioral measure– with a significant main effect of 
drug). For each frequency band and PANSS factor, a longitudinal regression was conducted by fitting a 
single GEE model with an unstructured working correlation matrix to the data of both ∆9-THC-active 
conditions transformed into composite z scores. The p-values of the resulting regression coefficients 
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were HB-adjusted for nine comparisons. All the analyses of this section were performed in SPSS 21 (IBM 
Corporation, Armonk, NY, USA). 
The analyses revealed that there was a significant main effect of drug condition on spectral 
power only for the 𝛽-band (Wald 𝜒2(2) = 20.294, pAdj < 0.001; psAdj > 0.1 for the other frequency bands). 
No significant coefficients (all pAdj > 0.1) were found for the regression of the behavioral effects on 𝛽-
band power for the ∆9-THC-active conditions. 
Analysis Comparing Information Contained in Binarized vs. continuous (Non-Binarized) Signals  
To obtain an estimate of the information shared by each frequency component of the EEG signals and 
the binarized full spectrum (0.5-100 Hz) signals used for calculating LZC, we calculated the mutual 
information (MI) between them. MI refers to the information shared between two signals expressed as 
an absolute (24).  In the calculation of MI, the same information between signals is captured only once. 
To illustrate this take the two sentences below: 
Sentence #1: Santa Claus is dressed in a red robe. 
Sentence #2: Santa Claus is dressed in a red robe. Santa Claus is dressed in a red hat.  Santa 
Claus is dressed in red shoes. 
To illustrate this further, assuming that each word represents 1 bit of information, in the calculation of 
the MI between sentences #1 and #2, the information of the words common to both sentences 
(highlighted in yellow) is counted only once, even though some words (Santa, Claus, is, dressed, in, a, 
red) are repeated three times in sentence two. The words hat and shoes (highlighted in green) are 
identified as the only pieces of information that are not present in both sentences. Thus, the MI 
between the sentences is calculated as 8 bits (Santa, Claus, is, dressed, in, a, red, robe).  
In the case of two identical signals, the MI between them (self-MI) is an index of the absolute 
amount of nonredundant information of each one of the (identical) signals. To illustrate this, take the 
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two sentences below: 
Sentence #1: Santa Claus is dressed in a red robe. Santa Claus is dressed in a red hat.  Santa 
Claus is dressed in red shoes. 
Sentence #2: Santa Claus is dressed in a red robe. Santa Claus is dressed in a red hat.  Santa 
Claus is dressed in red shoes. 
Assuming that each word represents 1 bit of information, there are 10 bits of nonredundant information 
in each sentence (Santa, Claus, is, dressed, in, a, red, robe, hat, shoes).  
 In order to calculate MI in our data, full-spectrum (0.5-100 Hz) EEG signals from electrodes Fz 
and Cz were bandpass-filtered to obtain the frequency components corresponding to the traditional 
frequency bands (delta [1-4 Hz], theta [4-8 Hz], alpha [8-13 Hz], beta [13-30 Hz], gamma1 [30-55 Hz], 
gamma2 [65-100 Hz]). For each subject, electrode, and trial (see the Methods section), the frequency 
components of the baseline period (-250 ms to -1 ms) were obtained, and the MI between each 
frequency component and the binary signal used for calculating LZC (full-spectrum [0.5-100 Hz] EEG 
signal binarized with the threshold (median)-crossing approach) was calculated. Finally, for each 
frequency component, MI was averaged across trials and then across electrodes in order to obtain a 
single MI per subject for each frequency component.  
 MI data were fitted with a 
GEE model with an unstructured 
working correlation matrix, and with 
frequency band as factor. Pairwise 
comparisons were performed and p-
values were adjusted with the HB 
method for 21 comparisons. The 
results showed a significant effect of 
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frequency band on MI (Wald 𝜒2(5) = 30358.481, pAdj < 0.001). Post-hoc analyses revealed that all pairwise 
comparisons were significant (all psAdj ≤ 0.001) and that from largest to smallest, MI per frequency band 
can be sorted in the following way (adjoining figure): delta > theta > alpha > beta > gamma1 > gamma2.  
Cortes-Briones et al. 
Table S1. Schedule of procedures 
Time Procedure Procedure 
~4 weeks 
before test day 
· Medical and psychiatric history, SCID,
cannabis/drug/alcohol use, confirmation of history
with collateral
· Chemistry, hematology, urine toxicology, urine
pregnancy, EKG, vital signs, height and weight
-120 (~8 am) · Is subject NPO after midnight?
· Last use of alcohol
· Last use of tobacco
· Check for recent stressors: No/Yes  (specify)
· Last use of THC
· Last use of caffeine
· Any meds in the past week? No/Yes (specify)
-90 (8:30 am) · Send urine tox: Positive/Negative
· Urine pregnancy test (female)
· Vital signs: BP (sitting);  Pulse
· Breathalyzer
· Insert IV lines
· Standard light breakfast
-60 (9 am) · PANSS · Vital signs: BP (sitting); Pulse
-30 (9:30 am) · EEG recording
-5 (9:55 am) · Vital signs: BP (sitting); Pulse · Blood sampling for THC/THC-COOH
0 (10 am) IV THC (0.0015 mg/kg, 0.015 mg/kg or 0.03 mg/kg) or Placebo over 10 minutes.  
+5 (10:05 am) · Vital signs: BP (sitting); Pulse
+10 (10:10 am) · Blood sampling for THC/THC-COOH
· Vital signs: BP (sitting); Pulse
· End of THC infusion
· PANSS
+30 (10:30 am) · ERP recording · Vital signs: BP (Sitting); Pulse
+80 (11:20 am) · Vital signs: BP (sitting); Pulse
· PANSS
· Blood sampling for THC/THC-COOH
+240 (2 pm) · Vital signs: BP (sitting); Pulse · Blood sampling for THC/THC-COOH
End of Test Day · Safety Checklist:
· MMSE (nursing)
· Field sobriety test
· Exit interview
· Discharge instructions
Safety Follow up: 1 and 3 months after last test day for cannabis use, psychiatric symptoms 
BP, blood pressure; EEG, electroencephalogram; EKG, electrocardiogram; ERP, event-related potential; MMSE, Mini-Mental State 
Examination; NPO, nil per os; PANSS, Positive and Negative Syndrome Scale.
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Figure S2. Δ9-THC-induced positive and disorganization symptoms versus Lempel-Ziv complexity 
uncorrected for signal power. The figure shows the linear regression lines and standardized coefficients 
of the positive (A) and disorganization (B) symptoms factors of the PANSS on Lempel-Ziv complexity 
(LZC) uncorrected for signal power. PANSS scores and LZC values are presented in z scores.  
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